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QUILL ON SCALPEL
PLUME ET SCALPEL

Laparoscopic Cholecystectomy in
Perspective
Gerald M. Fried, MD, FRCSC, FACS
Associate professor, Division o f General Surgery, McGill University, Rm. 9863, The Montreal
General Hospital, 1650 Cedar Ave., Montreal, PQ H3G 1A4

widespread early reluc
Despite
tance and much scepticism on
the part of surgeons, laparoscopic
cholecystectomy has proliferated.
The explosion of laparoscopic sur
gery has been driven to a great
extent by patient demand and com
mercial interests. General surgeons
have waited in line to take courses
to satisfy the requirements for ac
creditation by their institutions. The
financial implications of laparoscop
ic surgery to industry should not be
underestimated. By this time, at
many institutions, most cholecys
tectomies are being done laparoscopically. This issue of the CJS
reflects the interest in laparoscopic
cholecystectomy, and a number of
articles address several important
issues.
Both Sigman and colleagues
(pages 49 to 54) and Cohen (pages
59 to 63) describe the introduc
tion of laparoscopic cholecystecto
my into their respective institutions.
Cohen has rightly emphasized that
any surgeon attempting laparoscop
ic cholecystectomy must first be
competent to do open cholecystec
tomy. The requirement for experi
ence in a minimum of 15 cases of
diagnostic laparoscopic surgery is
curious, since it is difficult and
probably artificial to set an arbitrary
number of cases required for an
individual surgeon. It is important

to encourage prospective laparo
scopic surgeons to take an ap
proved university-run course rather
than an industry-run course. Such a
course should include didactic
teaching, video presentations, largeanimal operating experience and,
ideally, an opportunity to observe
one or more operations First hand in
the operating room, because edited
videos provide only a superficial
idea of laparoscopic cholecystecto
my in humans. The need for 2 days
of large-animal surgery can be
questioned. Despite the require
ments described by Cohen for credentialling in their institution, it is
of concern that the rate of serious
complications related particularly to
the common bile duct is so high,
with three such injuries in the first
189 cases. One would not accept
this rate of bile-duct injury in open
cholecystectomy, and justifying this
as a risk inherent to the learning
curve seems inappropriate. Sigman
and colleagues report a substantial
ly lower rate of serious complica
tions. These authors suggest that
pairing surgeons during the initia
tion of laparoscopic cholecystecto
my in an institution reduces the
risk of complications by having two
sets of experienced eyes to interpret
operative findings, and, at the same
time, increasing the experience of
both surgeons at a rapid rate. Once

these surgeons have progressed
through their learning curve, they,
in turn, spend time helping other
surgeons through this trying time.
The benefits of laparoscopic cho
lecystectomy, when uncomplicated,
have been emphasized in all arti
cles, and the economic savings can
be considerable. Lessons learned
from management of patients after
laparoscopic cholecystectomy can
be applied to those who undergo
open cholecystectomy, resulting in
some cost savings. At the recent
annual meeting of the Canadian
Association of General Surgeons
Barkun (unpublished data, 1991)
reported on the McGill randomized
prospective comparison of open ver
sus laparoscopic cholecystectomy.
The data showed that, although
there is definite benefit with laparo
scopic cholecystectomy, the quanti
tative difference between patients
managed optimally after mini
cholecystectomy is less than we
would like to believe.
The report by Smith and col
leagues (pages 55 to 58) provides
helpful information concerning the
ultrasonographic and radiologic
findings on the first day after lapa
roscopic cholecystectomy. They
have shown that usually little or no
fluid is seen in the subhepatic space
on the first postoperative day, and a
large amount of fluid should raise
CJS, VOL. 35, NO. 1, FEBRUARY 1992
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concern about a possible bile leak.
This is best confirmed by radionu
clide scanning. As we would expect,
most gas should be absorbed from
the peritoneal cavity by the first
postoperative day when carbon di
oxide is used for insufflation. The
presence o f significant amounts of
gas in the peritoneum and gastroin
testinal tract may occur, however,
and since it is unlikely that this gas
is carbon dioxide, it may persist for
longer periods. This must be taken
into consideration when advising
patients about air travel early after
surgery. The reduced pressure in an
airplane may lead to expansion of
the gas, acute abdominal pain and
distension, as I observed in a pa
tient o f mine — a pilot who flew on
the fourth postoperative day.
Probably the most controversial
area currently in laparoscopic cho
lecystectomy is the appropriate
management of the common duct
as clearly discussed by Dion and
associates (pages 67 to
74).
There is an enormous variation
from those who would recommend
routine operative cholangiography
to those, like Sigman and col
leagues, who rarely perform opera
tive cholangiography.
Despite the insistence by some
authorities that routine cholangiog
raphy reduces the likelihood of
common-duct injuries, there are no
data to support this. Injuries to the
common duct can occur from dis
section before cholangiography or
from perforation o f the common
duct by the catheter used for the
investigation.1 Cholangiography is
no substitute for careful dissection,
although its value in selected cases
in which anatomy is obscure should
be obvious. Certainly every surgeon
doing laparoscopic cholecystectomy

8
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should be able to perform cholangi
ography if indicated.
The issue o f diagnosis and treat
ment of choledocholithiasis is
equally controversial. Resolution of
these controversies requires careful
analysis of available literature and
planned prospective comparison of
rational approaches. It is certain
that routine cholangiography will
lead to the diagnosis o f more com
mon-duct stones than selective cho
langiography. It will also result in a
false-positive diagnosis in 2% to 8%
o f cases.2 All the available methods
to treat common-duct stones result
in some increase in rates o f morbidi
ty and, probably, death, compared
with laparoscopic cholecystectomy
alone. Endoscopic papillotomy has
been associated with a morbidity
rate of approximately 10% and a
death rate of 1%, with a substantial
ly higher morbidity in patients with
a small duct.3 Open common-duct
exploration also carries substantial
ly increased rates of morbidity and
death compared with open chole
cystectomy alone.4 There is no rea
son to believe that performing com
mon-duct exploration laparoscopically either by direct approach or
through the cystic duct will avoid
this risk. Although Dion and col
leagues have shown that laparo
scopic clearance of the biliary tree
is possible in selected cases, current
data are insufficient to appreciate
the true risk to the patient of this
intervention. On the basis of the
available data, it seems appropriate
that patients with known commonduct stones or a high probability of
stones preoperatively, especially
when associated with a dilated duct,
undergo attempted clearance of
their common duct endoscopically
before operation. Inability to do this

should dictate clearance o f the duct
at the time of surgery. If the sur
geon is sufficiently facile, and the
necessary fluoroscopic and choledochoscopic equipment is available,
exploration through the cystic duct
is likely the safest approach. If this
is not feasible, open exploration
should be performed. Patients with
intermediate risk o f common-duct
stones (history o f pancreatitis or
jaundice in the past, mild to moder
ate elevation o f liver-function test
results preoperatively, minimal dila
tation of common duct), should
undergo operative cholangiography.
Patients found to have moderately
large stones (more than 3 mm in
dimension) should be treated either
by common-duct exploration at the
time o f surgery or by a postopera
tive endoscopic approach. Patients
with silent small stones should
probably be observed, since most of
these stones will be passed. Other
patients with a low risk of commonduct stones do not require cholangi
ography, since the risk associated
with their diagnosis and treatment
probably exceeds the risk of ap
proximately 0.3% that they will re
turn with complications or com
plaints related to choledocholithia
sis.
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QUILL ON SCALPEL

Laparoscopic Surgery — What Next?
N. Schmidt, MD, FACS, FRCSC
Member, Editorial Board, Canadian Journal of Surgery. Clinical professor and director o f
continuing medical education, Department o f Surgery, University o f British Columbia,
Vancouver, BC

ide-ranging opinions, from
opposition to optimism,
about laparoscopic cholecystectomy
can be found on scanning published
papers in this and other surgical
journals over the last 18 months.
Someone has argued that doing
surgery laparoscopically is like
learning to drink water while stand
ing on one’s head. It is entirely
possible, but what is the advantage?
Generally the barriers raised ini
tially against laparoscopic cholecys
tectomy have tumbled. The proce
dure has caught on and is truly
fantastic, especially for the patient,
providing rapid recovery and early
return to full activity. Instrumenta
tion is now widely available, train
ing criteria have been fulfilled and
patients by the thousands have
been operated on successfully. The
initial concerns over complications
have diminished as the skills and
experience of surgeons have in
creased.
In this issue of the journal, sever
al papers from Canada and the
United States report individual and
collective experience with laparo
scopic cholecystectomy. The litera
ture is full of publications attesting
to the authors’ techniques, pitfalls,
experience, results and notes of
caution. Laparoscopic cholecystec
tomy is now accepted and has es
sentially replaced open cholecystec
tomy as the standard approach to
uncomplicated chronic cholecystitis,
and with increased experience more
complicated biliary problems are
also being successfully treated lapa
roscopically. Soon it will be difficult
to publish even large series of cases
unless something unique can be
offered to the reader.

W

The program and process of
teaching laparoscopic surgery in a
group of university-affiliated hospi
tals, as described by Sigman and
colleagues (pages 49 to 54) has
been repeated across Canada in sev
eral centres. Their experience is not
unique, and the results are familiar
and similar to those of most publi
cations. These findings are repeated
in the paper by Cohen from Denver
(pages 59 to 63), who attempts to
tie the advantage of laparoscopic
cholecystectomy to an increased
gross national product. I wish the
economy could be so simply cor
rected. The paper by Smith and
colleagues (pages 55 to 58) on the
imaging of patients who undergo
laparoscopic cholecystectomy and
the one by Drover, Nguyen and
Pace (pages 65 and 66), reporting
laparoscopic cholecystectomy in a
patient with situs inversus viscerum, are helpful and interesting.
Of greatest interest, though, is the
review of laparoscopic cholecystec
tomy and choledocholithiasis by
Dion and Morin (pages 67 to 74).
Simple removal of the gallbladder
laparoscopically is being done fre
quently in most community hospi
tals. It begs the question of when to
obtain bile-duct x-ray films and
what to do if stones are detected.
Dion and Morin open the whole
subject of advanced biliary-tract la
paroscopic surgery. Does one leave
the stone for later and use alterna
tive treatment methods? Does one
open the patient for conventional
common-bile-duct exploration?
Does one have the skill and instru
mentation to perform “on-table”
endoscopic retrograde cholangio
pancreatography with papillotomy,

laparoscopic choledochoscopy or la
paroscopic common-bile-duct explo
ration with T-tube insertion, requir
ing advanced skills of intra-abdomi
nal suturing and knot tying?
Where do we go from here? The
necessary skills, equipment and
case load will begin to dictate the
progression of what surgeons can
and should do in laparoscopic sur
gery. The technical gulf between
laparoscopic cholecystectomy and
advanced biliary-tract techniques,
hernia repairs, vagotomies, fundoplications, bowel resections for ma
lignant lesions and transthoracic
Heller myotomies, to name a few, is
very wide. Having worked on the
advanced techniques of all these,
one realizes that not all surgeons
will become skilled at all laparo
scopic operations. The operations
are difficult, and the eye-hand co
ordination, instrumentation and fre
quency of procedures are individual
ly variable and unique.
Why are we surgeons doing all
this? Is it really for our patients’
benefit only? Will we have the pa
tience to proceed slowly and moni
tor the outcome with proper pro
spective studies and observations?
Symptomatic gallbladders once re
moved usually are not associated
with late sequelae. The same is true
for laparoscopic appendectomies.
But what about the recurrence rate
of hernia repairs, the failure rate of
vagotomies and the recurrence rate
of poorly excised malignant tu
mours? Would the increased recov
ery rate from the wizardry of lapa
roscopic surgery justify the risk of
recurrence? Does a faster discharge
rate justify the extended hours that
some of these procedures will take?
CJS, VOL. 35, NO. 1, FEBRUARY 1992
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Is the patient really better served?
Time will tell. There will always be
those who dare to stand on their
head to drink water, and I suppose
that is a valid challenge and accom
plishment. It definitely will not be
for everyone, and we must not be

critical of those who wish to contin
ue drinking water standing up or
who wish to advise conventional
surgery until more results of lapa
roscopic treatment become avail
able.
What is the advantage of laparo

scopic surgery and what happens
next? Clearly the advantage lies in
rapid recovery for the patient. What
happens next will depend on the
evolution of safe, effective surgical
skills performed with confidence
and with the correct indications.*

SESAP VI Question / Question SESAP VI

Item 54
A 41-year-old man was hospitalized because of acute pancreatitis related to alcohol abuse. He was otherwise well
and able to work after release from the hospital, but complained of epigastric discomfort.
Three months later, the patient is afebrile and has a normal WBC count, but a mass is palpable in the
epigastrium. The computed tomographic (CT) scan shown above is obtained.
The best treatment is
(A) percutaneous transabdominal catheter drainage
(B) distal pancreatectomy
(C) observation with repeat CT scan in one to two months
(D) cyst gastrostomy
(E) celiotomy and external drainage
For the incomplete statement above select the one completion that is best of the five given.
For the critique of Item 54 see page 26.
(Reproduced by permission from SESAP VI Syllabus; Surgical Education and Self-Assessment Program No. 6.
For enrolment in the Surgical Education and Self-Assessment No. 6, please apply to the American College of
Surgeons, 55 East Erie St., Chicago, IL 60611.)
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T h e Surgeon’s Dilemma: Fibrocystic
“Dis” “ease” of the Breast
W.J. Temple, MD, FACS, FRCSC
Director o f surgery, Tom Baker Cancer Centre, Calgary, Alta. Member, Editorial Board,

Canadian Journal of Surgery

he hysteria, anxiety and sleep
less nights suffered by young
women who have breast symptoms
from benign lesions easily equal
those of the far fewer women who
have the misfortune of having
breast cancer. The report by Sterns
in this issue (pages 41 to 45), one
of the largest to date, is a com
mendable attempt to provide data to
deal more rationally with this prob
lem. The article is highlighted by
Sterns’s experience that 60% of
women referred for breast disease
had no detectable abnormality. Al
though a lump in the breast was
the indication for most of the biop
sies, associated pain, nodularity and
skin changes were all noted as
being associated with cancer.
Therefore no fail-safe formula is
available by which a surgeon can
reassure a patient that her lesion is
benign without the need for excisional biopsy. This results in a high
rate of benign biopsies for each
cancer diagnosed. In many series
the false-negative rate ranges from
1 in 10 to 1 in 20 for women
younger than 40 years and from 1
in 5 to 1 in 10 for women 40 to 50
years of age. Moreover the recom
mendation of a biopsy in patients
with benign lesions further height
ens the anxiety, which is only
slightly lessened by a subsequent
pathological diagnosis of fibrocystic
disease!
How can the false-negative biop
sy rate be decreased? Needle cyto
logic analysis of breast lesions is an
effective microbiopsy technique that

T

provides a much more accurate pic
ture than clinical examination
alone. A 1% false-positive rate and a
5% false-negative rate were noted in
our series of 521 patients, studied
from 1984 to 1990, in whom needle
cytologic findings correlated with
subsequent excisional biopsy find
ings (Duggan MA, Kara R, McGre
gor SE et al: Unpublished data).
Our experience was similar to that
of other large studies.1"3 Although
the needle cytologic technique is
not absolutely accurate it does
allow a thickening of the breast to
be followed for a few months with
some reassurance. Ultimately the
patient’s expectation of 100% accu
racy demands an open biopsy for all
persistent lesions despite clinical,
radiologic and cytologic indications
of the benign nature of the lesion.
To add to this dilemma, we are
being deluged with mammographically and even ultrasonographically
detected abnormalities of which
only 10% to 15% of the former are
cancers. This accounts for even
higher negative biopsy rates in both
pre- and postmenopausal women.
It is important to realize that all
this effort is driven by the assump
tion that early diagnosis does im
prove survival. The earliest diagno
sis possible using current technolo
gy may not be as beneficial as we
would like to believe, particularly in
women under 50 years of age, who
have the highest rate of negative
biopsies. Unlike other tumours,
such as colonic cancers and melano
mas, for which early diagnosis does

improve survival, the detection of
breast cancer by repeated physical
examination by the woman and her
doctor4 and by mammography has
shown only a 30% benefit in the 50to 69-year age group.5 In this age
group there are other competing
causes of death that largely abro
gate the overall survival benefit ac
crued by routine screening.5 There
fore we must be aware that the
thrust of managing lumps in the
breast aggressively, at all ages, as
we do now is one of philosophy not
one based on strong scientific evi
dence that this effort actually im
proves survival.
Nevertheless early diagnosis of
breast cancer does decrease morbid
ity. First, it reassures patients of
the option of breast conservation
surgery. Second, in those with a
diagnosis of cancer in situ, particu
larly the ductal variety, it provides a
unique window in which prophylac
tic treatment may be considered.
Although the option of bilateral
total mastectomy is usually rejected
it does provide the best protection
to date.6-7 However, ongoing re
search may identify agents, such as
tamoxifen, that will provide equiva
lent protection. Third, in the
woman over 50 years of age, the
early diagnosis of a small lesion,
less than 2 cm in dimension, may
also avoid the necessity of routine
radiotherapy of the breast after a
local excision (Temple WJ, Paterson
L, Huchcroft SA: Unpublished data,
1991).8 Whether these advantages
justify the huge economic investCJS, VOL. 35, NO. 1, FEBRUARY 1992
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ment into early diagnosis of breast
cancer is best determined by contin
ued research. Studies in progress,
such as the Canadian Breast
Screening Study, may delineate this
problem further to justify our cur
rent aggressive philosophy of early
diagnosis using the available tech
nology.
Our current approach, however,
is not nihilistic but one of compro
mise in recognizing that we may
seriously have to re-evaluate our
position as more results of research
are published. Meanwhile at the
Foothills Hospital, affiliated with
the University of Calgary, we have
embarked on providing a most eco
nomical and efficient service for
patients needing breast biopsies.
Four years ago our divisions of
general surgery and surgical oncol
ogy started an outpatient breast
biopsy program. It utilizes a minor
operating theatre in the emergency
department, which provides only
local anesthesia and basic sterile
precautions of gloves, mask and
minimal draping. This has allowed
booking of patients within 2 to 5
days of the decision to do a biopsy.
Needle localization biopsies are also
routinely done using only local an
esthesia in this setting. The total
cost for a biopsy, including hospital
and physician charges, is $170, less
than the cost of two mammograms.
The infection rate in our first 300
patients was 0.3%. We have elimi
nated an estimated 800 bed-days
and 400 operating hours yearly in
the major operating rooms of the
Foothills Hospital. A survey done
on our patients showed that 95% of
them were “well” or “extremely”
satisfied with this service.
In conclusion, I would emphasize
that we have to keep an open mind
about the ultimate value of aggres
sive management of benign-appear
ing lumps in the breast. Although I
continue to be an advocate of early
diagnosis of breast cancer, it is
12
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clear that we need new techniques
for earlier and more accurate detec
tion than we have at present. The
challenge that we face as general
surgeons is not so much how to
manage the malignant lesions of the
breast but how to eliminate the
“dis” “ease” of the far more com
mon problem of fibrocystic thicken
ings in the breast. I congratulate
Dr. Sterns on his initial study of
this perplexing problem and look
forward to his further analysis.
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Retention Sutures: Are They Really
Necessary?
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his issue contains an article on
gauze roll padding for reten
tion sutures by Dr. M.T. Troy
(pages 15 and 16), who describes a
technique to avoid cutting the skin,
which is traditional with retention
sutures. Although this technique
has considerable merit and is one of
a number of such techniques avail
able for skin protection in these
circumstances, it is my contention
that the use of retention sutures in
today’s surgical practice is anachro
nistic and probably should be dis
carded.
With the availability of swedged
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heavy suture materials, both ab
sorbable and nonabsorbable on
large needles, my practice has been
to avoid placing such retaining su
tures through the skin at all. By
carefully placing the large needle in
the subcutaneous plane and taking
wide and deep bites of either side of
the entire abdominal wall, the su
tures can be approximated in the
subcutaneous tissues. This avoids
skin puncture in situations, like
those described in Dr. Troy’s arti
cle, in which the use of retention
sutures might be considered. The
wound is then simply dressed with a

moist gauze dressing in the subcu
taneous tissues. This dressing can
be placed right over the tied suture
material, and granulation tissue
soon fills the gap. The main con
cern relating to the placement of
sutures through the skin is the
inevitable gram-positive infection
that arises from skin organisms
present at the puncture sites.
I have found this technique to be
readily applicable whenever there is
concern about wound closure, with
or without dehiscence, either as
prophylaxis or therapy for wound
disruption. ■
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Gauze Roll Padding for Retention Sutures
M. Tuszewski Troy, MB, BS, FRCSC, FACS
he use of retention sutures for
wound closure is well estab
lished. They are used whenever
there is concern that wound healing
may be complicated or delayed. The
standard technique calls for the use
of strong, nonabsorbable suture
material, such as nylon or wire, on
large cutting needles. The sutures
are inserted in a through-andthrough manner to include skin,
subcutaneous tissues, fascia and
muscle layers, either outside the
previously closed peritoneum or to
include it. Before the retention su
tures are tied, fascia and other
tissue layers may first be closed or
left open. Finally the retention su
tures, often threaded through short
lengths of rubber or plastic tubing,
are tied reasonably tightly.
The short lengths of tubing that
are frequently threaded over the
retention sutures to lie on the skin
surface minimize skin pressure ne
crosis from the tightly cinched su
tures. By spreading the pressure of
the sutures on larger surface areas
of the skin, the tubing segments
serve to decrease the anticipated
skin damage. Nevertheless pressure
damage to the skin occurs frequent
ly, sutures cut through the skin
and infection often follows. At best,
the patient is left with unsightly
scars. At worst, complications and
sequelae of infection occur that can
be fatal.
Increasing the amounts of pad
ding under the sutures spreads and
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minimizes the intensity of pressure
on the skin under each suture,
preventing sutures from cutting
through the skin. This can be
achieved by tying the sutures over
rolled gauze bolsters interposed be
tween suture and skin. Tubing seg
ments can still be used or can be
dispensed with. They are still of
use, in that their presence on the
sutures makes for easier subse
quent removal of the gauze, when it
is desirable to keep the retention
sutures longer.
A refinement of the method al
lows for retightening, as necessary,
during dressing changes.

Operative Technique
On completion of the operation,
retention sutures are placed in a
through-and-through manner in the
usual way (Fig. 1). The various
wound layers are closed or not
closed as deemed necessary. Bol
sters of surgical cotton gauze are
fashioned by rolling gauze sponges
into tight rolls about 2 cm in diame
ter (Fig. 2). Two such rolls are
prepared and are placed by the
assistant, one on either side of the
incision. The retention sutures are
then tied, reasonably tightly, over
the gauze rolls (Figs. 3 and 4).
At the time the dressings are
removed, surgeons have a choice.
They can cut the retention sutures
and remove the gauze rolls, leaving

From the Department o f Surgery, Calgary General Hospital, Calgary, Alta.
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Reprint requests to: Dr. M. Tuszewski Troy, 460 Marlborough Professional Bldg., 433
Marlborough Way NE, Calgary, AB T2A 5H5

skin-edge closure staples or stitches
in place for a longer time. Alterna
tively, they can tease out the rolled
gauze first from under the retention
sutures. This allows an opportunity
to inspect the wound, to remove
some or all of the skin-edge clo
sures before removing the retention
sutures and to retighten the sutures
if this appears advantageous.
Teasing out the gauze rolls from
under the constricting sutures is
accomplished easily with practice.
The tight loop of the suture is
elevated with a forceps. The gauze
roll is pushed through the loop,
trimmed with scissors and pushed
through the next loop and the next
until it is out. Having short lengths
of tubing threaded over the sutures
before their insertion makes this
manoeuvre easier still. The proce
dure is well tolerated by patients.
On removing the gauze rolls in
this manner it will be apparent
whether wound healing is delayed
or dehiscence has occurred or is
imminent. In these instances the
retention sutures can be retightened
immediately. I use sterilized plastic
coffee stir sticks inserted under the
suture loops then twisted in tourni
quet fashion. Segments of stiff,
sterile plastic tubing may serve as
well.

Results
I have used the gauze-roll meth
od to pad retention sutures for
several years. Results have been
uniformly satisfactory. Patients find
that the appearance of the scar
after use of this method is infinitely
more acceptable cosmetically than
CJS, VOL. 35, NO. 1, F E B R U A R Y 1992
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FIG. 3. Rolls of padding are placed over retention sutures.
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FIG. 2. Gauze is rolled into pads 2 cm in diameter.

that of wounds treated in the stan
dard manner. Removal of the gauze
rolls from under the retention su
tures is sometimes tedious, especial
ly if blood or discharge from wound
margins has dried and hardened.
But, with a little practice, even
the very hard, dried-out gauze
rolls can be teased out satisfac
torily, and there have been no com
plications.
An incision in which incipient
dehiscence was encountered on re
moval of the gauze rolls is shown in
Fig. 5. Coffee stir sticks were
slipped under the retention sutures
and were then twisted, thus reap
proximating the wound. Reopera
tion to resuture the incision was
avoided.*
16
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FIG. 4. Retention sutures are tied quite tightly over gauze
rolls.
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FIG. 5. Retention sutures have been tightened by using plastic coffee stir sticks in
tourniquet fashion.
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Symposium. Trauma Update: Field Triage
Guidelines and Aspects of Early
Resuscitation — What’s New
1. Field Triage — Help or Hindrance?
D.E. Wesson, MD, FRCSC; R. Scorpio, MD
Field triage protocols have potential benefits in urban trauma systems, but for
optimal effect they must be tailored to local needs and tested in each system for
sensitivity and specificity. They should be implemented only by experienced
physicians and surgeons who can monitor and adjust the protocol when necessary.

Les protocoles de triage sur le terrain peuvent avoir des avantages au sein des
systemes de soin aux blesses en milieu urbain mais, pour exercer un effet optimum,
ils doivent etre ajustes aux besoins locaux et testes dans chaque systeme pour en
mesurer la sensibilite et la specificite. Ces protocoles ne devraient etre mis en
application que sous la conduite de medecins et chirurgiens experim ents, capables
de les contrller et de les ajuster au besoin.

riage is the sorting of individu
al injury victims according to
the severity of injuries that may be
life threatening. When triage occurs
in the prehospital setting it is called
field triage. This implies that there
is a choice of hospitals within a
reasonable time and distance (less
than 30 minutes) of the injury
scene and that one or more hospi-
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tals might be bypassed during the
initial transfer of the patient to
hospital. Therefore triage is only
feasible in urban trauma systems.
Does field triage help or hinder
patient care? The answer to this
question depends on the accuracy
of the triage and on differences in
care delivered at trauma centres and
nontrauma hospitals.
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Early Resuscitation — What’s N ew " by the Canadian Association o f Emergency Physicians and
the Trauma Association o f Canada at the 59th annual meeting o f the Royal College o f
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Accuracy
The main determinants of triage
accuracy are undertriage and overt
riage. Undertriage occurs when pa
tients with life-threatening injuries
are taken to nontrauma centres,
and overtriage occurs when patients
with injuries that are not life threat
ening are taken to designated trau
ma centres. Field-triage protocols
should keep undertriage below 5%
and overtriage below 50% (sensitivi
ty 95%; specificity 50%).'
Field triage is useful because it
minimizes the time from injury to
definitive treatment for patients
with life-threatening injuries and, at
the same time, screens out most
patients with injuries that are not
life threatening, who can be treated
in nontrauma hospitals. This keeps
down the costs of trauma care and
avoids overburdening designated
trauma centres. It is important to
minimize time to definitive treat
ment because about 50% of all
trauma deaths occur in the field and
about 25% within 4 hours of reach
ing hospital.2 Most experts estimate
that only 5% of injury victims in
urban trauma systems will require
level I trauma-centre care. Field
CJS, VOL. 35, NO. 1, F E B R U A R Y 1992

19

WESSON AND SCORPIO

triage must be accomplished by
nonphysicians with limited informa
tion as expeditiously and accurately
as possible. Many methods of field
triage have been described, but they
are all based on two factors: (a) the
judgement of experienced prehospi
tal providers and (b) objective proto
cols using anatomic, physiologic
and incident characteristics.

Differences in Trauma Systems
Each trauma system has unique
characteristics, which include case
load, case mix, training and experi
ence of prehospital providers, re
sources in receiving hospitals,
urban geography and availability of
helicopter transfers. Routine fieldtriage protocols must be adjusted
according to these local factors.
The incident components are
meant to identify injury events with
high-energy transfers that are likely
to cause life-threatening injuries.
The most widely used physiologic
criteria are the Trauma Score (TS)3
and the Glasgow Coma Scale
(CGS).4 The CRAMS scale has also
been tested in several trauma sys
tems and seems to be reasonably
sensitive.5 The Pediatric Trauma
Score (PTS) was designed for chil
dren 0 to 14 years of age.6 The
Revised Trauma Score (RTS) has
largely replaced the TS and has the
advantage that it can be used for
patients of all ages.7 Recently Eichelberger and colleagues8 showed
that the RTS is valid even for
children.

Protocols
The most widely utilized fieldtriage protocol, which uses a combi
nation of criteria, was described by
the Committee on Trauma of the
American College of Surgeons2
20
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(Fig. 1). In Canadian cities, online
medical control from base-hospital
physicians is available only where
paramedic advanced life-support
(ALS) programs exist. This allows
for some flexibility in triage deci
sions, but where ALS programs are
not in place, field triage must be
done by protocol. In this type of
system medical control is still very

STEP 1

important but must be confined to
setting policy, continuing education
of prehospital personnel and quality
assurance.
There are many outstanding
questions and problems in this area.
• What is the definition of a
true positive? Although most
studies have focused on threat to
life, there are other variables that

Measure vital signs and level of consciousness
Glasgow Coma Scale score < 13 or
Systolic blood pressure < 90 mm Hg or
Respiratory rate < 10/min or > 29/min

NO

YES

Assess anatomy of injury
and mechanism of injury
•
___ •
•
•

Take to trauma centre

Penetrating injury to chest, abdomen, head, neck, groin
Two or more proximal long-bone fractures
Combination with burns of > 15%, face or airway
Flail chest

STEP 2

Evidence of high impact
• Falls of 6.7 m or more
• Crash speed (mean velocity) 30 km/h or more
• 75 cm deformity of automobile
■ Rearward displacement of front axle
• Passenger compartment intrusion; 45 cm on patient
side of car, 60 cm on opposite side
• Ejection of patient
• Rollover
• Death of same car occupant
■ Pedestrian hit at 30 km/h or more

NO

YES

Age < 5 or > 55 yr
Known cardiac or respiratory disease
(lowers the threshold of severity, resulting
in need for trauma centre care)

NO
Re-evaluate with
medical control

Take to trauma centre

YES
Consider taking to trauma centre
for moderate-severity injuries

WHEN IN DOUBT TAKE PATIENT TO A TRAUMA CENTRE

FIG. 1. Triage decision scheme.

FIELD TRIAGE

are relevant, such as the need for
specialized services not available at
most general hospitals. This would
include neurosurgery, reimplanta
tion surgery, pediatric critical care
and pediatric surgery.
• Can ALS providers apply
triage guidelines accurately in the
field? This question has seldom
been directly addressed. A recent
study from California9 indicated
that even paramedics often fail to
perform such simple tasks as mea
suring blood pressure, which are
essential to the proper application
of existing protocols.
• Does the triage protocol meet
the sensitivity and specificity stan
dards? This question also has sel
dom been addressed on a system
level. Most studies have concerned
only patients who were transferred
to trauma centres and whose inju
ries were scored on arrival at the
trauma centre and not in the field;
no data have been presented on
patients taken to local hospitals.
These studies are unable to answer
questions on sensitivity.

Comment
What has field triage done for
patient care? The answer is that
there is no convincing proof of any
benefit. But in an era of rationaliza
tion of services, superspecialization
and recognition that a general hos
pital cannot be all things to all
people, field triage in densely popu
lated areas is almost unavoidable.
Field-triage protocols have poten
tial benefits in urban trauma sys
tems, but they must be tailored to
local needs and tested in each sys
tem for sensitivity and specificity.
Field-triage protocols must be im
plemented under the advice and
control of experienced physicians
and surgeons who can monitor and
adjust the protocol whenever neces
sary.
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Medifilms Inc.
announces the release of
METHOD OF LAPAROSCOPIC
CHOLECYSTECTOMY:
a learning-curve videotape
This 67-minute videotape has been produced for Medifilms by
Dr. Steven M. Strasberg, director of the laparoscopic cholecys
tectomy course at the University of Toronto. It is intended for
surgeons who have taken a basic course in laparoscopic
cholecystectomy and are now on the “ learning curve” . It
contains many practical and new technical tips on the safe
performance of this important procedure.
The tape is divided into 11 sections and treats each part of the
procedure in detail. The tape is time-indexed to allow easy
reference to particular sections. Three sections are of particular
interest to all surgeons — “Conclusive Ductal Identification”
shows four strategies for sure identification of the anatomical
structures, “Dissection Techniques in the Triangle of Calot”
shows how each of the laparoscopic instruments is used for
best effect and greatest safety and “Difficult Cholecystecto
mies” takes the viewer through several difficult operations
showing what to do and what not to do in these demanding
cases.
Available to certified surgeons or surgical residents only. Send
$99 plus $8 for regular mail or $23 for FEDEX, plus copy of
office stationary or proof of residency status to Mr. Mark Smith,
Medifilms Inc., 235 St. Clair Ave. W, Ste. 309, Toronto, ON
M4V 1R4.
CJS/MEDFLM

CJS, VOL. 35, NO. I, FEBRUARY 1992

21

1

T

1 1

| n
L H 1 1 u

I

n

T

LEDERLE
SURGICAL
Each year two
fellow sh ips are
offered by Lederle
Laboratories in cooperation with the
Canadian A sso cia tio n o f G eneral
Surgeons. Last year, one award was given

for research in colorectal surgery
and another in
surgical infectious disease. Please join us
in congratulating the successful recipients
of this highly competitive award.

L E D E R L E F E L L O W S H I P IN S U R G I C A L I N F E C T I O U S D IS E A S E
Dr. Francois Flammond
“The Morphology of the Gastro-lntestinal Tract During Sepsis.”
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2. Air Versus Land Transport
of the Critically Injured Patient
Barry A. McLellan, MD, FRCPC*
Trauma patients frequently require transport from the hospital to which they are
admitted initially to a trauma unit for further assessment and management. Canada’s
geography and demography provide unique challenges when transporting the
severely injured patient by air or land. The author describes and compares air and
land transport for the trauma patient. These complementary modes of transport are
an integral part of a comprehensive trauma system.

Les accidentes doivent souvent etre transports de l’hopital les ay ant initialment
regus vers un service specialise de soins pour traumatises, pour fins d’examens plus
pousses et de traitement. Quand il s’agit de transporter un patient gravement blesse
par terre ou par air, la geographie et la demographie canadiennes constituent un
defi de taille. L’auteur decrit et compare le transport des grands blesses par voie
aerienne ou terrestre. Ces modes de transport complementaires sont partie
integrante d’un systeme de soins aux accidentes.

critically injured patient may
need to be transported from
one institution to another, when the
referring hospital’s staffing, space,
equipment or medical expertise are
not optimal.1 In Canada, the majori
ty of trauma results from motor
vehicle crashes, which occur mainly
in rural centres, often many hun
dreds of kilometres from designated
trauma units or tertiary-care facili
ties.2 Canadian geography and de
mography provide unique chal

A

lenges for transporting the multiply
injured patient.
The single most important step
for ensuring successful patient
transfer is appropriate initial assess
ment and stabilization of the patient
before transport. The American Col
lege of Surgeons Advanced Trauma
Life Support Course provides an
excellent framework for the initial
assessment and stabilization of the
multiply injured patient.3 When in
dications for transfer are met, the

From the Sunnybrook Health Science Centre, Toronto, Ont.
Presented as part o f the symposium “ Trauma Update: Field Triage Guidelines and Aspects o f
Early Resuscitation — What’s N e w " by the Canadian Association o f Emergency Physicians and
the Trauma Association o f Canada at the 59th annual meeting o f the Royal College o f
Physicians £ Surgeons o f Canada, Toronto, Ont., Sept. 16, 1990
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Accepted for publication Apr. 8, 1991
Reprint requests to: Dr. B.A. McLellan, Rm. 15, B-Wing, 2075 Bayview Ave., Sunnybrook
Health Science Centre. North York, ON M 4N 3M5

main objective is to transport the
patient as quickly and as safely as
possible, considering the critical
“out of the hospital’’ phase, during
which the patient’s condition is
most likely to deteriorate. Long
distance critical care transport,
whether by land or air, presents a
unique challenge, requiring both
technical and medical expertise.
The decision to transport the seri
ously injured patient by air or land
is based on many factors; these two
modes of transport should be con
sidered as “complementary” and
not “competitive.”

The Transfer Process
The transfer process is outlined
in Fig. 1. Regardless of the mode of
transport used, the patient must
first be assessed, and life-threaten
ing conditions must be stabilized in
the primary care institution. The
criteria for determining whether a
patient requires transfer should be
predetermined for each institution.
The transfer process should be initi
ated as soon as possible after as
sessment of the injured patient. For
example, a patient with a severe
head injury will require assessment
in a neurosurgical facility; in such a
case, the process of transfer can be
initiated very early, while ongoing
resuscitation and investigations are
undertaken at the primary care in
stitution. The sooner physician-tophysician contact can be arranged
CJS, VOL. 35, NO. 1, F E B R U A R Y 1992
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between the sending and receiving
facilities, the sooner an appropriate
land or air vehicle can be made
available for the transfer. During
this period of physician-to-physician
communication, appropriate steps
for stabilization can be planned and
the method of transport (i.e., land
versus air) agreed upon.

Land Versus Air Transport
A number of factors are involved
in deciding how best to transport a
trauma patient (Table I). When pa
tients require transfer over a great
distance, air transport may be the
only reasonable option. If transport
distances are shorter and air vehi
cles are not available, land transport
becomes the only alternative. There
are, however, many cases that fall
into the “ grey zone.” Factors fa
vouring land transport include the
ready availability of land ambu
lances in most circumstances (com
pared with air transport where the
aircraft usually needs to be flown to
the site) and the fact that a second
ary assessment by a paramedic or
transfer crew may not be necessary
(i.e., hospital sends staff already
familiar with the patient’s condi
tion). However, land transport is
slower than air transport, and the
sending hospital will need to dis
patch nursing or respiratory thera
py personnel, or both, to accompa
ny the patient. The need for “aeromedical procedures” prior to trans
port has been mentioned as a factor
favouring land transport.4' 7
Air transport is usually by either
helicopter or fixed-wing aircraft.
The former usually flies at a height
of 1000 m or less above ground,
whereas the latter flies much high
er. It is important to have an under
standing of the type of aircraft used
and the pressurization capabilities
available. There are currently fixedwing aircraft that pressurize to or
24
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used. Some of the negative effects
of altitude specifically related to
transport of a trauma patient are
outlined in Table II.4-7

even below sea level, thereby elimi
nating or reducing the effects of
altitude. In these circumstances, the
effects of trapped gas are mini
mized. The belief that certain proce
dures are necessary simply because
of air transport is usually false. If a
patient has a traumatic pneumotho
rax and requires transfer, placement
of a chest tube is indicated whether
the patient is transferred by land or
air. The need for “prophylactic”
insertion of chest tubes in high-risk
patients should not necessarily be
dictated by the type of transport

T a b le

1. C o m p a r is o n

Sunnybrook Health Science
Centre Air Transport
Experience
The Regional Trauma Unit at
Sunnybrook Health Science Centre
has had experience with the trans
fer of over 3000 trauma patients in
the last 14 years. A dedicated heli-

o f th e A d v a n t a g e s a n d D is a d v a n t a g e s o f L a n d a n d A ir T r a n s p o r t o f T r a u m a
P a tie n ts
Land

A d v a n ta g e s

R e a d ily a v a ila b le

D is a d v a n t a g e s

S l o w e r s p e e d , th e r e fo r e
g re a te r " out o f
h o s p ita l" tim e

A ir

D e c re a s e d “ o u t o f h o s p it a l” tim e
M a y b e fa s t e r o v e ra ll, d e p e n d in g o n d is ta n c e s
a n d t im e to tr a v e l t o s e n d in g h o s p ita l
F r e q u e n t ly s ta ffe d b y p a ra m e d ic s
M a n y d e d ic a te d a irc r a f t h a v e s p e c ia liz e d
t r a n s p o r t e q u ip m e n t (e .g ., p o rta b le
g a s - p o w e r e d v e n t ila t o r s )
L a n d in g s ite m a y b e r e m o v e d f r o m h o s p ita l,
n e c e s s ita tin g la n d t r a n s p o r t b e tw e e n
h o s p ita l a n d a ir v e h ic le a n d a d d itio n a l
p a tie n t t r a n s f e r
P o s s ib le n e e d f o r a e ro m e d ic a l p ro c e d u re s ?
C o m p lic a t io n s o f h ig h - a ltitu d e tr a n s f e r

TRANSPORT OF THE CRITICALLY INJURED

copter operating with Sunnybrook
as the base hospital services an area
with a radius of approximately 300
km. Dedicated fixed-wing aircraft
are available for transport distances
greater than 200 km. Compared
with land transport for which atten
dants are all trained to a basic life
support level, the dedicated air am
bulances in Ontario are most com
monly staffed by paramedics.
A recent study was undertaken of
air-ambulance transport to Toronto
trauma units. Table III outlines the
duration of time from the traumatic
incident to arrival at a Toronto
trauma unit for patients transferred
by air ambulance from July to De
cember 1989. It is notable that the
time is more than 4 hours for these
seriously injured patients. This
delay emphasizes the importance of
early aggressive resuscitation and

stabilization. Selected time intervals
are highlighted. The time from the
original incident until contacting
the Integrated Trauma Program
(the “one number to call” system
used in Toronto for accepting trau
ma patients) is just under IV2
hours. The time from when the call
is received by the Integrated Trau
ma Program to the time when pa
ramedics arrive at the patient’s side
is also close to D/2 hours. This time
includes the physician-to-physician
contact and the time needed to
dispatch the aircraft and travel to
the patient. The time between pa
ramedics assessing the patient and
arrival at a trauma centre is again
just under IV2 hours.
In an effort to streamline the air
transport of trauma patients, a
number of these areas have been
highlighted. The first step has been

Table II. Complications of High-Altitude Transport*
Expansion of gases
Within body cavities or tissues
Pneumothorax
Pneumocephalus
Perforating eye injuries
Gas gangrene
Within equipment
Air splints
Pneumatic antishock garment
Endotracheal cuff
Casts on edematous tissue
Other
Hypoxemia related to lack of oxygen
Decompression sickness for diving-related accidents

to encourage physicians at referring
hospitals to identify patients appro
priate for transfer early after arrival
to reduce the time taken to call the
Integrated Trauma Program. Many
patients can be identified early after
their arrival as requiring transfer to
a trauma unit. When a call is re
ceived by the Integrated Trauma
Program, there are now specific
criteria by which the air ambulance
may be dispatched immediately (i.e.,
before physician-to-physician con
tact) if the sending physician agrees
(Table IV). Through this system the
aircraft may be flying to the prima
ry hospital during the time that the
two physicians discuss the patient’s
condition and determine an appro
priate plan of resuscitation and sta
bilization. During the study period
(July to December 1989), the time
for paramedic assessment at the
scene was 42 minutes. The parame
dics recently have been taught an
abbreviated assessment, which has
reduced this time to under 26 min
utes. Nevertheless, it is evident
that, even in the relatively densely
populated area of south central On
tario, patients may still be arriving
at trauma units “hours” after the
original incident.

Summary

*The decision to transport patients by air depends on their clinical status and other methods of
transport available. Special air vehicles are available, which allow cabins to be pressurized to and
below sea-level values, thereby minimizing or eliminating these high-altitude problems.

Land and air transport (whether
by fixed wing or helicopter) should

Table III. Air Ambulance Transport to Toronto Trauma Units, July to December 1989 (68 Patients)
Median times, min
Traumatic incident
Arrival at hospital #1
Call received at ITP headquarters
Air ambulance arrives at
landing site
Paramedic arrives at patient
Paramedic departs for
hospital
Air ambulance departs from
landing site
Air ambulance arrives
Toronto trauma unit

0
35
51
69
19
42
20
26

Selected time intervals
Time from
incident to
call to ITP,
86 min
Time from
paramedic’s
arrival
to arrival
at Toronto
trauma unit,
88 min

Time from
call to
Toronto
trauma unit
and paramedic’s
arrival,
88 min

Time from
incident to
arrival at
Toronto
trauma unit,
262 min (4 h
22 min)

ITP = Integrated Trauma Program
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Table IV. Criteria for Early Dispatch of the Helicopter
1.
2.
3.
4.

Age > 8 yr* and
Traumatic injury (motor vehicle or recreational vehicle accident, fall from a height etc.) and
Less than 24 h after injury and
Injuries:
to at least two anatomical systems or
head injury with depressed level of consciousness or
spinal cord injury or
extremity injuries with other system injury or
extremity injury with neurovascular compromise or
penetrating injury to chest or abdomen and
5. At least one adult trauma centre open with a status report < 24 h old______________________
'Patients < 8 years old are accepted by the ITP, but the trauma team leader must be contacted
before the air ambulance is dispatched.

not be looked upon as competitive
aspects o f patient transfer. They are
complementary, and each has rela
tive benefits and problems. The goal
is to transfer the trauma patient as
quickly and efficiently as possible
using available resources. In view of
Canadian geography, transport
times will remain prolonged for
many patients, and the initial as

sessment and stabilization of these
patients will continue to have a
marked influence on ultimate pa
tient outcome.

After the Implementation o f a Rapid
Transport System.”
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SESAP VI Critique / Critique SESAP VI
Item 54
Cyst gastrostomy simplifies the management of pseudocysts, which occur in less than 10% of patients after
acute pancreatitis. Two thirds of pseudocysts develop in the head of the pancreas or the uncinate process, thus
providing an effective site for drainage into the stomach by cyst gastrostomy. Operation is usually postponed for
six weeks or more unless the patient develops an abscess requiring urgent drainage. The decision to perform
cyst gastrostomy is based on the location o f the pseudocyst.
External drainage (by percutaneous catheter or celiotomy) is appropriate for infected pseudocysts. This
approach is associated with a high incidence of complications, recurrences, and persistent symptoms. Distal
pancreatectomy may be appropriate for small pseudocysts located in the tail o f the pancreas. Observation with
repeat computed tomographic (CT) scan may be appropriate for small pseudocysts disclosed shortly after an
episode o f acute pancreatitis. Although small pseudocysts sometimes regress, hemorrhage a n d /or abscess
formation remain possibilities. For larger and persistent pseudocysts, a properly timed cyst gastrostomy is the
most appropriate treatment.

—

R e fe re n c e s

5 4 /1 . Frey CF: Pancreatic pseudocyst — Operative strategy. Ann Surg 188: 6 52 -6 6 2 , 1978
5 4 /2 . Schumer W: Cystogastrostomy for pancreatic pseudocyst, in Nyhus LM, Baker RF (eds): Mastery of
Surgery. Boston, Little Brown & Co, 1984, pp 765 -7 69
5 4 /3 . Shatney CH, Lillehei RC: Surgical treatment o f pancreatic pseudocysts. Ann Surg 189: 386 -3 94 , 1979

26

JCC, VOL. 35, N ° 1, FEVRIER 1992

k~

h

CANADIAN ASSOCIATION OF EMERGENCY PHYSICIANS

3. Airway Management in the Blunt
Trauma Patient: How Important
Is the Cervical Spine?
Ron M. Walls, MD, FRCPC
Emergency airway management in the patient with blunt trauma is a clinical
dilemma. Many of these patients require immediate airway management, but each
method carries its own set of risks and benefits. At the heart of the issue is the
long-standing belief that oral intubation is hazardous in the presence of an unstable
injury to the cervical spine. In this article, the issues surrounding selection of an
appropriate technique for airway management are reviewed critically.
Recommendations are made for management of the airway in this high-risk group of
patients with injury to the cervical spine.

Le retablissement d’urgence de la permeabilite des voies respiratoires chez les
victimes de traumatismes fermes est un dilemme clinique. La plupart de ces patients
necessitent un retablissement immediat de la ventilation, mais chaque methode
comporte ses propres risques et avantages. Au coeur du probleme, il y a la croyance
bien ancree que l’intubation est risquee en presence d’une lesion instable de la
colonne cervicale. Dans cet article, les problemes entourant le choix d'une technique
appropriee de retablissement de la permeabilite des voies respiratoires sont revus de
fa$on critique. On propose une serie de recommandations pour retablir la ventilation
chez le groupe a risque eleve des patients souffrant de blessures de la colonne
cervicale.

anagement of the airway in
the victim of blunt, multiple
trauma remains a fundamental and
unresolved controversy. Although
many options for airway manage
ment exist, the three principally
advocated approaches are blind na
sotracheal intubation, oral intuba
tion with “ in-line stabilization’’ and
cricothyroidotomy.
When a particular airway ma-

M

noeuvre is being considered at the
bedside, the advisability or safety o f
that manoeuvre will depend on the
answers to three fundamental ques
tions as follows:
• What are the chances that the
patient has a cervical spine injury?
• If a cervical spine injury is
present, what is the risk o f each
proposed airway manoeuvre?
• What is the standard o f care?
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Presented as part o f the symposium “Trauma Update: Field Triage Guidelines and Aspects o f
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Incidence of Cervical Spine
Injury
Several authors1"5 have attempt
ed to correlate the presence of
cervical spine injury with certain
physical markers or patient attri
butes to identify prospectively pa
tients at risk for movement o f their
cervical spine. Sinclair and col
leagues1 studied 1050 blunt-trauma
victims to analyse the relation be
tween facial fracture and cervical
spine fracture. In their series, 62
patients (6%) had a cervical spine
fracture. Of the 168 patients with a
facial fracture, 7 (4%) had a cervical
spine fracture. Therefore, the inci
dence o f cervical spine fracture
among patients with facial fractures
was identical to that in the general
trauma population studied. McCabe
and Angelos2 showed that 43 o f 81
patients with cervical spine fracture
had no clinical evidence o f soft-tis
sue injury to the head or neck. In a
series from Northwestern University
and the Maryland Shock Trauma
System,3 almost 81% (982) o f pa
tients with proven cervical spine
injuries had no facial injury. Of 67
patients with a cervical spine injury
studied by Walter, Doris and Shaf
fer,4 31 (46%) had no evidence of
head or facial injury. Finally, Jacobs
and Schwartz5 attempted to identify
prospectively patients w ho would
have evidence o f injury on their
cervical spine x-ray films by a de
tailed questionnaire completed at
the time the film was ordered. In
CJS, VOL. 35, NO. 1, FEBRUARY 1992
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this series, of 233 patients x-rayed,
24 had cervical spine fractures.
Twelve of these were correctly iden
tified by prospective criteria, result
ing in a sensitivity of 50%.5
Numerous other studies have
corroborated the inability to identify
patients with cervical spine frac
tures by clinical criteria.

What Is the Risk of Each
Airway Manoeuvre?
Controversy continues to rage
concerning the relative safety of
each airway approach. In a land
mark editorial, Rosen and Wolfe6
questioned the existing dogma that
it is unsafe to intubate orally a
patient with an injured cervical
spine and challenged others to pre
sent irrefutable evidence of the dan
gers of this manoeuvre. In 1988,
Bivens and colleagues7 studied 17
victims of blunt trauma arrest and
found 4 who had unstable cervical
spine injuries. In a radiologically
assessed autopsy study, they ob
served 5 to 26 mm of distraction
and subluxation when oral endotra
cheal intubation was attempted with
traction on the cervical spine. Inter
estingly, it appears that the traction
itself was the principal cause of the
cervical spine shift, not the actual
intubating manoeuvre. Majernick
and associates8 studied cervical
spine movement during intubation
in 16 normal patients who under
went general anesthesia. They ob
served that oral endotracheal intu
bation resulted in significant move
ment of the cervical spine and that
this movement was reduced dramat
ically by in-line immobilization.
However, by their measurement, a
3.6-mm shift in the bony vertebral
column occurred in these complete
ly normal subjects during con
trolled elective anesthesia. Apprahamian and colleagues9 created
a surgical model of cervical spine
28
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instability by sectioning all of the
supporting ligaments at C5-6 with
out inflicting any muscle damage.
They observed that oral endotrache
al intubation caused a dramatic
shift in the bony cervical column
and that this situation was not
improved when the spine was
placed in a semi-rigid cervical col
lar. They also observed, in this
limited study, that nasotracheal in
tubation appeared to result in insig
nificant movement of the cervical
spine.
Applicable clinical studies are
scarce. Rhee and colleagues10 stud
ied 237 blunt trauma patients and
found cervical spine injuries in 21
patients. Of these, 17 had oral
endotracheal intubation, 2 had na
sotracheal intubation and 2 had
cricothyroidotomy. They reported
no increase in neurologic deficit in
any of these patients when compar
ing their neurologic status before
and after the airway manoeuvres.
Unfortunately, it is not clear from
the study how many of the 17
patients who were intubated orally
underwent full neuromuscular
blockade, which is the general ap
proach taken in a trauma room. In
addition, of the 17 orally intubated
patients, 8 were quadriplegic before
the airway manoeuvre was under
taken, so the real study group can
not be considered to be larger than
9 patients. Two of these nine pa
tients had isolated fractures of the
spinous process, one had a posteri
or fracture of the ring of Cl and
one had a Hangman’s fracture, so it
might be argued that the actual
number of patients with potentially
unstable cervical spines that were
intubated in this series was only
five. Holley and Jorden,11 from the
University of Mississippi, studied
133 patients with 140 unstable cer
vical spine fractures as defined by
Panjabi, Pelker and White.12 One of
these patients was intubated orally
in the field, 9 were intubated by a

blind nasotracheal approach in the
emergency department and 123
were intubated in the operating
room. Of these 123 patients, 94
underwent nasotracheal intubation
awake and 29 underwent oral endo
tracheal intubation awake. Al
though the study was retrospective,
it appeared that there was no
change in neurologic deficit in any
of these patients due to the airway
manoeuvres. All of these patients
were stabilized “by an assistant.”
The unfortunate limitation of this
study was that all the patients were
intubated while they were awake or
under semielective or fully elective
circumstances in the operating
room. Again, extrapolation of these
data to the trauma room, where
patients are rarely intubated while
awake, may not be valid.
There are virtually no data, other
than Apprahamian’s study9 and a
wealth of clinical experience, to
demonstrate convincingly that ei
ther nasotracheal intubation or sur
gical cricothyroidotomy are safe in
the patient with an unstable cervical
spine. In fact most of the argument
against emergency cricothyroidoto
my has been with its complication
rate, as reported initially by McGill,
Clinton and Ruiz in 1982.13 In this
series of 38 cricothyroidotomies
from the Hennepin County Medical
Center, a complication rate of 40%
was reported. Although this study
is frequently quoted, careful analy
sis of the indications and complica
tions for this procedure reveal a
number of shortcomings in this
retrospective report. The authors
themselves recognized these short
comings and published a second
series of 39 cricothyroidotomies in
1989.14 In the latter series, the
complication rate dropped to 23%,
and in none of these cases was
there a long-term adverse event or
failure to secure the airway. The
authors speculated that the changes
in complications between their first
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and second series were due to en
hanced attending supervision, use
of a no. 4 Shiley tracheostomy tube
only, mandatory vertical skin inci
sion and enhanced use of percuta
neous transtracheal ventilation as a
temporizing measure.14 At the Van
couver General Hospital we per
formed 13 emergency cricothyroidotomies between July 1987
and December 1989 (unpublished
data). There were two emergency
tracheotomies for emergency airway
control, but these were undertaken
in the operating room. Of the 13
cricothyroidotomies, 12 were for
traumatic conditions, including
failed oral endotracheal intubation
with in-line stabilization, failed na
sotracheal intubation with in-line
stabilization, facial smash or ob
struction of the upper airway and
severe multiple trauma with un
known cervical spine status. Four
patients sustained complications,
three of which were insignificant —
two had slowly healing wounds and
one had a cuff leak. In one patient,
after initial stabilization of the air
way with a cricothyroidotomy, there
was a ventilatory failure. This ne
cessitated removal of the crico
thyroidotomy tube and oral endo
tracheal intubation in the operating
room.
Our complication rate of 23%
was comparable to that noted by
Erlandson and colleagues.14 There
have also been two published series
of prehospital cricothyroidoto
my.15’16 In one of these series15 of
20 patients the complication rate
was 0%. In the second series, a
review of 16 cricothyroidotomies,
there was a 12% failure rate and a
3% complication rate overall.16 The
actual safety of surgical crico
thyroidotomy in the hands of those
with limited skill is unknown. It
appears, however, that the proce
dure can be performed quickly and
safely by those with appropriate
training.13-16

What Is the Standard of Care?
Numerous a u th o rs6-8' 1011' 1718
have attempted to editorialize on
the impact of these studies. When
one dispenses with all of the rheto
ric, a few central principles become
clear.
• Axial traction should not be
used as a stabilizing manoeuvre for
the potentially injured cervical
spine. The correct technique is to
immobilize the cervical spine and
maintain the existing relationship
between the head and the neck and
between the neck and the body
without the application of traction.
This will always require the pres
ence of a second person in addition
to the physician performing the
intubation. The sole function of this
second person is to provide immobi
lization during airway management.
• Although considerations of
cervical spine injury are extremely
important, airway management is
paramount. Failure to obtain an
airway because of theoretical con
siderations of cervical spine injury
is not acceptable. Instead the opera
tor must ensure that immaculate
cervical spine stabilization is under
taken throughout the course of any
airway manoeuvre and that the
highest degree of skill and responsi
bility is used to perform the ma
noeuvre itself.
• There is no solid support for
any one approach over another.
Therefore the operator is the cru
cial variable.

Conclusions
In my review of the literature
that attempts to address this con
troversy and as a result of personal
experience in four major trauma
centres, I believe that the standard
of care in the blunt, multiple trau
ma patient is as follows: given the
exact circumstances of the patient’s

injury, the hospital in which the
patient is received, and the training
and experience of the physicians
and surgeons available to care for
that patient on that occasion, the
airway manoeuvre selected should
be the one that will optimize the
patient’s prospects for a good out
come, minimize the possibility of
serious adverse consequences or
complications and be capably per
formed in a timely and efficient
manner. No further statement can
be made about the superiority or
inferiority of one technique over
another with respect to the issue o f
safety in the context o f the poten
tially injured cervical spine.
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4. Small-Volume Resuscitation
L. Dontigny, MD, FRCSC, FACS*
Small-volume resuscitation with hypertonic saline is an attractive modality but is
still at an early stage of experimental and clinical investigation. Aggressive
resuscitation from traumatic, hypovolemic shock could be facilitated during the
prehospital phase, but hypotension remains a physiological and beneficial
compensatory mechanism to minimize active bleeding until definitive care is
provided. Despite encouraging results, the author concludes that, at present,
hypertonic saline cannot be considered a truly “magic potion” for resuscitation of
the trauma patient.
La reanimation a l’aide de petits volumes d’un solute sale hypertonique represente
une modalite interessante mais elle reste aux stades precoces des essais
experimentaux et cliniques. Une reanimation agressive d’un choc traumatique
hypovolemique peut etre facilitee pendant la periode prehospitalisation, mais
l’hypotension demeure un mecanisme compensatoire physiologique benefique pour
minimiser l’hemorragie en attendant que des soins plus importants puissent etre
administres. En depit de resultats encourageants, l'auteur conclut que, pour
l’instant, le solute sale hypertonique ne peut etre considere comme une vraie
«potion magique».

fluid replacement
A ggressive
with large volumes remains the

gold standard in the management of
hypovolemic shock from trauma.
During and after World War I saline
was used to correct hypovolemia,
and this allowed investigators and
clinicians to understand better the
physiology of acute volume deple
tion and to prevent renal failure.
There has been some experimental
work on hypertonic solutions since
1960, but until recently nobody
could envisage the resuscitation of

human beings with sea water with
out catastrophic consequences to
the blood and other organ tissues.
De Filippe and colleagues from
Sao Paulo, Brazil,1 were the first to
carry out a clinical study on hyper
tonic saline for resuscitation. They
used 7.5% sodium chloride to resus
citate 12 patients in hypovolemic
shock who were unresponsive to
current treatment. The shock state
was reversed in 11 patients, and 9
of them survived to be discharged
from the hospital. This 25% mortal

Presented as pa rt o f the symposium “ Trauma Update: Field Triage Guidelines and Aspects o f
Early Resuscitation — What’s N ew ” by the Canadian Association o f Emergency Physicians and
the Trauma Association o f Canada at the 59th annual meeting o f the Royal College o f
Physicians and Surgeons o f Canada, Toronto, Ont., Sept. 16, 1990
*Clinical professor o f surgery, Universite de Montreal, Hopital du Sacre-Coeur, Montreal, Que.

ity, compared with a virtual 100%
mortality usually experienced, sti
mulated research into the use of
hypertonic saline.
What makes this new approach
so attractive during the constricted
time frame of prehospital trauma
management is the fact that ade
quate resuscitation can be accom
plished with small amounts of fluids
through regular peripheral intrave
nous lines in just a few minutes.

Pathophysiology
Acute sodium load in the vascu
lar compartment creates an osmotic
pressure that leads to cell dehydra
tion. On the other hand hypovolem
ic shock induces an obligatory extravascular sequestration that leads,
most likely through failure of the
sodium pump, to intracellular mobi
lization of sodium and water and
then to cell edema. At the risk of
oversimplification, the sodium load
from hypertonic saline merely coun
teracts cellular edema of the shock
state, thus avoiding cell dehydra
tion (Fig. 1). Several concentrations
have been tried (Table I), but 7.5%
sodium chloride in 6% dextran 70
seems to confer the greatest benefit
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FIG. 1. Action of hypertonic saline in
resuscitation.
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without the detrimental effects of
higher concentrations. The action is
very limited in time, but the addi
tion of a plasma expander will main
tain intravascular fluid mobilization
for up to 60 minutes.

Beneficial Effects (Table II)
The basic mechanism of smallvolume resuscitation with hyperton
ic saline is the intravascular mobili
zation of fluids, with increased

blood pressure and cardiac output,
and with decreased vascular resist
ance.2 The typical response of the
mean arterial pressure after experi
mentally induced hemorrhagic
shock is represented schematically
in Fig. 2. The control animals re
main in shock until large volumes
of conventional crystalloids are giv
en. In the treatment group, hyper
tonic saline and dextran infusion
results in an immediate increase in
the blood pressure to normal levels,
which are maintained until conven
tional therapy is initiated. Also a

mm Hg

FIG. 2. Response of mean arterial pressure in experimentally induced hemorrhagic
shock to administration of hypertonic saline infusion (solid line) and infusion of
Ringer’s lactate solution (control, broken line). Hatched bar = infusion time (mean
2 min).
Table 1. Osmolarity of Hypertonic Solutions
Solution
1.8% NaCI
3% NaCI
5% NaCI
7.2% NaCI
7.5% NaCI
10% NaCI
7.5% NaCI/4.2%
dextran 70
7.5% NaCI/6%
dextran 70
7.2% NaCI/10%
dextran 60
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Na+,
mmol/L

Cl ,
mmol/L

Osmolality,
mOsm/kg

308
513
855
1232
1283
1711

308
513
855
1232
1283
1711

616
1027
1710
2464
2567
3422

1283

1283

2567

1282

1283

2567

1232

1232

2464
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much smaller amount of crystalloid
is required in the treated group.
Other beneficial effects are specula
tive, but increased regional flow has
been demonstrated with improved
kidney function3 and brain perfu
sion.4 Clinical data also suggest an
increased survival rate.5

r

Potential Adverse Effects
(Table III)
Several problems have been an
ticipated but have not materialized.
The most notable manifestations of
acute hypernatremia and hyperos
molar disorders are neurologic
ones, primarily a consequence of
cellular dehydration.6 Restlessness,
irritability, lethargy, muscular
twitching, hyperreflexia and spastic
ity may occur and culminate in
coma, seizures and death. Although
these manifestations could occur
after rapid infusion of hypertonic
solutions, the clinical picture ap
pears to be time dependent in terms
of hours if not days. The highly
concentrated solution (2400
mmol/L) is well tolerated, and vein
thrombosis or tissue necrosis from
extravasation has not been report
ed. The possible anaphylactic reac
tion related to the use of small
amounts of dextran seems to be
Table II. The Beneficial Effects of
Hypertonic Saline-Dextran Infusion
Increased systemic pressure
Increased cardiac output
Decreased systemic vascular resistance
Increased regional flow
Increased urine output
Sustained effect
Increased survival rate

Table III. Potential Adverse Effects of
Hypertonic Saline-Dextran Infusion
Vein thrombosis
Local necrosis (extravasation)
Anaphylactic reactions
Hypervolemia
Extravascular lung water
Increased intracranial pressure
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neutralized by the endogenous epi
nephrine reaction due to shock.
The high sodium load with overhy
dration in certain situations, such
as in elderly patients with poor
cardiac function or overestimation
of fluid loss, has to be considered as
a potential danger clinically. In
creased lung water with a lower
partial pressure of oxygen and a
higher shunt fraction does not seem
to follow intravascular fluid mobili
zation.7 Finally a recent experiment
using a porcine model of shock
associated with brain injury has
shown that hypertonic resuscitation
increased cerebral blood flow and
lowered intracranial pressure.4

Clinical Experience in Trauma
The first clinical paper in which
7.5% sodium chloride and dextran
70 was used for resuscitation of
trauma patients was reported re
cently by Maningas and colleagues.8
Forty-eight patients with penetrat
ing injuries and a prehospital sys
tolic blood pressure of 90 mm Hg
or less were selected prospectively
and given, on the scene, either 250
mL of crystalloid plasma expander
(group 1) or 250 mL of hypertonic
saline-dextran (group 2). The ulti
mate survival of 80% in group 1 (20
of 25) and 87% in group 2 (20 of
23) does not reach statistical signif
icance, considering also that most
of the patients who died presented
with unsalvageable lesions. On the
other hand the two groups were
perfectly comparable with respect to
trauma score, injury severity score
and total prehospital time, includ
ing response time on the scene and
transport time. The protocol was
adhered to the letter — all patients
had an intravenous line placed, the
250 mL of fluid was administered in
a mean period of 2 minutes and
there was no interference with
transfer to the hospital. The

amount of blood required later for
successful resuscitation was less in
the group receiving hypertonic sali
ne-dextran. No complications were
encountered. This encouraging re
port is also supported by other
series, including the pioneering
work of Holcroft and colleagues in
California.5

The “Uncontrolled”
Hemorrhage Concept
Recently a group of investigators
in Jerusalem, Israel, conducted a
research study in dogs comparing
“controlled” with “uncontrolled”
hemorrhagic shock from induced
intra-abdominal bleeding.9 During
the shock state, resuscitation was
achieved with hypertonic saline. In
the “controlled” hemorrhage situa
tion the bleeding was stopped dur
ing resuscitation, and hemodynamic
parameters were immediately im
proved. On the other hand, in the
“uncontrolled” hemorrhage situa
tion, intra-abdominal bleeding was
maintained during resuscitation
with hypertonic saline, and the he
modynamic parameters further de
teriorated leading to early death. It
is speculated that the beneficial ef
fects of hypertonic saline resuscita
tion with increased blood pressure
and cardiac output, together with
peripheral vasodilation, will increase
blood loss from continuing internal
bleeding and lead to irreversible
shock and death. The condition of
multiple trauma patients in shock
should be considered as “uncon
trolled” until proven otherwise.

investigation. Aggressive resuscita
tion from traumatic hypovolemic
shock could be facilitated during
the prehospital phase, but hypoten
sion remains a physiological and
beneficial compensatory mechanism
to minimize active bleeding until
definitive care is achieved. Despite
encouraging results, we cannot
conclude yet that small-volume hy
pertonic saline is a true “magic
potion” in the resuscitation of trau
ma patients.
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5. Traumatic Intracranial Mass Lesions:
How Soon for Evacuation?
R.J. Moulton MD, FRCSC
The purpose of this paper is to identify, by simple clinical parameters, those
patients who are at particular risk for traumatic intracranial hematomas following
accidental injury and to review the effects of delays in treatment on death from head
injury. The findings indicate that vehicle occupants 30 years of age or younger are
significantly (p < 0.001) more likely to suffer from a “diffuse” head injury and
serious truncal injury than they are to suffer a traumatic intracranial mass lesion.
Conversely, older patients (60 years of age or older) injured in falls are more likely
to have operable intracranial mass lesions without significant injury to the torso (p
< 0.001). Recommendations concerning early diagnosis and treatment of accident
victims are made from these data.

Le but du present article est d’identifier, a partir de parametres cliniques simples,
quels sont les patients qui sont particulierement a risque de presenter un hematome
intracranien traumatique suite a une blessure accidentelle, et d’etudier les effets
d’un delai de traitement sur les deces resultant d’un traumatisme cranien. Les
resultats indiquent que les occupants d’un vehicule ages de 30 ans ou moins sont
significativement (p < 0,001) plus susceptibles de souffrir d’un traumatisme cranien
«diffus» et de serieuses blessures thoraciques que d’un hematome
intracranien traumatique. Au contraire, les patients plus ages (60 ans ou
plus) blesses dans des chutes sont plus susceptibles de presenter une masse
intracranienne operable sans blessure importante au thorax (p < 0,001). Des
recommandations relatives au diagnostic precoce et au traitement des victimes
d’accidents sont tirees de ces donnees.

raumatic intracranial mass le
sions are extradural, subdural
and intracerebral hematomas (or
contusions) that are sufficiently
large to jeopardize the patient’s life
or neurologic function. They may
exert direct pressure on adjacent
brain parenchyma or alter intra
cranial pressure-volume dynamics,
causing remote effects from brain
shifts. Uncal and tonsillar hernia
tion are the most common of these
remote effects. It is important to

T

recognize and treat intracranial
mass lesions because the distur
bance in brain function that is due
to mass effect is potentially revers
ible for some time after injury,
whereas the dysfunction attribut
able to immediate impact damage is
not treatable. Consequently, a prin
cipal goal of the management of
head injury is the prompt diagnosis
and earliest possible surgical eva
cuation of mass lesions. This may
seem straightforward, but the issue

is considerably complicated because
often it is impossible to judge pre
cisely how much of an, individual’s
neurologic injury is the result of a
mass lesion and how much is the
result of the coexisting immediate
impact injury.1 Further, the tempo
ral relationship between the onset
of intracranial bleeding and irrevers
ible brain damage varies considera
bly between patients, making it dif
ficult to establish a “ golden” inter
val for operative evacuation of a
mass. In cases involving or poten
tially involving trauma to other
organ systems, priorities must be
set, often from limited clinical infor
mation, for the investigation and
management of all the patient’s
injuries. This may force a delay in
the diagnosis and treatment of in
tracranial masses. On the other
hand, focusing on the possible pres
ence of an intracranial mass to the
exclusion of other injuries may re
sult in preventable morbidity and
mortality from life-threatening inju
ries to other body systems.2
In this paper I will focus on two
aspects of the management of pa
tients with head injury: recognition
of those patients with a head injury
who are at particular risk for intra
cranial hematomas and the effect of
delay in transfer to a neurosurgical
centre on the outcome of head
injury.
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Incidence of Traumatic
Intracranial Mass Lesions
Among adult head-injury patients
admitted to hospital in coma (Glas
gow Coma Scale [CCS] score < 8),
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the rate of operable intracranial
mass lesions varies from 30% to
50%.3-5 In my institution 46% of
comatose patients and 28% of all
patients admitted to hospital after
receiving a head injury have opera
ble intracranial mass lesions. Most
of these are acute subdural hemato
mas (present in 74% of patients
with operable mass lesions). Often
mass lesions coexist. The most fre
quent combination is an acute sub
dural hematoma accompanying a
cerebral contusion.
At St. Michael’s Hospital, we
have identified several clinical pre
dictors of intracranial mass lesions.
These are as follows: injury by
falling, the severity of the neurolog
ic injury (measured by the GCS
score), increasing age and the pres
ence of pupillary-size asymmetry on
initial neurologic examination.6
Head injury to motor vehicle occu
pants and injury to younger pa
tients are significantly less likely to
result in an intracranial hematoma.
Forty-seven percent of all patients
who received a head injury in a fall
had an intracranial mass lesion. The
rate was 13% for patients who were
vehicle occupants. Other injuries
were intermediate in their associa
tion with intracranial mass lesions.
Falls and injuries to vehicle occu
pants are important not only for the
wide range in rate of mass lesions
but also because they account for
most blunt head injuries.
Increasing age is also a signifi
cant (p = 0.0000) predictor of the
presence of an intracranial mass
lesion. Older patients are more like
ly to sustain an intracranial mass
lesion from all causes and at all
levels of severity of injury.
The same relationships do not
appear to exist with respect to
serious torso injury and age and
mechanism of injury. Among 646
admissions to our trauma unit, the
incidence of severe torso injury was
not significantly different for age or
36
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cause. Only tachycardia and hypo
tension were predictive of serious
torso injury.7 However, because of
the strong relationship between the
presence of an intracranial mass
lesion and injury type, injury severi
ty and age, one may distinguish
with a fair degree of accuracy,
patients who are at particular risk
for an intracranial mass lesion from
those who are more likely to have
diffuse head injury and injury to
other major organ systems (Fig. 1).

Impact of Treatment Delay on
Mortality From Intracranial
Mass Lesions
The role of treatment delay with
respect to death from head injury in
general, and mass lesions in partic
ular, remains controversial. Delay in
the treatment of intracranial mass
lesions is the leading cause of death
in patients who “talk and die” after
a head injury.8 Yet delay in the
treatment of these patients is most
often the result of a failure of
timely diagnosis of a mass lesion
rather than delay in the transporta

tion of a head-injured patient. Also
these patients represent a special
subset of head-injury patients in
that they have sustained relatively
little impact injury, and their neuro
logic deficit is almost exclusively
due to an expanding mass. The
more typical patient with a mass
lesion is unconscious from the time
of injury, and the effects of the
mass lesion are added to those of
diffuse injury, so that the potential
for recovery is not completely de
pendent on prompt evacuation of
the intracranial mass. Jennett and
colleagues3 addressed the issue of
delay in treatment and head-injury
mortality in 1977. Despite widely
varying transportation times to neu
rosurgical units in three different
countries, the death rates from
head injury were strikingly similar.
This series was not specific to pa
tients with mass lesions. Many
other important variations in treat
ment from one centre to another
were also uncontrolled. A priori,
one would not expect delayed ad
mission to a neurosurgical unit to
have a significant impact on the
death rate from “diffuse” head inju-

FIG. 1. Percentage incidence of severe injury to chest, abdomen and pelvis (light
dotted bars) versus incidence of intracranial mass lesions (dark dotted bars) in four
injury population categories. Actual incidence is shown at top of each bar. All
differences are significant (p < 0.001, y} goodness of fit). GCS = Glasgow Coma
Scale score.

TRAUMATIC INTRACRANIAL MASS LESIONS

ry provided patients have adequate
airway management (intubation and
ventilation of comatose patients)
and proper management of other
systemic insults (hypotension, ane
mia etc.).
Delay in operation has been
shown to have a major impact on
deaths from extradural hemato
mas.9 However, as with patients
who “talk and die,” those with
isolated extradural hematomas form
a relatively small fraction of pa
tients with head injury, so the re
sults cannot be applied to most
patients with head injuries and
mass lesions. Also, as in the case of
patients who “talk and die,” most
delays were in recognizing the exis
tence of the hematoma rather than
in transportation time per se. Seelig
and colleagues10 examined mortality
in 100 consecutive patients admit
ted with acute subdural hematomas
and found a significant reduction in
mortality in those who had evacua
tion of their hematomas within 4
hours of injury. Unfortunately this
result has not been duplicated in a
subsequent series.11 A logistic anal
ysis of 400 consecutive admissions
to our neurosurgical unit failed to
show any independent effect of
transfer delay on the death rate
after acute head injury.12 The analy
sis was controlled for the presence
or absence of intracranial mass le
sions, injury severity, age and pres
ence of injury to other organ sys
tems. The reasons for this failure to
demonstrate an element of time
dependence on mortality have al
ready been discussed.

Conclusions
It is possible to some extent, on
the basis of limited clinical informa
tion, to identify patients who are at
particular risk for an intracranial

mass lesion, particularly older pa
tients injured in falls. Conversely,
young vehicle occupants are more
likely to sustain diffuse head injury
and injury to other major organ
systems. Also we could not show a
difference in mortality between pa
tients admitted directly to our neu
rosurgical unit after head injury
and those treated and stabilized
initially at another centre. An in
crease in mortality related to de
layed treatment in patients who
deteriorate after head injury is more
often the result of delay in diagno
sis than a delay in transportation.
Therefore, there is no justification
for “shortchanging” the manage
ment of life-threatening systemic
injuries in the interest of the earli
est possible admission to a neuro
surgical unit. On the basis of the
above findings, the following rec
ommendations are warranted:
• In young (less than 30 years)
patients involved in vehicular trau
ma, attention should first be direct
ed to diagnosis and emergent man
agement of life-threatening injuries
to the chest, abdomen and pelvis.
Investigation and treatment of in
tracranial injuries, including trans
fer to a neurosurgical unit, should
wait until the patient is systemically
stable.
• Older patients injured in falls
are more likely to be suffering from
operable intracranial hematomas,
and attention should be directed to
diagnosis and treatment of the head
injury at a very early stage. In a
patient with stable vital signs, in
vestigation of the central nervous
system injury should take prece
dence. Patients older than 60 years
who have lost consciousness be
cause of a fall should undergo com
puted tomography.
• Patients who suffer a marked
deterioration in their neurologic
status after injury and have not

suffered a seizure, almost certainly
have an intracranial mass, and
should be managed accordingly.
• All patients with an insecure
airway or unstable vital signs
should be managed according to
the “ABCs” of trauma management
regardless of the relative likelihood
of an intracranial hematoma.
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The first
major advance
in the
treatment of
DukesrD
colorectal
cancer in
30 years

Leucovorin plus 5-FU is an
effective therapy that offers
superior response rates and
significant palliative benefits16
*advanced, metastatic or recurrent disease

Significantly improved patient
response compared to 5 -F U alone
In a number o f clinical trials16, 30 to 4 4 % o f
patients responded in the Leucovorin followed
by 5-F U treatment groups versus only 7 to 1 3%
of patients in the groups receiving 5 -F U alone.1"6

Leucovorin plus 5 -F U is generally
well tolerated by patients
The dose-limiting toxicities, oral mucositis and
diarrhea are generally manageable and reversible,
but should be carefully monitored in elderly
or debilitated patients.5 Myelosuppression,
though evident, is not troublesome.3

Improved therapeutic index
Although Leucovorin may enhance the toxicity
of 5-FU , it also significantly increases the
efficacy of 5-FU , resulting in an improved
therapeutic index.12-5

Significant palliative benefits
compared to 5-F U alone
Leucovorin plus 5-F U is associated with signi
ficant improvements in performance status
(measured on the EC O G scale) and symptoms,
which are associated with an improved quality
of life.2And, despite an increase in m ucosal tox
icity, weight gain was also more com m on in the
Leucovorin plus 5 -F U arm1-2, indicating a possible
overall improvement in patient well-being.1
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The first major advance in the treatment of
Dukes' D colorectal cancer in 30 years12
SINCE LEUCCJVORIN MAY ENHANCE THE TOXICITY OF FLUOROURACIL, LEUCOVORIN/ FLUOROURACIL COMBINATION
THERAPY FOR ADVANCED COLORECTAL CANCER SHOULD BE ADMINISTERED UNDER THE SUPERVISION OF A PHYSICIAN
EXPERIENCED IN THE USE OF ANTIMETABOLITE CANCER CHEMOTHERAPY. PARTICULAR CARE SHOULD BE TAKEN IN THE
TREATMENT OF ELDERLY OR DEBILITATED COLORECTAL CANCER PATIENTS AS THESE PATIENTS MAY BE AT INCREASED
RISK OF SEVERE TOXICITY. DEATHS FROM SEVERE ENTEROCOLITIS, DIARRHEA AND DEHYDRATION HAVE BEEN REPORTED
IN ELDERLY FATIENTS RECEIVING LEUCOVORIN AND FLUOROURACIL. CONCOMITANT GRANULOCYTOPENIA AND FEVER
WERE PRESENT IN SOME BUT NOT ALL OF THE PATIENTS.

ACTIONS, CLINICAL PHARMACOLOGY
LEDERLE LEUCOVORIN Calcium (calcium folinate), the calcium salt of folinic acid (citrovorum factor), is a mixture of the
diastereoisomers of the 5-formyl derivative of tetrahydrofolic acid. The biologically active component of the mixture is the (-)-Lisom er It is a metabolite of folic acid and an essential coenzyme for nucleic acid synthesis
LEUCOVORIN is a reduced form of folic acid, which is readily converted to other reduced folic acid derivatives (e g .
tetrahydrofolate). Because it does not require reduction by dihydrofolate reductase as does folic acid, LEUCOVORIN is not affected by
blockage of th is enzyme by folic acid antagonists (dihydrofolate reductase inhibitors). This allows purine and thym idine synthesis,
and thus DNA, RNA, aid protein synthesis, to occur LEUCOVORIN may lim it METHOTREXATE action on normal cells by competing
w ith METHOTREXATE for the same transport processes into the cell. LEUCOVORIN rescues bone marrow and gastrointestinal cells
from METHOTREXATE but has no apparent effect on pre-existing METHOTREXATE nephrotoxicity.
LEUCOVORIN is extensively converted to 5-methyltetrahydrofolate in the intestine prior to absorption. In this form, it is a major
com ponent of the total active human serum folate. Oral absorption is saturable at doses above 25 mg.
LEUCOVORIN enhances the cytotoxicity of fluoropyrimidines such as 5-fluorouracil (5 FU) by their metabolites, methylene
tetrahydrofolate and fluorodeoxyuridine monophosphate, forming a stable ternary complex with thymidylate synthase, and thereby,
decreasing intracellular levels of that enzyme and the product thymidylate. The cell then dies as a result of thym ine starvation.

INDICATIONS

rapidly eliminated in the urine.
Folic acid has low acute and chronic toxicity in man. No adverse effects have been noted in adults after the ingestion of 400 mgAiay
for 5 months or 10 mg/day for 5 years.
Excessive amounts of LEUCOVORIN may nullify the chemotherapeutic effect of folic acid antagonists.

DOSAGE AND ADMINISTRATION
LEDERLE LEUCOVORIN Calcium for Injection cryodesiccated powder 50 m g/vial and 350 mg/vial may be used after reconstitution
for intravenous or intramusculuar administration. The liquid injection 350 m g/35 mL is used for intravenous or intramusculuar
administration.
When LEDERLE LEUCOVORIN Calcium is used for LEUCOVORIN pre-treatment followed by 5-fluorouracil (5 FU) in the treatment
of patients with advanced colorectal cancer intravenous adm inistration is employed.
Because of the Ca++ content of LEUCOVORIN solutions, no more than 160 m g of LEUCOVORIN should be injected intravenously
per minute.

Dosage
Advanced Colorectal Cancer
LEUCOVORIN is administered a 200 m g /n f by slow intravenous injection immediately prior to dosing with 370 m g /n f 5 FU
(fluorouracil) by slow intravenous injection, for five consecutive days.
This 5 day treatment course may be repeated at 4 week (28 day) intervals, provided that the patient has completely recovered from
the toxic effects of the prior treatment course.
In subsequent treatment courses, the dosage of fluorouracil should be adjusted based on patient tolerance of the prior treatment
course. The daily dosage of fluorouracil should be reduced by 20% for patients who experienced moderate hematologic or
gastrointestinal toxicity in the prior treatment course, and by 30% for patients who experienced severe toxicity. For patients who
experienced no toxicity in the prior treatment course, fluorouracil dosage may be increased by 10%. LEUCOVORIN dosages are not
adjusted for toxicity.

For pre-treatment followed by 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal
cancer

STABILITY AND STORAGE RECOMMENDATIONS
LEUCOVORIN Calcium Injection (350 mg/35 mL)

CONTRAINDICATIONS

Vials of 350 mg/35 m L liquid should be stored at refrigerated temperatures (2-8*C). The liquid formulation should be used
immediately once removed from refrigeration. Discard any unused portion. Not for multidose use. The liquid formulation when
diluted with one of the recommended diluents for intravenous infusion should be used within 24 hours following dilution when
stored at room temperature (15-30°C).

Not to be administered for the treatment of pernicious anemia or other megaloblastic anemias where Vitamin Bc is deficient.
A hem atologic remission may occur while neurologic manifestations continue to progress.

WARNINGS
Cryodesiccated powder reconstituted with Bacteriostatic Water for Injection containing benzyl alcohol should only be used at doses
below 10 m g /n f. (See PRECAUTIONS.)
Treatment-related deaths have been sporadically reported in patients treated with LEUCOVORIN plus fluorouracil combination
therapy regim ens. In general, diarrhea or stom atitis/m ucositis are the first indications that severe and potentially life-threatening
toxicity could develop. Patients who experience these symptoms while receiving any com bination therapy regim en incorporating
LEUCOVORIN plus fluorouracil should be carefully followed and further therapy should be withheld until these sym ptom s resolve.
LEUCOVORIN enhances the toxicity of fluorouracil. When these drugs are adm inistered concurrently in the palliative therapy of
advanced colorectal cancer the dosage of fluorouracil must be reduced. Although the toxicities observed in patients treated w ith the
com bination of LEUCOVORIN plu s fluorouracil are qualitatively sim ilar to those observed in patients treated with fluorouracil alone,
gastrointestinal toxicities (particularly stomatitis and diarrhea) are observed more com m only and may be more severe in patients
receiving the combination (See PRECAUTIONS).
Therapy w ith LEUCOVORIN/fluorouracil must not be initiated or continued in patients who have symptoms of gastrointestinal
toxicity of any severity, until those symptoms have resolved. Patients with diarrhea must be monitored with particular care until the
diarrhea has resolved, as rapid clinical deterioration leading to death can occur Elderly or debilitated patients are at greater risk for
severe toxicity receiving this therapy.

PRECAUTIONS
Because of the C a ^ content of LEUCOVORIN solutions, no more than 160 mg of LEUCOVORIN should be injected intravenously
per minute.
If the cryodesiccated powder is reconstituted with Bacteriostatic Water for Injection containing 0.9% benzyl alcohol, doses greater
than lO rng/m- are not recommended due to the benzyl alcohol content. If greater doses are required (see DOSAGE &
ADMINISTRATION), LEUCOVORIN Calcium for Injection (cryodesiccated powder) should be reconstituted with Sterile Water for
Injection USP and used immediately, or the preservative-free liquid form, LEUCOVORIN Calcium Injection, should be used.

Dmg Interactions
Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the
frequency of seizures in susceptible children.
Prelim inary anim al and human studies have shewn that small quantities of systemically administered LEUCOVORIN enter the CSF
prim a rily as 5-methyltetrahydrofolate and, in humans, remain 1-3 orders of magnitude lower than the usual METHOTREXATE
concentrations following intrathecal administration. However high doses of LEUCOVORIN may reduce the efficacy of intrathecally
adm inistered METHOTREXATE.
LEUCOVORIN may enhance the toxicity of fluorouracil. (see WARNINGS.)

Pregnancy - Teratogenic Effects
Reproduction studies have been performed in rats and rabbits at doses at least 50 tim es the human dose and have revealed no
evidence of harm to the fetus due to LEUCOVORIN. There are, however no adequate and well-controlled studies in pregnant woman.
Because anim al reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if
clearly needed.

Nursing Mothers
It is not known whether this dm g is excreted in human m ilk. Because many drugs are excreted in human milk, caution should be
exercised when LEUCOVORIN is administered to a nursing mother

Pediatric Use
See Drug Interactions

LEUCOVORIN Calcium for injection (sterile cryodesiccated powder 50 mg/vial, 350 m g/ vial)
Vials of cryodesiccated powders should be stored at controllled room temperature (15-30’ C).

i) Reconstituted Solutions
Reconstituted solutions for intravenous or intramuscular administration should be used immediately after reconstitution when
Sterile Water for Injection USP is used as the diluent due to the possibility of microbial contamination during preparation. When
reconstituted with Bacteriostatic Water for Injection USP for intramuscular injection, solutions should be used within 24 hours when
stored at room temperature (15-30°C) or w ithin 72 hours when refrigerated (2-8’ C).

ii) Diluted Solutions for IV Infusion
Reconstituted solutions that haw been prepared w ith Sterile Water for Injection USP and then further diluted with one of the
recommended diluents for intravenous infusion should be used w ithin 24 hours following dilution when stored at room temperature
(15-30oC).
Dextrose 5 % a id 10% in water
Dextrose 10% in saline
Ringed Injection USP
Lactated Ringer's Injection USP
Physiological Saline

AVAILABILITY
Single Dose Vials of 10 mg/mL
Single 35 mL vial. Each vial contains 350 mg LEUCOVORIN as LEUCOVORIN Calcium in solution. Product Code 4545-23.

Vials of Cryodesiccated Powders (50 m g/Vial, 350 m g/Vial)
I . 10 x 10 mL vials. Each 10 mL vial contains 50 mg of LEUCOVORIN as LEUCOVORIN Calcium. Product Code 5330-72.
II. Single 30 mL vials. Each 30 mL vial contains 350 mg of LEUCOVORIN as LEUCOVORIN Calcium. Product Code 4645-77.
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ADVERSE REACTIONS
Allergic sensitization has been reported following both oral and parenteral adm inistration of folic acid.
In com bination regimens, the toxicity profile of 5 FU is enhanced by LEUCOVORIN. The most comm on manifestations are
m ucositis, stom atitis, leukopenia, and/or diarrhea which may be dose-lim iting. In clinical trials w ith this drug com bination these
toxicities were found to be reversible w ith appropriate modification of 5 FU administration.

SYMPTOMS AND TREATMENT OF OVERDOSAGE
F olic acid is a water soluble vitam in converted in the body by the action of folate reductase to folinic acid (LEUCOVORIN) which is
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Age-Related Breast Diagnosis
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Of the three commonest symptoms found in 3294 patients referred to a specialty
breast clinic — mass, nodularity and pain — only nodularity was age related. Only
30% of the patients had a clinically localized abnormality, and only 19% of these
abnormalities were suggestive of carcinoma. The majority of suggestive lesions were
in women over 55 years of age. Of the patients seen because of a breast lump,
46% were found to have a significant mass. Most abnormalities were found in
patients presenting with a mass or nipple discharge, and the significance was age
related. Symptoms associated with the lowest rate of positive biopsies were
nodularity, pain and skin or nipple changes. The biopsy and cancer rates were
significantly age related. The cancer rate in women 40 years of age and under was
0.8%, between 41 and 55 the rate was 5%, and in those over 55 it was 21%. The
predominant finding in young women was a fibroadenoma. In the middle age range
fibrocystic change was most common, and in postmenopausal women most of the
lesions were malignant.

Des trois symptomes les plus frequemment retrouves chez 3294 patientes revues a
une clinique du sein (masse, nodularite, douleur), seule la nodularite etait reliee a
l’age. Seulement 30 % des patientes avaient une anomalie cliniquement localisee et
un carcinome n’etait soup?onne que chez 19 % de celles-ci. La majorite des lesions
douteuses etait retrouvee chez les femmes de plus de 55 ans. Parmi les patientes
vues pour une tumefaction du sein, 46 % avaient une masse importante.
La plupart des anomalies furent retrouvees chez les patientes qui avaient une masse
ou un ecoulement du mammelon et il existait une signification statistique reliee a
l’age. Les symptomes associes avec le plus faible taux de biopsies positives furent la
nodularite, la douleur et les changements de la peau ou du mammelon. Les taux de
biopsie et de cancer etaient significativement relies a Page. Le taux de cancer pour
les femmes de 40 ans ou moins etait de 0,8 %, celui des femmes de 41 a 55 ans, de
5 % et celui des femmes de plus de 55 ans, de 21 %. La principale observation chez
les femmes jeunes etait les fibroadenomes. Chez les femmes d’age moyen, les
changements fibrokystiques etaient les plus frequents, alors que la plupart des
lesions chez les femmes en post-menopause etaient malignes.
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edia attention and the empha
sis on screening for breast
cancer are bringing more women to
the attention of surgeons. This
trend will prove beneficial only if
the number of cancers diagnosed is
significant in relation to the number
of biopsies performed. Unfortunate
ly the difficulty in assessing breast
problems leads to the use of biop
sies to resolve clinical uncertainty.
Whereas some surgeons believe
that a biopsy is indicated regardless
of the magnitude of cancer risk,
others restrict biopsy to patients in
whom there is a significant risk of
cancer. Unfortunately there are few
standards against which to evaluate
these divergent philosophies.
This study was initiated to assess
the importance of breast symptoms
in patients of different ages referred
for surgical opinion.

M

Methods
The patients were referred for
assessment to the breast clinic at
the Kingston General Hospital be
tween 1976 and 1990. Clinical data
were collected prospectively. The
patient’s dominant symptom was
recorded. Symptoms were a lump,
nodularity, nipple discharge, pain
and skin or nipple changes. Asymp
tomatic women referred because of
a physician-discovered mass or an
abnormality on a screening mam
mogram were excluded.
The clinical diagnosis was the
finding at the initial assessment.
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Patients were classified as having a
normal breast or a localized abnor
mality or diffuse nodularity.
Recommendation for biopsy was
based on the clinical and mammographic findings not on the symp
tom. Histologic diagnoses were fi
brocystic change, fibroadenoma,
mammary-duct ectasia, miscella
neous benign problems and carcino
ma. The miscellaneous group in
cluded ductal papilloma, nonspecific
fibrosis, lipoma, acute and chronic
inflammation, and sclerosing adeno
sis.
The data were analysed by age
group — under 41 years, 41 to 55
years and over 55 years.
We sought answers to the follow
ing questions:
• What is the relative frequency
of breast symptoms and is there a
difference with age ?
• What is the relation of symp
toms to significant clinical abnor
malities?
• What is the relation of symp
toms to biopsy rate?
• What is the relation of symp
toms to cancer diagnosis?
Differences were analysed by Stu
dent’s t-test.

were more common in post
menopausal women (p < 0.001).
Although the difference was not
significant, pain was more common
in older women. Pain in pre
menopausal women was usually cy
clic and premenstrual whereas pain
in postmenopausal women was usu
ally continuous, caused by shoulder
or chest-wall problems.
Association o f Symptoms and
Clinical Findings (Table I)
Although all patients were symp
tomatic and had been assessed by a
physician before referral, 1965 pa
tients (59.6%) were clinically normal
and only 999 (30.3%) had a local
ized abnormality. Of the patients
with a localized abnormality, 192
(19%) had lesions that were clinical
ly suspicious for malignancy and
74% of these suspicious lesions
were in women over 55 years of
age. Of the study group 333
(10.1%) patients had diffuse nodula
rity.
Sixty-eight percent of patients
presenting with nodularity, 84%
with pain and 88% with skin or
nipple changes had no clinical ab
normality.
Nearly half (46%) the women

who presented with a mass had
clinically normal breasts. Confirma
tion of a significant localized mass
increased with age. The clinical sig
nificance of nipple discharge also
increased with age.
Nodularity was confirmed in only
17% of patients who presented with
this symptom and in only 7% of
women over 55 years of age (p <
0.025).
Clinically significant (p < 0.05)
findings were noted in 27% of
women under 41 years of age, in
31% between 41 and 55 years and
in 38% over 55 years. More patients
over 40 years of age presenting
with a lump (p < 0.01) and nipple
discharge (p < 0.001) had abnormal
findings.
Symptoms and Biopsy Rate (Fig. 2)
Biopsy was performed on 504
patients. The biopsy rate increased
with age. It was performed in 10%
of women less than 41 years of age,
in 16% of those between 41 and 55
years and in 32% of those over 55
years. The differences were signifi
cant (p < 0.001).
Seventy-one percent (358 of 504)
of the biopsies were performed in
patients presenting with a mass.

4
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Results
% of total

We reviewed 3294 patients. The
majority (1706 [51.8%]) were 40
years of age or younger, 1005
(31.5%) were between 41 and 55
years of age and 583 (17.7%) were
older than 55 years.

60

T"

Symptom Frequency
4

The most common symptoms
(Fig. 1) were a breast mass (46%),
diffuse nodularity (23%) and pain
(18%). Only nodularity and skin or
nipple changes differed in frequency
with age. Nodularity was more com
mon in premenopausal women (p <
0.001) and skin or nipple changes
42
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M ass

Nodularity

Pain

Skin/nipple

Discharge

FIG. 1. Relation of symptoms to age. Black bars represent women under 41 years of
age, hatched bars represent women 41 to 55 years of age and dotted bars represent
women over 55 years of age.

BREAST DIAGNOSIS

The number of biopsies increased
significantly (p < 0.05) with in
creasing age. The highest biopsy
rate (58% [Table I]) was in women

over 55 years of age who presented
with nipple discharge, and the low
est biopsy rate was in women (all
ages considered) who presented

Table 1. R ates o f O ccu rre n c e , B io p s y and C a n ce r in th e T h re e A ge G ro u p s o f W o m e n A c c o rd in g to
T h e ir S y m p to m s o r S ig n s

Age, yr
Sign/symptom
M ass
N o. (%)*
L o ca l abn, % t
B io p sy , %§
C ancer, %H
N o d u la rity ,
N o. (%)
L o ca l abn, %
B io p sy , %
C ancer, %
Pain
N o. (%)
L o ca l abn, %
B io p sy , %
C ancer, %
S k in /n ip p le
N o. (%)
L o ca l abn, %
B io p sy , %
C ancer, %
N ip p le d isch a rg e
N o. (%)
L o ca l abn, %
B io p sy, %
C ancer, %
‘ Num ber
tP e r c e n t
§ P e rc e n t
U P e rce n t

<41
( n = 1706)

4 1 -5 5
(n = 1005)

8 8 7 (5 2 )
42
16
1

4 1 8 (4 1 )
50
22
9

265 (4 6 )
55
49
37

4 1 9 (2 5 )
14
4
0

2 9 0 (2 9 )
19
9
3

8 6 (1 5 )
16
13
7

281 (1 6 )
7
3
0

2 1 2 (2 1 )
8
7
3

135 (2 3 )
13
7
8

4 3 (3 )
14
7
0

4 8 (5 )
19
15
4

71 (1 2 )
28
28
11

7 6 (4)
22
5
0

3 7 (4)
54
32
4

2 6 (4 )
77
58
11

> 55
(n = 583)

(p e rc e n t) o f p a tie n ts in age g ro u p w h o had th e s y m p to m .
o f p a tie n ts w ith s y m p to m in w h o m a lo c a liz e d a b n o rm a lity w a s d e te c te d c lin ic a lly .
o f p a tie n ts w ith s y m p to m w h o had a s ig n ific a n t a b n o rm a lity w a rra n tin g b io p sy.
o f p a tie n ts w ith s y m p to m in w h o m a c a n c e r w a s d ia g n o s e d .

with nodularity (11% [55 of 504]),
pain (7% [33 of 504]) and skin and
nipple changes (6% [31 of 504]).
Many women who presented with
one or more discrete masses were
found to have macroscopic cysts
and were managed by percutaneous
aspiration. The highest occurrence
of macrocysts coincided with the
peak age at which fibrocystic
change was reported in open biop
sies. The peak occurrence of mac
rocysts was between 41 and 50
years.
The Association o f Symptoms With
Cancer (Fig. 3)
Only 13 cancers (0.8% of all the
cancers) were diagnosed in women
younger than 41 years. All these
women presented with a self-discov
ered breast mass. The overall can
cer rate in women aged 41 to 55
years was 5% (51 cancers); 75% of
the cancers were found in women
presenting with a mass. The same
was true in women over 55 years.
In this age group 120 (21%) can
cers were diagnosed. Eleven percent
of postmenopausal women with nip
ple discharge and skin or nipple
changes had cancer (Table 1).
The histologic diagnosis was sig
nificantly age related (Fig. 4). In
women younger than 41 years, 46%
had fibroadenoma, 28% fibrocystic
change and 8% cancer. In women
41 to 55 years of age, only 11% had
fibroadenoma, 40% had fibrocystic
change and 34% had cancer. In
women over the age of 55 years,
only 2% had fibroadenoma and 18%
had fibrocystic change, but 65%
had cancer.

Discussion

FIG. 2. Biopsy rate of patients for each symptom related to age. Black bars
represent women under 41 years of age, hatched bars represent women 41 to 55
years of age and dotted bars represent women over 55 years of age.

If the data from Scotland1 apply
in North America, general practi
tioners see few patients with breast
problems and have little opportuni
ty to acquire expertise. This is one
CJS, VOL. 35, NO. I, F E B R U A R Y 1992
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reason for the skewed age distribu
tion among the patients referred to
our breast clinic. Over 80% were
premenopausal or perimenopausal.
The physician’s lack of experience
may not, however, be as important
as the patient's request for a second
opinion. Many young women are
anxious about breast cancer but do
not realize how uncommon it is at
their age. By contrast, many elderly
patients labour under the misappre
hension that breast cancer is un
common after menopause. It is pos
sible that better instruction of phy

Mass

Nodularity

sicians and more realistic and less
sensational patient education would
decrease anxiety and lessen the
number of surgical assessments re
quired.
In this series most breast symp
toms were not age related. A breast
lump was the most common symp
tom in all age groups. Nodularity
was common in all age groups,
including the elderly, implying that
many women do not appreciate the
character of normal breasts. This is
exemplified by the finding that no
dularity was confirmed clinically in

Pain

Skin/nipple

Discharge

FIG. 3. Cancer detection rate of patients for each symptom related to age. Black
bars represent women under 41 years of age, hatched bars represent women 41 to
55 years of age and dotted bars represent women over 55 years of age.

%biopsies

FIG. 4. Histologic diagnosis by age at biopsy. + = fibroadenoma, • = fibrocystic
change, * = carcinoma.
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only 7% of postmenopausal women
presenting with this symptom.
A lump in the breast and breast
pain are the most common prob
lems seen in general practice.12 Cy
clic mastalgia is said to occur in
50% of young women,3 This rate
provides a large population for po
tential referral unless women are
educated about the significance of
mastalgia, and physicians are selec
tive in whom they refer. Pain,
which was the third most common
reason for referral, increased in fre
quency with age. In most post
menopausal women pain was
caused by conditions unrelated to
the breast. Because of the public
perception that pain and cancer are
synonymous, patients with breast
discomfort will seek medical help.
Patients presenting with nodularity
and pain had the lowest biopsy and
cancer rate.
In older women, changes in the
skin of the breast and nipple were
often cancer related, but similar
com plaints in premenopausal
women were usually inconsequen
tial.
The finding that more than 60%
of the women had no clinical abnor
malities, and this included nearly
half the women who presented with
a breast lump, is significant and
supports the contention that physi
cians are uncomfortable with breast
assessment or are pressured to ar
range for specialist opinion. Older
women had more abnormal findings
probably because clinical evaluation
is easier when cyclic functional
changes do not confuse the picture.
Most important clinical abnormal
ities were associated with a lump
and nipple discharge. Biopsy and
cancer rates in these patients were
age related. Our approach to nipple
discharge was similar to that re
ported by Leis and colleagues.4
Clear serous and sanguineous dis
charge was considered important,
particularly if it was limited to one

BREAST DIAGNOSIS
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duct orifice. Turbid green or yellow
discharge from multiple ducts in
one or both breasts in pre
menopausal women had the same
significance as macro- and microcystic changes.
The biopsy rate increased with
age. Over 70% of biopsies per
formed were in patients who pre
sented with a mass. The rate was
less than 10% for other symptoms
in women under 41 years of age. In
this group fibroadenoma was the
most common lesion, fibrocystic
change was less common and can
cer was rare. In women 41 to 55
years of age fibrocystic change was
the most common diagnosis, but
the rate of cancer was greater than
that in the younger age group. At
this age many women with breast
masses were confirmed to have
macroscopic cysts.5 Cancer was the
dominant finding in women over 55
years of age.

Conclusions
V

Cancer is uncommon in women

40 years of age and younger, irre
spective of the patient’s symptoms.
Biopsy is rarely required for prob
lems other than a breast mass. At
this age, patients with pain, nodula
rity and nipple discharge can be
managed confidently by the family
physician. The most common mass,
a fibroadenoma, does not require
excision unless it is larger than 2
cm in dimension.6
Women over 55 years of age
have the highest cancer rate. Diag
nosis is least complicated in this
age group and mammography af
fords additional support. Although
a breast lump is the most common
symptom associated with cancer, no
symptom can be ignored in post
menopausal women.
The most challenging age group,
diagnostically, is women between
41 and 55 years of age. In this
group fibrocystic change is domi
nant, and the rate of cancer is
significant. Mammography is useful
but may be misleading in women
with radiologically dense breasts.
Percutaneous aspiration of cysts,
fine-needle aspiration for cytologic

examination, clinical review after a
short period of observation and pos
sibly ultrasonography will reduce
the number of women subjected to
biopsy for benign breast problems.
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R ole of the Teaching Hospital
in the Development of a Laparoscopic
Cholecystectomy Program
Harvey H. Sigman, MD, FRCSC;* Gerald M. Fried, MD, FRCSC;t E. John Hinchey, MD, FRCSC,
FACS;t Joseph Mamazza, MD, FACS;$ Marvin J. Wexler, MD, FRCSC, FACS;§
Jacob Garzon, MD, FRCSC;* Jonathan L. Meakins, MD, FRCSC§
Laparoscopic cholecystectomy was introduced at McGill University-affiliated
hospitals in a planned manner to evaluate the safety and results of this new
procedure while training attending and resident surgeons. Laparoscopy was
performed with the intent of carrying out cholecystectomy in 500 consecutive
patients (70% female, 30% male), whose age averaged 48 years (range from 7 to 93
years). Thirty-seven percent had undergone intra-abdominal surgery previously, and
9.1% had had acute cholecystitis. There were two common-bile-duct injuries and one
major small-bowel injury. The procedure had to be converted to open
cholecystectomy in 25 (5%) patients. There were no deaths. The mean duration of
surgery was 88 minutes. Fifty-five percent of patients were discharged home in 24
hours or less after surgery, and 75% were back to normal activity within 1 week of
discharge. Fourteen attending staff and 8 senior residents achieved competence to
carry out laparoscopic cholecystectomy independently.

La cholecystectomie laparoscopique fut introduite dans les hopitaux affilies a
TUniversite McGill, de fa?on planifiee afin d’evaluer Tinnocuite et les resultats de
cette nouvelle technique, tout en faisant la formation des chirurgiens et residents.
Une iaparoscopie fut pratiquee dans I’intention de realiser une cholecystectomie
chez 500 patients (70 % des femmes, 30 % des hommes) dont Page moyen etait de 48
ans (ecart de 7 a 93 ans). Trente-sept pourcent avaient deja subi une chirurgie
abdominale et 9,1 % avaient souffert de cholecystite aigue. On a enregistre deux
lesions importantes du choledoque et de Tintestin. Pour 25 patients (5 %)
Tintervention dut etre modifiee en cholecystectomie ouverte. II n’y eut aucun deces.
La duree moyenne de la chirurgie fut de 88 minutes; 55 % des patients re?urent leur
conge en moins de 24 heures et 75 % avaient repris leurs activites normales en
moins d’une semaine. Quatorze chirurgiens et 8 residents seniors atteinrent le
niveau d’expertise requis pour pratiquer seuls la cholecystectomie laparoscopique.

he introduction of laparoscopic
cholecystectomy (LC) as an ac
ceptable and safe method of remov
ing the gallbladder has led general
surgeons to seek out means of
learning the procedure as quickly as
possible. Most publications on LC
have stressed the need for proper
training and credentialling. There
has also been general acknowledge
ment that a learning curve in ac
quiring this technique exists, and
that this implies a higher incidence
of complications in the early use of
the technique for each surgeon.
The Division of General Surgery of
McGill University wished to develop
laparoscopic surgery at its universi
ty-affiliated hospitals in a planned
and disciplined way, with the hy
pothesis that the safety and efficacy
of the procedure could be main
tained as increasing numbers of
surgeons became involved. The ex
perience with our first 500 consecu
tively attempted LCs is presented.

T

From the Division o f General Surgery, McGill University, Montreal, Que.

Method

Presented at the 14th annual meeting o f the Canadian Association o f General Surgeons, held in
conjunction with the 60th annual meeting o f the Royal College o f Physicians and Surgeons o f
Canada, Quebec, Que., Sept. 21, 1991

Divisions of general surgery at
three McGill University-affiliated
hospitals decided in May 1990, in
dependently but with sharing of
information and plans, to have se
lected surgeons with a m ajor inter
est in biliary-tract surgery learn LC.
An initial group of five surgeons
learned the technique in a variety of
ways, including doing laparoscopy
with gynecologists, visiting the few
existing experts at that time, using
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carried out LC on their own pa
tients while the preceptor acted as
surgeon or assistant. The surgeons
began to work independently when
a proctor decided that the surgeon
had gained sufficient skill and expe
rience. It was understood that there
was also a responsibility on the part
of the preceptor to train residents in
the program as well as surgeons
who came from outside the institu
tion to take formal LC courses.
Surgeons at the participating
hospitals completed prospectively
developed data sheets on all their

training boxes and practising on
porcine models. The surgeons ini
tially worked in pairs and visited
within the university group of hos
pitals in order to share experience.
A fourth institution began its pro
gram 3 months later, in a similar
way, but entirely in the McGill
system. Once expertise developed in
an institution, other surgeons were
gradually introduced to the opera
tion. They were also given laborato
ry experience and participated in
human surgery as assistants with
increasing responsibility. They then
Name ________

□

U n it# _________

Difficulty removing GB through wall?
1 minimal; 2 mod; 3 very

Sex __________

Size of smallest stones in m m ________________

DOB (yy/mm/dd)

Size of largest stone in mm __________________

Age __________
Referring M D __
Sym ptom s____

No. of stones _____________________________

CD Cholangiogram done? 1 no; 2 yes; 3 attempted
CD Cholangiogram: 1 nl; 2 abn (describe)
CD Intraop complications? 1 lost stone; 2 bile spill;
3 bleeding; 4 other (describe)

□

Preop LFT: nl 1; abn 2

CD Lap required? 1 no; 2 yes

□

Preop US CBD; 1 nl; 2 dilated

□

CD Preop US GB wall: 1 nl; 2 thickened
CD Past abdominal surgery: 1 none; 2 lower;

Postop drain: 1 no; 2 yes

Addl procedures___________________________

3 upper

CD Body habitus: 1 slim; 2 avg; 3 obese;
4 morbidly obese
Surgeons_________________________________
Date of OR _______________________________
Duration of anesthesia ______________________
Duration of surgery_________________________

CD Postop complications: 0 none; 1 wd infn;
2 hernia; 3 intra-abd abscess; 4 bleeding;
5 other (describe)

CD Postop shoulder pain: 1 none; 2 mild; 3 severe
Days of postop fever > 38°C _________________
Time in hr postop to full d ie t__________________

□

Problems with insuffln: 1 NO; 2 YES (describe)

CD Open insertion of cannula: 1 no; 2 yes

Time in hr postop to discharge________________
Time days to return to usual activity___________

patients (Fig. 1). The data were
entered into a centralized, comput
erized database. At first there was
an attempt to select patients for LC
who were not overly obese, who
had not had previous upper abdomi
nal surgery and who had been ad
mitted for elective surgery. As the
experience of the surgeons in
creased, the contraindications for
LC became few and were at the
discretion of the surgeon.
The operation and variations in
technique have been described.1-4
The majority of the procedures in
this series were carried out, though
not exclusively, with Storz instru
mentation. Surgeons used a variety
of techniques with respect to an
open or blind approach to insuffla
tion, position of the port used for
dissection (e.g., below the xiphoid
process or to the left of the midline)
and position of the patient.
Surgeons at one institution were
trained in Europe, and they placed
patients in the lithotomy position
with the camera operator standing
between the lower limbs and the
surgeon on the patient’s left. The
positioning of patients in the lithot
omy position was not associated
with clinical evidence of thrombo
phlebitis or pulmonary embolism.
These surgeons now use the pa
tient-supine position because extra
time is required to place patients in
the lithotomy position, which does
not afford any major advantage.

Total mg of postop D em erol__________________
□

Dissn of GB: 1 easy; 2 mod; 3 difficult

□

GB decompressed: 1 no; 2 yes

CD Energy level at f wk: 1 normal; 2 mildly

□

CBD clearly seen: f yes; 2 no

diminished; 3 severely diminished

□

Dissn of artery: 1 easy; 2 mod; 3 difficult

CD Dissn of cystic duct: 1 easy; 2 mod; 3 difficult
CD GB wall thickness: 1 thin; 2 mod; 3 thick
CD Rupture of GB: 1 no; 2 yes
□

Adhesions to GB: 1 minimal; 2 mod; 3 dense

□

Dissn with: t cautery; 2 laser; 3 both

FIG. 1. McGill University LC data sheet.
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Total mg of postop codeine __________________

Comments _______________________________

Findings
LC was attempted in 500 patients
(350 men, 150 women) by 14 at
tending surgeons and 8 senior resi
dents over a 10-month period. Dur
ing the first 5 months the number
of procedures performed was small
because the instruments were on
loan and were available only sporad
ically.
The mean age of the patients was

UNIVERSITY LAPAROSCOPIC CHOLECYSTECTOMY PROGRAM

48.5 years (range from 7 to 93
years). Of the 500 patients 125
(25%) were obese and 15 (3%) were
morbidly obese. One hundred and
seventy-five (35%) patients had had
lower intra-abdominal surgery and
10 (2%) had an upper abdominal
scar. Those with upper abdominal
incisions included one of each of
the following: pyloromyotomy for
infant pyloric stenosis; vagotomy
and antrectomy; vagotomy and an
trectomy complicated by pancreati
tis and duodenal stump leak; smallbowel resection; transperitoneal left
radical nephrectomy; small-bowel
obstruction with lysis of adhesions
and subsequent repair of incisional
hernia. Acute cholecystitis was evi
dent in 45 (9%) patients, and 9 (2%)
patients had acute pancreatitis. Six
women (1%) were within 1 month
post partum.
The mean duration of LC surgery
from the time of first incision to
closure of the last incision was 88
minutes (range from 35 to 270
minutes). The mean duration relat
ed to the cumulative volume of
patients on a monthly basis is illus
trated in Fig. 2. In 25 (5%) patients
the procedure was converted to
open cholecystectomy (Table I). The
relation between the cumulative in
cidence of conversions and the cu
mulative volume of procedures over
time is shown in Fig. 3. Operative
and postoperative complications are
listed in Table II. There were no
deaths.
Endoscopic cholangiography was
attempted selectively on 29 (6%)
patients and was completed in 23
(5%) patients. The cholangiogram
was considered normal in 18 pa
tients. Ten patients returned be
tween 5 and 15 months after suc
cessful LC with symptoms sugges
tive of a retained common-duct
stone. One of these was known to
have choledocholithiasis on the
basis of a cholangiography per
formed during LC. Endoscopic ret

rograde cholangiopancreatography
(ERCP) was carried out on these 10
patients; 5 were found to have
stones and were treated by papil
lotomy. One additional patient,
whose LC was converted to open
cholecystectomy, subsequently pre
sented with a retained stone and
was treated by ERCP and papilloto
my.
Of the 500 patients 275 (55%)
were discharged within a day of the
operation and 145 (29%) within the
next 24 hours; 80 (16%) remained
in hospital more than 2 days after
surgery, including the 25 patients
who had their LC converted to open
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cholecystectomy. The average
length of stay after operation for
those with conversion was 7.5 days
(median 6 days, range from 2 to 31
days). Seventy-five percent of the
patients were able to resume normal
activities by 7 days after discharge
from hospital.
Most (96%) insufflations were
performed by blind insertion of the
Veress needle and trocar. Open in
sertion of the trocar sheath under
direct visualization followed by in
sufflation was performed in 4% of
patients. The reasons for open in
sertion included difficulty with in
sufflation or a scar in the perium-

TIME (min)
-

Jun

Jul

Aug

Sep

O ct

Nov

D ec

Jan

Feb

M ar

A pr

MONTH
FIG. 2. Mean duration of laparoscopic cholecystectomy (LC) surgery by month.

T a b l e 1. Laparoscopic C ho le cyste cto m ie s C onverted to Standard Open C h o le c y s te cto m y
R eason

N o . o f p a t ie n t s

C ystic-duct leak
Bleeding
Obesity
Dense adhesions
Acute ch ole cystitis (gallbladder c a rc in o m a - 2)
C om m o n -bile -du ct injury
Failure of lig h t source
Failure to enter peritoneal cavity
S m all-bow el o b s tru ction (gallbladder ca rcin o m a )
Total

1*
2*
2*
6
10
1
1
r

1
2 5 (5% )

'P ro b a b ly related to inexperience
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carried out in 3% of patients at one
of the institutions early in the expe
rience, but electrocautery has been
used subsequently.

bilical region. Drains were inserted
in 5% of patients, but almost all of
these were used early in the group
experience. Laser dissection was

FIG. 3. Relationship between cumulative incidence of conversions to traditional
cholecystectomy (black bars) and cumulative volume of operations performed for LC
(hatched bars) over time.
Table II. Complications of Laparoscopic Cholecystectomy
Complication
Operative
C om m on-duct injury
S m all-bow el injury
C ystic-duct leak (through clip)
S m all-bow el puncture
(Veress needle)
Duct of Luschka leak
Clipped accessory right
hepatic duct
G allbladder lost in cul de sac
Bile spill
Gallstone loss
Subcutaneous emphysema
Bleeding

Management

No. of patients

2

Repair

1

1

Delayed repair
Converted to open
cholecystectomy
Observation
Drainage

1

Intact CBD verified

1
1

1
60
16

Acute hypoxemia
Postoperative
Subhepatic collection
W ound infection
W ound hematoma
Persistent pain and fever
M yocardial infarction
Urinary infection
Urinary retention
Respiratory distress
Pulm onary edema
Pulm onary embolism
Upper respiratory infection
Jaundice
Gout
C olitis due to Clostridium difficile

7

9
1

2
3
2
1
1
3
2
6
1
1
1
1

1
1

Retrieved
Irrigation/suction
Retrieved/neglected
None
Endoscopy (7)
Laparotomy (2)
Coelom deflated
Aspiration (1)
Drained (2)
Drained (1)
ERCP normal
Expectant
Antibiotics
Catheter
Intubation (2)
Medication
Medication
Medication
ERCP papillotom y
Medication
Medication

CBD = com m on bile duct, ERCP = endoscopic retrograde cholangiopancreatogram
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Discussion
The introduction of LC into sev
eral university-affiliated hospitals
can be done in a cooperative,
planned way so that the procedure
can be carried out effectively and
safely with results that compare
favourably with those of large, sin
gle, institutional centres. The dura
tion of surgery was longer at the
beginning of the series but seemed
to reach a plateau even though
other surgeons were being intro
duced to the technique and resi
dents were increasingly involved.
This is probably a result of precep
tor support. The rate of conversion
did not rise as a result of new
surgeons learning the procedure,
probably for the same reason. It is
important to stress that asking an
experienced colleague for help or
advice, or converting to traditional
cholecystectomy is a mark of pru
dence and not failure. An important
factor influencing both the duration
of operating time and the conver
sion rate was the fact that, whereas
at the outset these were often de
pendent on the minimal experience
of the group, later in the series
more difficult operations were being
attempted. It should be noted that
more difficult surgery was not asso
ciated with serious complications.
Most of the insufflations were
carried out by blind access using
the Veress needle followed by trocar
insertion. One patient had a recog
nized small-bowel puncture which,
after the gallbladder had been ex
tracted, was reinspected but not
treated. Another patient, im
munocompromised by multiple my
eloma and chemotherapy, had an
unrecognized small-bowel injury
that was discovered at laparotomy
for postoperative peritonitis. Blind
insertion of a Veress needle fol
lowed by a trocar certainly carries a
small risk of bowel or vascular
injury. Therefore patients who have

UNIVERSITY LAPAROSCOPIC CHOLECYSTECTOMY PROCRAM

had laparotomy through periumbili
cal incisions or a history of peritoni
tis, should have open insertion of a
sheath through a small midline fas
cial and peritoneal incision in the
region of the umbilicus. Gas leak
can be prevented in this latter
group of patients by a pursestring
suture placed around the sheath or
by the use of a Hasson sheath.
Inadvertent opening of the gall
bladder with resulting bile spillage
and possible stone loss into the
peritoneal cavity occurred more fre
quently during the early experience
of surgeons but was not associated
with peritonitis, infection or subhepatic collection. Bile can readily
be aspirated at the end of the
procedure, and stones can some
times be sucked up through a no.
32 French chest tube that will pass
through a 10-mm to 11-mm port.
Spoon-shaped forceps are also avail
able for stone removal. This compli
cation does not require insertion of
a drain.
The number of laparoscopic cholangiograms obtained in this series
was small even when compared with
series in which cholangiography is
done selectively. The number of
patients who returned with choledocholithiasis, unrecognized at the
time of LC, has also been very low
(4 of 475, 0.8%), which is in con
trast to a reported incidence of
common-duct stones associated
with traditional cholecystectomy as
high as 18%.5 This may indicate
that many common-duct stones are
of no clinical significance and in
many cases probably pass through
into the duodenum spontaneously,
as has been suggested by McEntee,
Grace and Bouchier-Hayes.6 In their
series of 100 LCs without cholangi
ography, in patients who had no
clinical evidence of choledocholithiasis, only one patient showed
evidence of choledocholithiasis
postoperatively.6 Clearly the man
agement of the common bile duct

will have to be evaluated over a
longer follow-up period. These data
will become particularly important
as the ability to access the common
duct during laparoscopy increases
with technical advances in instru
mentation and an enlarged surgical
experience. However, it is important
for laparoscopic surgeons to be able
to cannulate the cystic duct and
image the biliary tree.
We recommend that LC surgeons
should learn the technique of cho
langiography, but we have difficulty
in suggesting that all patients have
cholangiography for the purpose of
training the surgeon. We believe
that this goal can be accomplished
by doing cholangiography selective
ly. Another reason presented for
doing cholangiography is to clarify
confusing anatomy of the biliary
tree.78 This may not prevent bileduct injury, but it may limit the
extent of the injury, which could
then be managed with a T tube or
repair and may obviate the need for
a complicated delayed repair. One of
the two common-duct injuries in
our series occurred early in the
experience of one of the five origi
nal surgeons and was only recog
nized through ERCP carried out to
investigate postoperative jaundice.
It should be noted that this patient
had conversion to an open opera
tion to complete the cholecystecto
my because of light-source failure,
but the bile-duct injury was not
detected. The other injury occurred
in the hands of a surgeon experi
enced with LC, who discovered the
problem during the course of the
procedure. The anatomy had ap
peared normal in both cases. Cho
langiography is not a substitute for
careful dissection of the structures
of the triangle of Calot from the
infundibulum of the gallbladder
down to the cystic duct and for
converting to open cholecystectomy
when the anatomy is not clear.
Extensive dissection to visualize the

common duct before clipping the
cystic duct is not recommended. It
is more important to be certain that
the origin of the cystic duct from
the gallbladder, particularly on the
hepatic side, is clearly seen before
the cystic duct is divided.
The demands on the preceptor’s
time are very high because this
person is expected to teach resi
dents as well as staff surgeons and
surgeons coming from other insti
tutions to learn the technique. Also
formal courses are given at inter
vals. It is important that time con
straints do not force the resident to
compete with the staff surgeon who
is anxious to learn as quickly as
possible. The order of priorities
should be clearly stated when an
institution decides to introduce a
laparoscopic program. For academic
institutions, training of the senior
general surgical resident should be
high on the list. It is also important
that each institution develop criteria
by which surgeons can become credentialled. Guidelines for credentialling and allocation of privileges
have been presented by a number of
academic societies.910
Institutions should prospectively
record data on LCs performed by
their surgeons. This will provide
the information required for quality
assurance programs and to evaluate
the safety and monitor the results
of this new surgical technique.

References
1. R eddick EJ, O lsen DO: Outpatient lapa
roscopic laser cholecystectomy. Am J
Surg 1990; 160: 485 -4 8 9
2. Zucker KA, Bailey RW, Gadacz TR et
al: Laparoscopic guided cholecystecto
my. Am J Surg 1991; 161: 3 6 -4 4
3. Gadacz TR, T alamini MA, L illemoe KD
et al: Laparoscopic cholecystectomy.
Surg Clin North Am 1990; 70: 12 4 9 1262
4. S igman HH, L aberce JM, C roitoru D et
al: Laparoscopic cholecystectomy — a
treatment option for gallbladder disease

CJS, VOL. 35, NO. 1, FEBRUARY 1992

53

SIGMAN ET AL

in children. J Pediatr Surg 1991; 26:
1181-1183
5. H ermann RE: Surgery for acute and
chronic cholecystitis. Surg Clin North
Am 1990; 70: 1263-1275
6. M c Entee G, Grace PA, Bouchier-H ayes

D: Laparoscopic cholecystectomy and
the common bile duct. Br J Surg 1991;

78: 385-386
7. Berci G, S ackier JM, Paz -P artlow M:
Routine or selected intraoperative cho
langiography during laparoscopic chole
cystectomy? Am J Surg 1991; 161:
355-360
8. Hunter JG: Avoidance of bile duct inju
ry during laparoscopic cholecystectomy.

Am J Surg 1991; 162: 71-76
9. Dent TL: Training, credentialling, and
granting of clinical privileges for laparo
scopic general surgery. Am J Surg
1991; 161: 399-403
10. K eith RG: Laparoscopic cholecystecto
my: Let us control the virus [editorial].
Can J Surg 1990; 33: 435-436

choosing a particular technique, and
their cases are well selected. They take
us from the reconstruction of a small
breast, using a simple silicone implant,
to that of a large pendulous breast,
using the lower TRAM flap. The latter
is overemphasized to some degree,
showing the editors’ bias. This tech
nique nevertheless is in vogue today,
and there is general agreement that in
the right patient it gives the best recon
struction using autogenous tissue and
avoiding silicone implants.
This book will be a useful addition to
the library of the plastic surgeon who
performs breast reconstructions and the
plastic surgical resident who may not
obtain exposure to all methods of
breast reconstruction during training. It
will also be an excellent textbook for
the general surgeon who performs
breast resections, by making him or her
aware of the amazing results that can
be achieved today with these latest
techniques.

fixed-tissue technique to the current
fresh-tissue micrographic approach. As
such, this book was needed to bring
together old and new information on
this surgical technique and to present it
in a readable fashion.
This is a well-written book, presented
in a clear, concise, organized fashion. It
has 22 chapters, each of which is amply
supported by many good illustrations,
clinical and histologic photographs and
a complete bibliography.
The book begins with an overview of
the evolution of Moh’s surgical tech
nique to its current state, followed by a
clear description of the surgical and
histopathological techniques used in
the performance of this type of surgery
and the indications for its use. After a
brief review of instrumentation, the
focus shifts to a clinical and histopatho
logical description of the premalignant
and malignant lesions commonly en
countered in a Moh’s surgical practice.
The remaining chapters cover many
areas. There are excellent reviews of
head and neck anatomy, local and re
gional block anesthesia, preoperative
patient assessment, medical and surgi
cal complications of surgery and their
management, and wound dressings and
wound healing. A description of the use
of Moh’s surgery in the treatment of
genital and perineal cancers, rare malig
nant tumours and malignant melanoma
is presented, as is the use of Moh’s
surgery in cancer of the nail.
There are chapters of interest on
medical photography, maxillofacial
prosthetics, practical pointers and un
usual cases encountered by the editor

BOOK REVIEWS
CRITIQUES DE LIVRES

ATLAS OF BREAST RECONSTRUC
TION. Edited by Luis 0 . Vascon, Ma
deleine Lejour and Mabel GamboaBobadilla. 228 pp. Illust. Gower Medi
cal Publishing, New York. 1991. Price
not stated. ISBN 0 -3 9 7 -4 4 6 6 2 -4

The prognosis for women with breast
cancer has not changed substantially in
the last 20 years. However, the same
cannot be said about breast reconstruc
tion. During this period, significant ad
vances have been made in this field. The
patient and the surgeon are no longer
happy with the creation of a breast
mound to obviate the external prosthe
sis. In the last two decades, many
techniques have been introduced, which
are constantly modified and improved to
produce an esthetically pleasing breast.
This atlas takes us through the most
commonly used techniques in breast
reconstruction. In 16 well-illustrated
chapters, which are easily read in a few
hours, the editors explain the various
operations, from the simple submuscular silicone implants for the small
breasted patient, to the use of tissue
expanders and the transverse rectus
abdominis muscle (TRAM) flap. They
summarize their considerable experi
ence on this subject, and share with us
important “pearls” in the reconstruc
tion of the breast. They also stress the
pitfalls associated with the various sur
gical manoeuvres.
Although this is an atlas of breast
reconstruction, the text accompanying
the excellent pictures is adequate to
enhance the understanding of the vari
ous procedures. Since the breast can be
reconstructed in various ways, the au
thors give us their indications for
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Achilleas Thoma, MD, FRCSC, FACS
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Hamilton, ON
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MOH’S MICROGRAPHIC SURGERY.
Edited by George R. Mikhail. 405 pp.
Illust. W.B. Saunders Company, Phila
delphia, 1991. Price not stated. ISBN
0-7216-3415-X

With the rapid development and expan
sion of the field of dermatologic sur
gery, Moh’s micrographic surgery has
kept pace and evolved from the initial

continued on page 58
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Ultrasonographic and Radiologic
Evaluation of Patients After Laparoscopic
Cholecystectomy
R. Smith, MD;* D. Kolyn, MD;* H. Pymar, BA;* E. Sauerbrei, MSc, MD, FRCPC;t
R.F. Pace, MD, FRCSC, FACS*
The first 30 patients scheduled to undergo laparoscopic cholecystectomy at the
Kingston General Hospital, Kingston, Ont., were studied by abdominal
ultrasonography and abdominal roentgenography 24 hours after the procedure.
The ultrasonogram appeared normal in 21 of the 29 patients in whom
laparoscopic cholecystectomy was successful. In six of the eight patients with an
abnormal ultrasonogram a tiny collection of fluid was identified in the gallbladder
fossa; in two patients retained intraperitoneal stones were identified (one of these
patients also had a small fluid loculus); and one patient had a small amount of free
fluid in Morrison’s pouch. This last patient was subsequently found to have a
retained common-bile-duct stone, which required endoscopic removal.
Plain films showed moderate to large amounts of retained gas intraperitoneally in
only three patients. Colonic distension was recorded in 23 of the 28 patients studied,
suggesting a partial colonic ileus. Residual pneumoperitoneum and colonic
distension did not correlate with any untoward clinical findings.
This study demonstrates that most patients have complete reabsorption of their
pneumoperitoneum within 24 hours of laparoscopic cholecystectomy and that small
amounts of fluid in the gallbladder fossa and mild to moderate colonic distension are
not significant in terms of operative complications.

Les 30 premiers patients qui subirent une cholecystectomie laparoscopique a
l’Hopital general de Kingston, a Kingston, Ont. ont fait l’objet d’echographies et
radiographies abdominales, 24 heures apres l’intervention.
L’echographie parut normale chez 21 des 29 patients chez qui la cholecystectomie
laparoscopique avait reussi. Chez six des huit patients ayant une echographie
anormale, une petite accumulation de liquide fut identifiee dans la fossette cystique;
chez deux patients, des calculs intraperitoneaux residuels furent decouverts (un de
ces patients presentait aussi une petite loge de liquide); enfin, un patient presentait
une petite quantite de liquide libre dans la poche de Morrison. On decouvrit
subsequemment chez ce dernier un calcul residuel dans le choledoque qui necessita
une ablation par voie endoscopique.
Les radiographies simples revelerent des gaz intraperitoneaux en grande ou
moyenne quantite chez seulement trois patients. Une distension colique suggerant
un ileus partiel etait presente chez 23 des 28 patients examines. Les
pneumoperitoines residuels et la distension colique n’etaient relies a aucune
observation clinique indesirable.
Cette etude a montre, chez la plupart des patients, une reabsorption du
pneumoperitoine, moins de 24 heures apres la cholecystectomie laparoscopique. Elle
a demontre, en outre, que les petites accumulations de liquide dans la fossette
cystique et la distension colique legere a moderee ne sont pas des complications
operatoires importantes.

lthough the first successful la
paroscopic cholecystectom y
was performed by Philipe Mouret in
France in 1987, it was not until the
reports by Dubois and associates1
and Reddick and Olsen2 that laparo
scopic cholecystectomy became an
acceptable technique. Almost over
night there was an explosion of
interest in this innovative proce
dure, and laparoscopic cholecystec
tomy has now virtually replaced
“open” cholecystectomy in most
parts of the developed world. In the
rush to learn the technical skills
required, however, many surgeons
became preoccupied with develop
ing large patient volumes rather
than carefully and scientifically
comparing laparoscopic cholecys
tectomy with the gold standard of
“open” cholecystectomy.3’4
Patient demand for this new pro
cedure is now so strong that it may
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be impossible to perform random
ized comparisons between the dif
ferent operative techniques,5 and we
are left with very little scientific
data pertaining to the effects of
laparoscopic cholecystectomy.6 In
an attempt to develop an under
standing of the “normal” postoper
ative changes, we used ultrasonog
raphy and routine abdominal films
to examine, prospectively, our first
30 patients who underwent laparo
scopic cholecystectomy, and we
compared the findings with the pa
tient’s clinical outcome.

Patients and Methods
All patients seen electively be
tween September 1990 and March
1991 with symptomatic gallstones,
confirmed ultrasonographically,
were offered laparoscopic cholecys
tectomy. Preoperative antibiotic
prophylaxis was given routinely,
and all patients had bladder and
gastric decompression before sur
gery. Laparoscopic cholecystectomy
was performed by a standardized
technique. Electrocautery was used
to dissect the gallbladder from the
liver bed. After removal of the ab
dominal trocars, 0.5% bupivacaine
with epinephrine, 1:1000, was used
to infiltrate the tissues surrounding
the skin incisions, which were then
closed with subcuticular sutures
and adhesive tape. The morning
after surgery, patients underwent
upper abdominal ultrasonography,
and three radiographic views of the
abdomen (flat plate, upright kidney,
ureter and bladder, and upright
diaphragm) were obtained. All ra
diographs and ultrasonograms were
initially examined by the on-call
radiologist. At the completion of
the study, with the radiologist
blinded to the clinical outcome of
the patients, all the films were re
viewed to look for trends in the
group as a whole. As soon as they
56
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felt comfortable, patients were dis
charged home; they were reassessed
in the clinic 2 weeks after the
procedure and thereafter as neces
sary, depending on their clinical
condition.

Results
Thirty patients (25 women, 5
men) were entered into the study.
They ranged in age from 20 to 69
years (mean 43 years). Twenty-eight
patients presented with biliary colic
and underwent elective laparoscopic
cholecystectomy. One patient was
admitted with acute cholecystitis 2
days before the planned elective
laparoscopic cholecystectomy. He
was operated on after 2 days in
hospital and was found to have
gangrenous cholecystitis. Another
patient presented with obstructive
jaundice due to a common-bile-duct
stone. After endoscopic retrograde
cholangiopancreatography (ERCP)
and endoscopic stone extraction,
laparoscopic cholecystectomy was
done.
The mean operative time was 73
minutes (range from 35 to 150
minutes) in the 29 patients who
underwent successful laparoscopic
cholecystectomy. Because of dense
scarring of the gallbladder and
obliteration of Calot’s triangle in
one patient, the procedure had to
be converted to an “open” chole
cystectomy. There were 13 in
stances of intraoperative bile spill
age due to gallbladder perforation
and 3 of intraperitoneal stone loss.
Intraoperative cholangiography was
not performed in this group of
study patients.
The patient who required an open
cholecystectomy remained in hospi
tal for 7 days whereas the other 29
patients were discharged from 1 to
4 days postoperatively. The mean
postoperative stay for all 30 pa
tients was 2.0 days (1.7 days for the

29 patients having a successful la
paroscopic cholecystectomy).
Seven patients had complications.
In four patients the complications
were minor; they included one
wound hematoma, two cases of
transient postoperative fever and
two instances of mild postcholecys
tectomy pain. Postoperative ERCP
failed to demonstrate any residual
biliary disease in either patient with
postcholecystectomy pain. Three
patients experienced major compli
cations. One patient returned 3
days postoperatively with diffuse
bile peritonitis due to a tiny biliary
radicle leaking from the gallbladder
bed. After laparotomy and oversew
ing of the offending ductule, she
was well. A second patient suffered
severe, localized pain in the right
upper abdominal quadrant, 4 days
postoperatively, which eluded diag
nosis despite extensive investiga
tions. Her pain resolved completely
over a 6-day hospital stay, and she
has since been asymptomatic. A
third patient had obstructive jaun
dice from a common-bile-duct stone
3 months after surgery and was
successfully treated by ERCP and
endoscopic sphincterotomy.
On ultrasonography in the 29
patients who had successful laparo
scopic cholecystectomy, 21 adominal ultrasonograms appeared entire
ly normal; there were no abnormali
ties in either the gallbladder fossa
or the perihepatic spaces. In five
patients tiny loculations of fluid
were identified in the gallbladder
fossa as the only ultrasonic abnor
mality. Each had an estimated vol
ume by ultrasonography of 2 to 5
mL. In two patients who had gall
bladder rupture during the opera
tive procedure residual stones were
identified in the subhepatic space
on the postoperative ultrasonogra
phy. One of them also had a tiny
fluid collection in the gallbladder
fossa of approximately 2.4 mL. One
patient had evidence of approxi-
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mately 8 mL of free fluid in Morri
son’s pouch, in addition to a tiny
loculation in the gallbladder fossa;
this patient was found to have a
retained common-bile-duct stone 3
months later.
Plain films of the abdomen (flat
plate, upright kidney, ureter and
bladder, and upright diaphragm),
obtained in 28 of the 29 patients
who had successful laparoscopic
cholecystectomy, disclosed no resid
ual free intraperitoneal gas in 14
patients and only trivial amounts of
free gas in 11 others. Only 3 (11%)
patients had moderate to large
amounts of free gas 24 hours postoperatively. Follow-up films were
not obtained on these patients to
determine the length of time re
quired for complete resolution of
the pneumoperitoneum.
Only 5 of the 28 patients were
considered to have a normal distri
bution of gas throughout the colon
and small bowel. Abnormal colonic
distension was evident in the re
maining 23 (82%) patients. The
mean colonic diameter measured at
the point of maximal distension in
these patients was 6.9 cm (range of
3.5 cm to 12 cm). The gaseous
distension tended to be evenly dis
tributed along the entire colon.
Four patients also had gaseous dis
tension of the small bowel. These
findings were suggestive of a partial
colonic ileus.

Discussion
Our radiologic investigations of
patients who have had a laparo
scopic cholecystectomy disclosed
several interesting findings. The ab
dominal ultrasonogram was normal
or showed only trivial fluid loculations in the gallbladder fossa in 28
of 29 patients. The single patient
with a subhepatic fluid collection
turned out to have a retained com
mon-bile-duct stone, suggesting

that the two might be related. The
common-bile-duct stone might have
caused a bile leak from the cystic
duct, which initially went undetect
ed. The ultrasonogram was unhelp
ful in confirming the clinical suspi
cion of bile peritonitis in one pa
tient; the diagnosis required a technetium-99m-HIDA (2,6-dimethylphenylcarbam oylm ethylim inodiacetic acid) scan for confirmation.7
The ultrasonographic findings sug
gest that any large fluid collection
found in a patient after laparoscopic
cholecystectomy is unusual and
should be carefully assessed, bear
ing in mind the patient’s clinical
condition.
Residual gas from the pneumope
ritoneum appears to be rapidly reab
sorbed after the surgery. Although
no significant effort was made to
remove the intra-abdominal gas
apart from opening the valves on
the trocars before removing them,
only three patients had a significant
amount of free gas remaining in the
peritoneal cavity 24 hours later.
Unfortunately these patients re
fused to return for follow-up of
their residual pneumoperitoneum.
However, the findings suggest that
in a patient with clinical deteriora
tion. large amounts of free gas
remaining in the peritoneal cavity
several days after laparoscopic cho
lecystectomy may be indicative of
an intestinal perforation.
The most unexpected finding
from our study was the frequency
of abnormal colonic distension,
which suggested a partial colonic
ileus. These findings did not corre
late with any abnormality of the
clinical course and, in particular,
were not related to excessive nau
sea or vomiting. The cause for the
colonic distension remains unclear,
but it could represent a colonic
ileus resulting from the use of mo
nopolar electrocautery in the ab
dominal cavity. Other possible ex
planations include the reaction of

the colon to the carbon dioxide
infused into the peritoneal cavity
during the procedure, manipula
tions or retraction of the colon, or
perhaps colonic distension has al
ways been present after cholecys
tectomy but was never before ap
preciated as an unusual finding. In
any event, the frequency of colonic
gaseous distension seen after an
uncomplicated laparoscopic chole
cystectomy detracts from the clini
cal significance of colonic disten
sion in patients with clinical deterio
ration after the procedure. Clinical
evaluation will remain the mainstay
of diagnosis in such cases.

Summary and Conclusions
Laparoscopic cholecystectomy is
a safe and effective alternative to
“ open” cholecystectomy and can
now be considered the procedure of
choice for uncomplicated gallstone
disease.8 Postoperative pneumoperi
toneum after laparoscopic cholecys
tectomy is rapidly reabsorbed. Tiny
fluid collections in the gallbladder
fossa are occasionally seen in the
uncomplicated patient. The only
consistent abnormality we found
was the presence of mild to moder
ate colonic distension 24 hours
postoperatively, which does not
have any specific clinical correlate.
We believe that in patients who
undergo a laparoscopic cholecystec
tomy, the presence of a large vol
ume of free intraperitoneal gas,
large fluid loculations in the gall
bladder fossa or the presence of free
intraperitoneal fluid collections may
represent a complication of the
operative procedure, and these
should be looked upon as signifi
cant findings.
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during the course of his practice. Per
haps the weak point in this book is a
chapter on data collection and analysis,
which seems to have been included to
justify the use of Moh’s micrographic
surgery but has no real practical value
in a book of this sort. In all, this book
is intended to be a guide to encompass
a broad base of physicians, from those
who perform this type of surgery to
those who may require the knowledge
to advise on alternative surgical man
agement of some cutaneous malignan
cies. The editor has provided an easy-toread book that is recommended to all
physicians involved in the treatment of
cutaneous malignant disease.
Louis Weatherhead, MB, FRCPC
Director of dermatologic surgery
Division of Dermatology
University of Ottawa
Ottawa, ON
K1Y 4E9

TRAUMA. 2nd edition. Edited by E.E.
Moore, R.L. Mattox and D.V. Feliciano.
1059 pp. Illust. Appleton & Lange,
Norwalk, Conn. 1991. $150. ISBN 0 8 3 8 5 -9 0 0 7 - 1

This second edition of Trauma, appear
ing just a short time after publication of
the first edition, is a testament to the
fact that trauma management is a dy
namic science. The book is edited by
three giants in the field of trauma.
Chapter contributions and updates are
from well-respected members of the
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increasing “trauma community,” which
now includes epidemiologists, surgeons
and surgeon-internists.
In my opinion, this is the most
comprehensive textbook available on
trauma. It should satisfy the needs of
surgical residents, fellows and attending
surgeons who are involved in both the
clinical management of injured patients
and the design and analysis of trauma
systems.
In fulfilling this goal, the editors
have divided the text into five sections:
trauma overview, general principles,
specific injuries, special problems and
complications. They have clearly laid
the groundwork for the next edition by
recognizing the changing challenges of
trauma management.
The section on trauma overview pro
vides an in-depth review of trauma
epidemiology including injury patterns
and scoring systems and provides a
much-needed boost to the surgeon’s
involvement in the area of injury pre
vention. The majority of trauma special
ists believe that all injuries are prevent
able. The second section on general
principles underscores the continuing
need for an organized approach to
clinical care regardless of the physi
cian’s background specialty. Updated
information regarding resuscitation flu
ids is presented succinctly. An excellent
chapter on trauma radiology has been
retained. Specific injuries are covered in
the third section, which is the longest
and provides in-depth schemes for man
agement of injuries to all body systems
and draws heavily on the expertise of
individual authors. The final two sec

tions continue to present current think
ing in the surgical care of the critically
ill trauma patient. Special problems are
refreshingly reviewed, in particular,
those of rehabilitation, organ procure
ment and the management of battle
casualties.
This textbook brings together a large
number of expert contributors. Despite
this, the editors have made it very
readable. I would recommend this book
to all surgical residents and surgeons
who devote their time and energy to the
total care of the injured patient.

A

Murray J. Girotti, BSc, MD,
FRCSC, FACS
Chief of surgery
Victoria Hospital
375 South St.
London, ON
N6A 4G5

A

PHACOEM ULSIFICATION
SU R 
GERY. Edited by Terence M. Devine
and William Banko. 130 pp. Illust.
Pergamon Press Inc., New York.
1991. $125. ISBN 0 -0 3 6 8 4 -4 1 8 5 -5

On first impression, this very attractive
and well-illustrated manual of phaco
emulsification (PE) surgery seems to be
limited in content and generally superfi
cial in its approach to the complex
subject of PE. In fact, this book superb
ly guides PE surgeons and would-be PE

continued on page 77

■v*

*

-

ORIGINAL ARTICLES
ARTICLES ORIGINAUX

Initial Experience With Laparoscopic
Cholecystectomy in a Teaching Hospital
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The safety of laparoscopic cholecystectomy and the necessary training are serious
concerns. This report describes both the surgical experience and the training and
credentialling process at a private community-based teaching hospital. All 140
laparoscopic cholecystectomies attempted during the initial 9-month experience
(March to December 1990) of 11 surgeons are detailed. There were no deaths. Eight
patients subsequently underwent open cholecystectomy, and another two patients
required reoperation for complications, which included one common-duct
transection. The mean operating time was 106 minutes, the mean hospital stay was
1.6 days and most patients resumed unrestricted activity within 1 week. Use of the
laser in 49% of patients was of no discernible benefit. This early experience indicates
that laparoscopic cholecystectomy is both safe and effective and should be
considered the technique of choice for elective cholecystectomy.
Des doutes ont ete exprimes quant a la securite de la cholecystectomie laparoscopique et de la formation que cette intervention necessite. Cet article decrit l’experience
chirurgicale ainsi que la formation et le processus d’agrement d’un hopital
communautaire prive ay ant une affiliation universitaire. Les 140 cholecystectomies
laparoscopiques tentees au cours des 9 premiers mois (de mars a decembre 1990)
par 11 chirurgiens sont exposees en detail. II n’y eut aucun deces. Huit patients
durent par la suite subir une cholecystectomie ouverte et deux autres patients
necessiterent une deuxieme operation a cause de complications, dont une dissection
transversale du choledoque. La duree operatoire moyenne fut de 106 minutes et le
sejour hospitalier, de 1,6 jours; la plupart des patients purent reprendre leurs
activites normales en moins d’une semaine. L’utilisation du laser chez 49 % des
patients ne fut d’aucun avantage notable. Cette experience precoce indique que la
cholecystectomie laparoscopique est a la fois sure et efficace et qu’elle doit etre
consideree comme technique de premier choix pour les cholecystectomies non
urgentes.

G

eneral surgeons have viewed
laparoscopy as a gynecologic
skill with little if any application to
the management of digestive dis
ease. Despite some enthusiasm,1 di
agnostic laparoscopy has failed to
capture the imagination of abdomi
nal surgeons. With the introduction

of laparoscopic cholecystectomy,
this jaundiced view has been trans
formed to one of near hysterical
advocacy. General surgeons who
have never looked through a lapa
roscope are now streaming in to
learn, in 2-day courses at a mini
mum cost of US $3000, how to
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perform laparoscopic cholecystec
tomy. This frenetic conversion of
the skeptics is, of course, being
ardently promoted by the instru
ment manufacturers but nonethe
less is occurring for legitimate rea
sons. First, the quality of the new
videoscopic instruments is greatly
superior to those available a few
years ago. Second, general sur
geons are rightly overjoyed to em
brace the first major advance in the
management of cholecystitis to
occur in most of their professional
lifetimes. In this paper I describe
the initial experience of 11 sur
geons with laparoscopic cholecys
tectomy at a private, universityaffiliated, teaching hospital.

Methods
Laparoscopic cholecystectom y
was first performed at Rose Medical
Center (RMC) on Mar. 7, 1990. In
July 1990 the centre organized its
own 2-day practical course of in
struction in the technique, which all
of the general surgeons who regu
larly operate at RMC attended.
RMC, on the advice of its Depart
ment of Surgery established the
following criteria for credentialling:
• The applicant must be creden
t i a l s to perform biliary tract sur
gery through a formal residency in
general surgery.
• The applicant must be creden
t i a l s in diagnostic laparoscopy.
For those not cred en tials, all of
the following are required: (a) inCJS, VOL. 35, NO. 1, F E B R U A R Y 1992
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struction in the indications, con
traindications, technique, risks,
complications and results of diag
nostic laparoscopy; (b) participating
(performing or first-assisting) in
enough procedures (minimum 15)
to become proficient in laparoscopy;
(c) the tutor(s) must certify in writ
ing that the applicant is competent
in both the understanding and tech
nique of diagnostic laparoscopy.
• Completion of a practical
course on laparoscopic cholecystec
tomy, one that is endorsed by the
Society of American Gastrointesti
nal Endoscopic Surgeons (SAGES)
or that includes at least 2 days of
hands-on experience in large ani
mals and is offered by a university
department.
• Surgeons currently perform
ing laparoscopic cholecystectomy at
another institution may substitute
the second and third requirements
with a letter from the chairman of
their department attesting to the
number of procedures performed
and the surgeon’s competence.
As with all new privileges grant
ed, this privilege is provisional for
the first year. The first two proce
dures must be supervised by a sur
geon credentialled to perform lapa
roscopic cholecystectomy, and addi
tional supervised procedures may be
required at the discretion of the
department chairman. The proctor(s) must certify in writing that
the surgeon is competent to per
form the procedure.
In addition, if the laser is to be
used during any procedure, sepa
rate written approval by the RMC
Laser Committee for that specific
laser must be acquired.
Careful records of all patients in
whom laparoscopic cholecystecto
my was attempted were kept. No
patients were excluded.
The technique of laparoscopic
cholecystectomy varied slightly
from surgeon to surgeon but was
essentially that recently described
60
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by others.2’3 All operations were
performed under general anesthesia
after informed consent had been
obtained for an open cholecystecto
my if necessary. All patients were
kept in hospital for overnight obser
vation. Initially no patients with a
diagnosis of acute cholecystitis
were scheduled for laparoscopic
cholecystectomy, but this contrain
dication was later partially relaxed.
The only absolute contraindication
was coagulopathy. Contraindica
tions were morbid obesity, multiple
previous abdominal operations and
severe cardiorespiratory disease.
Cholangiography was not rou
tinely performed but was used se
lectively. As experience with the
procedure was gained, cholangiograms were more often obtained. In
all cases, insufflation was with car
bon dioxide. Either laser (Nd:YAG)
or electrocautery was used to dis
sect the gallbladder from its bed. In
all patients the US Surgical Corp.
(Norwalk, Conn.) clip applier was
used to secure the cystic duct and
artery. The gallbladder was usually
extracted through the umbilical
port, but in some cases the epigas
tric port was used. Both reusable
and disposable trocars were used,
depending on operator preference.
Initially residents were permitted
to act only as first assistant or
camera operator. Only after resi
dents had obtained experience in
the animal laboratory and had as
sisted on at least 20 cases were they
allowed to perform the operation
assisted by a staff surgeon.
Results

Between Mar. 7, 1990 and Dec.
31, 1990, a total of 140 patients
underwent laparoscopic cholecys
tectomy at RMC performed by 11
surgeons. The sex ratio and age
range for cholecystectomy were
those usually found (Table I). Obe

sity was not a problem; two patients
weighed 120 kg, but the surgeons
reported that, as with other obese
patients, it was easier to perform
the cholecystectomy laparoscopically than it would have been as an
open procedure. It should be noted,
however, that obtaining the initial
pneumoperitoneum was sometimes
difficult in very obese patients, de
spite the use of a longer Veress
needle.
Previous abdominal surgery was
not a problem in any of the cases.
In some patients who had had sev
eral previous midline laparotomies,
the initial laparoscope insertion (us
ing a 5-mm instrument) was in the
right upper quadrant. This allowed
the standard umbilical port to be
placed under direct vision. In this
way, bowel injury was almost cer
tainly averted.
There was an approximately
equal preference for the use of laser
or electrocautery, and this choice
did not have any influence on either
operating or recovery time. Sur
geons who used the laser always
had electrocautery available and
usually used it to control trouble
some bleeding. Mean operating time
was 106 minutes (range from 40 to
240 minutes), which is undoubtedly
longer than for open cholecystecto
my.
Operative cholangiography was
performed in only 30 cases. This
reflects a reluctance on the part of
most surgeons during the early
learning period to add anything not
absolutely necessary to the opera
tion. In two patients, the cholangioT a b le 1. In itia l E xp e rie n ce w ith
L a p a ro s c o p ic C h o le c y s te c to m y , Rose
M e d ic a l C enter, 1 9 9 0
No. o f p a tie n ts
M a le ife m a le ra tio
M ea n age (ra n g e ), y r
M ea n w e ig h t (ra n g e ), kg
N o. (% ) o f p a tie n ts w h o
u n d e rw e n t p re v io u s
a b d o m in a l s u rg e ry

140
2 7 :1 1 3
49 (1 8 -8 5 )
73 (4 3 -1 2 0 )

5 9 (4 2 )
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gram revealed stones. One under
went endoscopic retrograde cholan
giopancreatography , sph incterotomy and stone extraction 2 days
later; the other had what appeared
to be a single stone, 2 mm in
dimension, at the lower end of the
bile duct without evidence of ob
struction, and nothing more was
done. At 3-month follow-up there
was no clinical or biochemical prob
lem.
Little difficulty was experienced
in exposing and dissecting the gall
bladder. Adhesions between the
gallbladder and the omentum, duo
denum or transverse colon could
readily be stripped from the gall
bladder by blunt dissection or, infre
quently, divided with either laser or
electrocautery. In almost half of the
cases, such dissection was neces
sary, and there were no injuries
resulting from these manoeuvres.
The mean size of the largest
calculus in the gallbladder was 10
mm (range from 1 to 43 mm). It
was surprisingly easy to retrieve
even very large stones by slightly
extending and dilating the fascial
incision used for the umbilical port.
Fascial incisions that were extended
were always sutured. In 41% of the
patients, the intact gallbladder with
contained stones could be simply
removed through either the umbili
cal or epigastric port. In 28% of
patients, the fascial incision was
extended but never by more than
0.5 cm. In the remaining cases,
retrieval was achieved after remov
ing bile or stones, or both, from the
opened gallbladder at skin level. In
17 cases, iatrogenic rupture of the
gallbladder facilitated its removal.
In several such cases, tiny stones
escaped into the peritoneal cavity
and could not be retrieved, but no
problems were encountered as a
result of this misadventure. Drains
were used rarely (6%) and were
placed easily, under direct vision,
into the pouch of Morrison and

brought out through one of the
lateral ports.
The mean length of hospital stay
for the 130 patients who underwent
successful laparoscopic cholecystec
tomy was 1.6 days (range from 1 to
10 days). The patient who remained
in hospital 10 days had a bile leak
that persisted for 7 days and was
accompanied by ileus and compli
cated by pneumonia. At the time of
discharge from hospital both the
leak and pneumonia had resolved,
and the patient was on a regular
diet. Overall morbidity in these pa
tients was very low (Table II).
In eight patients, the procedure
was converted to an open cholecys
tectomy for the reasons listed in
Table III. In two patients re
exploration was required for compli
cations. One patient had an injury
to the common duct just at the
insertion of the cystic duct; the
injury was successfully repaired 3
days after laparoscopic cholecystec
tomy. The second patient suffered a
complete transection of the com
mon bile duct, which was repaired
48 hours later by end-to-side choledochoduodenostomy. Both patients
recovered from these reoperations
without complications.
Follow-up was incomplete (75%)
because many patients were re
ferred from other communities. Al
most all (more than 90%) patients
Table II. Complications of Laparoscopic
Cholecystectomy
Mean hospital stay (range), d
No. of deaths
No. (%) converted to open
procedure
No. (%) needing
re-exploration
No. (%) of other
complications*
Ileus
Urinary retention
Fever
Pneumonia
Bile leak

1 .6 (1 -1 0 )
0
8 (6 )
2 (1 .5 )
7 (5 )
2
4
3
1
1

'Patients may have had more than one
complication.

followed up reported that they had
resumed unrestricted activity within
a week of their operation.

Discussion
The first laparoscopic cholecys
tectomy was performed in Lyon,
France in 1987 by Mouret. The
initial skepticism, particularly at
university centres, about laparo
scopic cholecystectomy has virtual
ly been dispelled by the clear advan
tages in terms of hospital stay and
convalescence as attested to by
both surgeons and their patients.
The economic advantages of laparo
scopic cholecystectomy are obvious.
Conway,4 on the assumption that
the average hospital stay for a pa
tient who underwent open cholecys
tectomy was 5 to 7 days, estimated
that in the United States alone
$4 billion would be saved in health
care expenditures. The increase in
gross national product from the
patient’s return to work in 1 rather
than 6 weeks would be substantially
greater. Questions remain, however,
about appropriate training, credentialling, whether laparoscopic chole
cystectomy may be more dangerous
than open cholecystectomy, what
should be done for patients with
suspected or proven stones in the
bile duct and lesser issues such as
whether laser or electrocautery is
the best dissecting modality.
There is unanimity among genTable III. Reasons for Open Laparotomy
Variable

No. of
patients

Immediate conversion
Adhesions
Perforation of gallbladder
Bleeding
Injury to intestine
Lost cystic duct
Technical problems
Re-exploration
Common-bile-duct injury
Transected common bile
duct

CJS, VOL. 35, NO. 1, FEBRUARY 1992
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2
2
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era] surgeons that only surgeons
trained formally in biliary-tract sur
gery should be permitted to perform
cholecystectomy, whether it be
done conventionally or laparoscopically. General surgeons best under
stand the indications for cholecys
tectomy and are most capable of
dealing with associated problems
and complications. Furthermore, at
any time, a laparoscopic cholecys
tectomy may have to be urgently
converted to an open operation.
Both the American College of Sur
geons and the Society for Surgery
of the Alimentary Tract have gone
on record with their opinion that
only general surgeons should be
credentialled by hospitals to per
form laparoscopic cholecystecto
my.5
Our initial experience confirms,
as would be expected, that when a
group of surgeons (all experienced
in biliary surgery) with varying la
paroscopic skills perform laparo
scopic cholecystectomy complica
tions are encountered. Most difficul
ties were encountered early in the
individual surgeon’s experience (Ta
ble IV). The first three unsupervised
cases of a single surgeon (bile-duct
injury, transected common duct and
a lost cystic duct requiring conver
sion to open cholecystectomy) rep
resent almost the entire morbidity
in this series. This clearly demon
strates that even supervision cannot
prevent complications completely,

but equally suggests that this oper
ation will become substantially safer
as surgeons gain more experience
with it. Our rate of conversion to
open cholecystectomy was perhaps
slightly higher than the rate others
have reported. It is likely that, with
greater experience, this could have
been avoided in several cases. The
lost cystic duct, resulting from in
advertent transection of the duct
while incising it for cholangiogra
phy, could probably have been
found and ligated by a more experi
enced operator. Similarly, the perfo
rations of the gallbladder could
have been closed with a ligature.
Open cholecystectomy was per
formed in one patient in frustration
after the surgeon had struggled for
3 hours with inadequate pneumope
ritoneum. It is essential that future
reports of this procedure give the
reason for conversion to an open
procedure. As surgeons become in
creasingly confident in their ability
to perform cholecystectomy laparoscopically, more complex cases will
be tackled, and a higher percentage
will be appropriately converted.
These cases must be carefully dis
tinguished from those converted to
open procedure because of injury or
other misadventure.
The morbidity in this series is
probably greater than would have
been experienced in a comparable
group of patients treated conven
tionally,6 but it was not excessive.

Table IV. S urgical “ L e a rn in g C u rv e ” : T e m p o ra l R e la tio n s h ip o f C o m p lic a tio n s to S u rg e o n 's
E x p e rie n c e

Surgeon
1
2

3
4
5
6

7
8

9
10
11
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Cases with major
complications

No. of operations
performed

Cases
converted

54
35

2

____

1
1

—

2

—

8
8
8
8
6
6

4

—

—

—

—

—

—

—

—

—

—

2

2

1

—
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However, morbidity in patients who
underwent successful laparoscopic
cholecystectomy (93%) was gratifyingly low (Table II). The total ab
sence of complications such as
wound infection, intra-abdominal
abscess, venous thrombosis, atelec
tasis and myocardial infarction was
striking. This experience represents
part of the “learning curve” for 11
surgeons. Yet there were no deaths,
and only one patient had a compli
cation (transection of the common
bile duct) that is likely to cause
long-term disability. This experi
ence demonstrates that laparoscopic
cholecystectomy is safe as well as
effective and suggests that it should
become the standard technique for
most patients needing cholecystec
tomy.
The best way to handle commonduct stones identified by operative
cholangiography remains highly
controversial. At present there are
no tested means of dealing with the
stones laparoscopically, although
this may soon become routine. The
current major options are to either
convert immediately to an open op
eration and remove the stones
through a choledochotomy or per
form endoscopic retrograde cholan
giopancreatography, sphincteroto
my and basket extraction. This
question needs to be answered by a
properly conducted prospective con
trolled trial. The best way to deal
with common-duct stones identified
preoperatively is no easier to deter
mine.
Less controversial is the role of
laser versus electrocautery for dis
section of the gallbladder bed. The
surgeons who introduced the opera
tion to the United States described
it as a laparoscopic laser cholecys
tectomy.2 As a result, some sur
geons and most patients believe
that the laser, rather than the video
camera, is the essential component
of this new technique. At our insti
tution we have used laser and elec-
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trocautery about equally. In my
opinion, the laser adds nothing to
either safety or efficacy. The hook
electrocautery device, by contrast,
permits the surgeon to achieve a
virtually three-dimensional view of
structures on the two-dimensional
video monitor and in my judgement
is a safer technique. This view is
shared by Voyles and colleagues,7
who also point out that the laser
costs alone for the 500 000 chole
cystectomies performed each year in
the United States could exceed
$250 million, with no discernible
benefit.
Finally, there is the issue of
whether it is appropriate to manage
the patient with acute cholecystitis
laparoscopically. Initially, we were
conservative about this and declined
to attempt the operation in patients
with known acute cholecystitis.
However, with more experience and
having successfully removed laparo
scopically some acutely inflamed
gallbladders, which were encoun
tered unexpectedly, I have revised
my approach. Now, even in the
presence o f pancreatitis, I will at
tempt laparoscopic cholecystecto
my, recognizing, and telling the
patient, that there is much greater
likelihood that an open procedure
will be necessary. In the same way
that there is no sense o f shame or
failure in performing a cholecystostomy for very severe acute cholecys
titis, it should not be considered as
failure to prudently convert laparo
scopic to open cholecystectomy to
avoid complications. I predict, how
ever, that open cholecystectomy

will soon be as infrequent an opera
tion as cholecystostomy is today.
Laparoscopic surgery is likely to
have many other applications. Al
ready in some European centres,
the appendix is routinely removed
laparoscopically.8 Adhesions have
been lysed, hernias have been re
paired9 and a perforated peptic ulcer
has been patched.10 It is now possi
ble to perform a highly selective
vagotom y laparoscopically, and
soon it will be possible to repair a
hiatal hernia and perform bowel
resection. It will become extremely
important to demonstrate that these
surgical tours de force are not only
as safe and effective as conventional
operations, but also that there is
benefit to the patient. It seems, for
example, that the advantage to the
patient o f a laparoscopic appendec
tomy is probably marginal. One
wonders if there was any benefit to
the patient from a more than
7-hour laparoscopic nephrectomy.11
We must guard against the danger
of being driven by technology rath
er than by what is best for our
patients.

Addendum
A further 178 laparoscopic chole
cystectomies have been attempted.
There have been two deaths. In 12
patients the laparoscopic cholecys
tectomy was converted to an open
procedure because of adhesions or
common-duct stones, and there
were two additional bile-duct inju
ries requiring repair. The average
operating time is now 90 minutes.

The operation is now routinely per
formed with a hospital stay o f less
than 24 hours.

1 am grateful to the nursing staff of the
operating rooms at Rose Medical Center
for their skill, good humour and pa
tience during this introductory period
and to the general surgeons for their
enthusiasm and support. I thank Ms.
Pat Martin for preparing the manu
script.
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Laparoscopic Cholecystectomy
in a Patient With Situs Inversus
Viscerum: a Case Report
J.W. Drover, BSc, MD;* K.T. Nguyen, MD, FRCPC;t R.F. Pace, MD, FRCSC, FACS*
A patient with known situs inversus viscerum of the abdomen and congenital heart
disease presented with symptomatic cholelithiasis in a left-sided gallbladder.
Laparoscopic cholecystectomy was carried out successfully, despite the reversed
anatomic relationships, and the patient made a smooth recovery. This is the first
case report of a successful laparoscopic cholecystectomy in a patient with a left-sided
gallbladder.

Un patient souffrant de transposition viscerale et de malformation cardiaque a ete vu
presentant les symptomes de cholelithiase d’une vesicule en position gauche. Une
cholecystectomie laparoscopique fut pratiquee avec succes en depit de l’inversion
anatomique, et le patient guerit sans probleme. II s’agit du premier cas signale de
cholecystectomie laparoscopique reussie chez un patient ayant une vesicule biliaire
en position gauche.

itus inversus viscerum has been
recognized since the time of
Aristotle.1 Various degrees of inver
sion of the abdominal and thoracic
organs have been described as have
other associated congenital abnor
malities and pathologic processes in
the malpositioned organs. Disease
of the biliary tract occurs in pa
tients with situs inversus, and sev
eral cases of cholecystectomy for
gallstone disease in a left-sided gall
bladder have been described.1-4 We
recently encountered a patient with
situs inversus who had symptomatic
gallstones and was managed by la
paroscopic cholecystectomy.

S

Case Report
A 29-year-old woman was seen
complaining of recurrent left-sided

upper quadrant abdominal pain for
6 months. The pain was precipitat
ed by fatty meals and was not
associated with a history of jaun
dice or pancreatitis.
The patient was known to have
situs inversus of the abdominal or
gans with cyanotic congenital heart
disease due to a single ventricle and
transposition of the great vessels. A
Fontan procedure had been per
formed 3 years earlier to ameliorate
her cardiac symptoms, and a hyster
ectomy and bilateral salpingooophorectomy had been done for
pelvic inflammatory disease. She
was taking Coumadin (5 mg orally
once daily) and amiodarone hydro
chloride (400 mg orally once daily).
She had mild central cyanosis
with a single second heart sound. A
nontender liver edge was palpable
at the left costal margin. Ul

trasonography of the abdomen dis
closed cholelithiasis in a left-sided
gallbladder and a non-dilated com
mon bile duct. Liver function tests
showed no evidence of cholestasis.
One week after stopping her
Coumadin, laparoscopic cholecys
tectomy was done. A 10-mm trocar
was placed in both the subumbilical
and subxiphoid locations, and two
5-mm trocars were placed in the left
subcostal region with the video
screen situated above the patient’s
left shoulder. The liver was of a
globular shape, with omentum ad
herent to a left-sided gallbladder
that was chronically inflamed but
otherwise appeared normal (Figs. 1
and 2). The orientation of the gall
bladder and the reversed equipment
set-up made it necessary for the
operator, who is right-handed, to
operate with the left hand. As a
result, the dissection of the cystic
duct and cystic artery proved diffi
cult, but it was still possible to
complete the cholecystectomy laparoscopically. No unexpected aber
rant anatomy was encountered as
predicted by preoperative ul
trasonography. The patient was dis
charged on the day after the proce
dure. Coumadin was restarted, and
she was well at 6-month follow-up.
Pathological examination of the
gallbladder showed cholelithiasis
with chronic inflammation of the
gallbladder wall.
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Discussion
Situs inversus viscerum is a rare
condition, occurring in 1:5000 to
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1:10 000 hospital admissions.4
Cholelithiasis has been reported in
left-sided gallbladders and is
thought to occur with the same
frequency as in the normal popula
tion.1 The pain of biliary colic in
patients with situs inversus may
occur in the epigastrium or the
right or left upper quadrant,3 and
earlier reports emphasized the need
to use full abdominal roentgeno
grams at the time of oral or intrave
nous cholangiography.5 With the
widespread use of ultrasonography
this is no longer an issue in diagno
sis. Although one must always be

FIG. 1. Laparoscopic view of right
upper abdomen. Liver has globular
shape, with falciform ligament (arrow)
to left of midline.

FIG. 2. Laparoscopic view of left upper
abdomen. Gallbladder has been elevat
ed by graspers inserted through left
subcostal trocars. Omental adhesions
(arrows) can be seen on undersurface
of gallbladder.
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wary of the possibility of aberrant
anatomy in patients with situs in
versus, we have not found any
reports of unexpected biliary rela
tionships that might cause difficulty
during cholecystectomy in these pa
tients.
The recent introduction of lapa
roscopic cholecystectomy has ush
ered in a new era in the surgical
treatment of biliary tract disease by
decreasing the postoperative mor
bidity attendant on surgical removal
of the gallbladder. Although the
laparoscopic approach has already
become the standard of care for
uncomplicated biliary tract disease
in many parts of the world, there is
concern that this technique may not
be applicable in patients with al
tered biliary anatomy, which might
make identification of the common
duct difficult and increase the risk
of inadvertent common-bile-duct in
jury.6 Careful dissection beginning
at Hartmann’s pouch with clear
identification of structures before
division will decrease the likelihood
of such catastrophic biliary injuries.
Intraoperative cholangiography may
help to define the anatomy if there
is concern, and conversion to open
cholecystectomy always remains an
option.
We have successfully carried out
the first reported case of a laparo
scopic cholecystectomy on a patient
with situs inversus viscerum despite
the reversed anatomic relationships.
The procedure is more difficult
technically due to the abnormal
spatial relationships of the gallblad
der, cystic duct and cystic artery,
but with care the experienced lapa
roscopic surgeon can successfully
perform laparoscopic cholecystecto
my in these patients.
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Laparoscopic Cholecystectomy and
Choledocholithiasis
Yves-Marie Dion, MD, MSc, FACS, FRCSC;* Jacques Morin, MD, FRCSC;* Guy Dionne, MD, FRCPCjt
Carl Dejoie, MD*
Between November 1990 and March 1991, five patients with cholelithiasis and
associated choledocholithiasis were treated by laparoscopic cholecystectomy and
common-bile-duct exploration (CBDE). Three patients had a successful CBDE, but in
two common-bile-duct stones had to be extracted surgically. Two patients had formal
laparoscopic CBDE, and three patients had CBDE performed through the cystic
duct. All patients recovered from surgery without complication. Laparoscopic CBDE
is difficult to perform because of lack of adequate instrumentation and limited
experience. Although the authors do not recommend that this procedure be
performed widely at present, they believe it will eventually replace many open
CBDEs. The authors review the pertinent literature and evaluate diagnostic means
for preoperative and peroperative detection of choledocholithiasis. They discuss the
alternatives to laparoscopic CBDE, their advantages and disadvantages. Finally, they
summarize their own policy with respect to laparoscopic CBDE.
Entre novembre 1990 et mars 1991, cinq patients porteurs a la fois de cholelithiase
et de choledocholithiase ont ete traites par cholecystectomie et exploration du
choledoque laparoscopiques. Trois patients ont subi une exploration du choledoque
fructueuse alors que chez deux l’exploration a du etre completee l’exploration par
voie chirurgicale. Deux patients ont eu une exploration du choledoque laparoscopique formelle et trois explorations furent effectuees par le canal cystique. Tous les
patients ont evolue normalement en periode postoperatoire, sans complication.
L’exploration laparoscopique du choledoque est presentement difficile a effectuer a
cause d’un manque d’instrumentation adequate et d’une experience limitee.
Bien que pour l’instant les auteurs ne recommandent pas cette approche pour
utilisation generalisee, ils sont convaincus que, dans le futur, elle remplacera une
grande partie des explorations du choledoque qui sont effectuees presentement par
voie ouverte. Les auteurs revisent la litterature pertinente et evaluent les moyens
diagnostiques pre et peroperatoires de la choledocholithiase. Ils discutent aussi des
alternatives a l’exploration laparoscopique du choledoque, leurs avantages et
inconvenients. Ils resument, en terminant, leur propre opinion sur le sujet.

e have performed 523 laparo
scopic c h o lecy stecto m ies
(LC) since our first report on the
technique.1 We have had no deaths

W

and minimal morbidity with the pro
cedure. However, the appropriate
treatment of associated choledo
cholithiasis is still being debated.
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We report here five cases of common-bile-duct exploration (CBDE)
performed during LC and review
pertinent literature.

Case Reports
Case 1

An 82-year-old man presented
with jaundice and right upper quad
rant pain. Endoscopic retrograde
cholangiopancreatography (ERCP)
revealed a stone obstructing the
distal common bile duct (CBD) (Fig.
1). An attempt at endoscopic
sphincterotomy (ES) was unsuc
cessful. During laparoscopic chole
cystectomy, a choledochotomy was
performed with Storz microscissors
(Karl Storz Gmbh, Tuttlingen, Ger
many) distal to the junction of the
CBD with the cystic duct. All ef
forts to remove the impacted stone,
using a red rubber catheter for
irrigation, a Fogarty biliary catheter
or a flexible choledochoscope, were
unsuccessful. The patient under
went formal surgical CBDE, which
led to a prompt recovery.
Case 2

A 32-year-old man was seen be
cause of biliary colic. He had elevat
ed serum bilirubin, alkaline phos
phatase and amylase levels. ERCP
revealed two stones in the CBD but
ES could not be performed (Fig. 2).
A choledochotomy was done laparoCJS, VOL. 35, NO. 1, F E B R U A R Y 1992
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scopically after cholecystectomy,
and a rigid choledochoscope (Karl
Storz Gmbh) was introduced into
the common duct through the
upper midline 5-mm incision, the
trocar at this site having been re
moved. The common duct was com
pletely cleared of stones with the
choledochoscope. Following this, a
no. 14 French T tube was inserted
into the CBD. The patient made a
smooth recovery.
Case 3

A 22-year-old women presented
with biliary colic. On preoperative
ultrasonography she was found to
have not only cholelithiasis but also
a 5-mm bile-duct stone. ERCP was
unsuccessful. With the help of the
radiologist (G.D.), we managed to
push the stone, under laparoscopy,
into the duodenum after manipula
tion through the cystic duct. Cho
langiography done after the proce
dure showed a normal cystic duct.
She was discharged 2 days after
operation.

Case 4

A 54-year-old man had biliary
colic, jaundice and elevated liverfunction test results. He refused
ERCP but was willing to undergo
laparoscopic CBDE and cholecys
tectomy. Operative cholangiogra
phy demonstrated a number of
stones in the distal CBD. We pro
ceeded as for case 3, but we re
trieved the stones through the cys
tic duct using a basket. We left a
no. 7 French modified urinary Cope
loop catheter (Cook Inc., Blooming
ton, Ind.) in the duodenum, inserted
through the cystic duct and secured
to it by an Endoloop (Ethicon Ltd.,
Montreal). A Davol sump drain (Davol Inc., Cranston, RI), inserted
through the right lateral port,1 was
left in the subhepatic space as a
precautionary measure. Postopera
tive cholangiography showed that
the bile ductal system was free of
stones. The patient made an un
complicated recovery. The Cope
loop catheter was removed 3 weeks
postoperatively, after another nor

mal cholangiogram had been ob
tained.
f-T -

Case 5

A 13-year-old girl, weighing 96
kg, presented with acute cholecysti
tis, elevated liver-function test re
sults and a dilated CBD demonstrat
ed by ultrasonography. ERCP
showed a single stone. ES was not
possible, so we attempted to remove
the stone laparoscopically. After de
compressing a thickened and
swollen gallbladder with a no. 14
French Cathlon (Critikon; Johnson
& Johnson Co., Tampa, Fla.) insert
ed percutaneously, we visualized
the cystic duct and the common
duct. We attempted to retrieve the
bile-duct stone through the cystic
duct with a basket. We were able to
introduce the stone into the basket
and bring the basket to the level of
the cystic duct (Fig. 3), which we
thought would be dilated by the
smooth basket. However, the stone
became impacted. A further attempt
to grab the stone caused it to fall
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FIG. 1. Case 1. Large common-bile-duct (CBD) stone impacted in distal CBD.
Attempts to remove stone laparoscopically were unsuccessful and open commonbile-duct exploration (CBDE) was performed.
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FIG. 2. Case 2. This 32-year-old man
had two stones in his CBD. Endoscopic
sphincterotomy (ES) was unsuccessful.
CBD stones were removed by formal
laparoscopic CBDE.
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back into the common hepatic duct.
Because of her young age, we be
lieved that she should not receive
any more radiation. Her weight con
vinced us not to attempt a choledochotomy by laparoscopy. Conven
tional surgery was done without
complications and she returned
home free of stones.

• What should be done when
choledocholithiasis is suspected
pre- or peroperatively?
• What role do ERCP and ES
play?
• Are the new operative tools on
hand adequate to allow the surgeon
to perform a safe laparoscopic
CBDE?
• What are the options?

Discussion

The Fate o f Retained CBD Stones

A number of issues must be
considered when laparoscopic cho
lecystectomy is performed. They are
as follows:
• What is the natural history of
CBD stones?
• Is it necessary to remove them
all, since only 20% of stones in the
gallbladder require removal?
• Is it possible to detect choledocholithiasis preoperatively?
• Should routine or selective
cholangiography be done?

Studies have demonstrated that,
in patients who undergo operation
for cholelithiasis, the incidence of
retained common-duct stones that
become clinically symptomatic after
cholecystectomy without CBDE,
when there are no clinical and bio
chemical indications of the presence
of common-duct stones, ranges
from 0.3% to 0.5%.2 Gerber and
Apt3 pointed out that from the
average experience (i.e., a 6% inci
dence of unsuspected stones) of
those who perform routine peroperative cholangiography, they should
have missed CBD stones in 26 of
438 patients who had cholecystec
tomy without operative cholangiog
raphy. They noted that since only 1
(0.2%) patient became symptomatic,
the stones either caused no problem
or passed spontaneously in all the
others. Gerber and Apt drew atten
tion to the experience of the Massa
chusetts General Hospital in which
there were only four instances of
initially unrecognized CBD stones
that were discovered later after
1280 cholecystectomies without
CBDE (a rate of 0.3%). The same
0.3% incidence was reported from
the New York Hospital-Cornell
Medical Center in an study of
10 008 cholecystectomies.3 Bergdahl and Holmlund,4 in a study of
4078 patients noted the same inci
dence of 0.3% of retained bile-duct
stones. They also documented that
stones smaller than 6 mm in dimen
sion are more likely to pass sponta-
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FIG. 3. Case 5. Stone being extracted
through cystic duct with basket. Un
fortunately, it became impacted in cys
tic duct and could not be removed.
This emphasizes importance of balloon
dilatation of cystic duct at least to size
of stone before extraction. Cystic duct
should likely not be dilated to more
than 9 mm.

neously into the duodenum than
larger stones.
However, stones that do not pass
spontaneously can give rise to
symptoms. The outcome of CBD
stones has been evaluated by many
investigators. Mickley and Reismann,5 over a period of 5 years,
followed up patients with residual
common-duct stones and noted that
all patients had symptoms during
that period. Cainzos and associates6
noted, from a retrospective study on
124 patients with choledocholithia
sis, that the predominant symptoms
were biliary colic in 99% of patients
and jaundice in 65%. Cholangitis
occurred in 5.6%.
Preoperative Screening for
Choledocholithiasis
Preoperative liver-function tests
(LFT) or intravenous cholangiogra
phy, or both, have been suggested
as screening measures along with
ultrasonography.
Liver-function tests as preopera
tive diagnostic investigations for
choledocholithiasis appear to be
valid although not universally ac
cepted. Kiechle, Weisenfeld and
Karcher7 observed that the serum
alkaline phosphatase level is not
useful either alone or in combina
tion with the serum bilirubin level
in determining the presence of CBD
stones. Saltzstein, Peacock and
Thomas8 noted that alkaline phos
phatase appears to be a better indi
cator of common-duct stones than
does bilirubin, but neither bilirubin
nor alkaline phosphatase are in
themselves significant indicators.
They noted, however, that the com
bination of a serum bilirubin level
greater than 51.3 ^m ol/L and a
serum alkaline phosphatase level
greater than 250 U /L (normal 110
U/L) was associated with a 76.2%
probability of a common-duct stone.
Hampson and associates9 made si
milar observations.
CJS, VOL. 35. NO. 1. F E B R U A R Y 1992
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Lacaine, Corlette and Bismuth10
stated that with no previous or
current jaundice, normal alkaline
phosphatase levels and a duct size
at surgery of less than 12 mm there
is less than a 5% risk of choledocholithiasis; elevated bilirubin or al
kaline phosphatase levels indicated
intermediate risks (33% to 66%) and
a duct size of 12 mm or greater,
with any combination of other fac
tors, indicated a 90% to 100% risk
of choledocholithiasis. Del Santo
and associates,11 in a retrospective
study of 195 consecutive patients
who underwent elective cholecys
tectomy (patients who had a history
of jaundice or other clinical indica
tions for CBDE were excluded),
found that when the results of all
preoperative liver-chemistry tests
(serum lactic dehydrogenase, serum
aspartate aminotransferase, serum
bilirubin and serum alkaline phos
phatase) were normal, there was no
incidence of choledocholithiasis. As
the number of test-result elevations
increased from one to four, so the
rate of choledocholithiasis increased
from 17% to 50%. They concluded
that liver-function test results in
patients who undergo elective cho
lecystectomy may provide the sur
geon with a valuable indication as
to whether operative cholangiogra
phy should be performed.
Preoperative intravenous cholan
giography (IVC) has fallen out of
favour over the past decade.12-14
Scott and colleagues15 reported on a
survey made in 30 academic radiol
ogy departments, showing that over
a 10-year period the number of
IVCs decreased from approximately
1728 in 1976 to 8 in 1986. This
finding coincides with the increased
availability of alternative proce
dures.
However, IVC has recently been
suggested as an alternative to rou
tine peroperative cholangiogra
phy.1516 Of 57 patients who had
both intravenous and peroperative
70

JCC, VOL. 35, N ° 1, FEVRIER 1992

cholangiography, Huddy and
Southam17 noted that only one
stone was not detected by IVC.
They suggested that added advan
tages to preoperative cholangiogra
phy are a reduction in the operating
time and advance knowledge of the
biliary anatomy.
Ultrasonography is generally con
sidered a poor indicator of choledo
cholithiasis.18 Birkigt and associ
ates19 examined 192 nonselected
surgical patients with clinically sus
pected gallstone disease by ul
trasonography and found that CBD
stones can be detected with high
accuracy only in patients with ob
structive jaundice and a dilated
common duct.
Although computed tomography
(CT) can reveal CBD stones in over
50% of the cases,18 it should not be
used as a basic examination because
of the high cost and limited avail
ability.14
In summary, the preoperative di
agnosis of choledocholithiasis can
be fairly accurate if the clinical and
biochemical measurements are con
sidered along with the results of
ultrasonography.20 IVC may prove
helpful in the future with the new
dyes on the market. During laparos
copy, palpation of the CBD is not
accurate. Although one cannot as
sume with certainty the impact of
this difficulty, it can be predicted
that it will not be enormous.
Routine or Selective
Cholangiography During LC?

Those who perform routine oper
ative cholangiography have as good
reasons as those who advocate se
lective use of cholangiography.21
Jeppsson and Bengmark22 found
that operative cholangiography per
formed with modern techniques and
fluoroscopy is very accurate, having
a diagnostic accuracy well above
95%. Shiveley and colleagues23 re
viewed 579 consecutive cholecys

tectomies done by one group of
surgeons in a small rural practice
over 8 years. Cholangiography dem
onstrated unsuspected CBD disease
in 5% of the procedures, whereas
12% of the patients were spared an
unnecessary choledochotomy after
a normal cholangiogram was ob
tained. These authors concluded
that routine cholangiography is a
safe, effective and helpful screening
examination. Thompson and Bennion24 used cholangiography routine
ly. In a prospective series of 328
patients, operative cholangiography
identified 19 (6%) patients with si
lent CBD stones. CBDEs were posi
tive in 62 (84%) of 74 operations.
Routine operative cholangiogra
phy during LC has been recom
mended. Phillips and colleagues25
performed cholangiography in 53 of
56 patients who underwent LC. Six
patients had common-duct stones;
five were unsuspected preoperatively. After the gallbladder was re
moved, three patients underwent
open CBDE. In another five cases,
anatomical anomalies were discov
ered. The authors concluded that
cholangiography performed via the
cystic duct before any structures
are divided can prevent the most
serious complication — commonduct injury. They suggested that
cholangiography should be attempt
ed on all patients who undergo LC.
Reddick and colleagues26 performed
routine peroperative cholangiogra
phy during LC.
It appears to us that a policy of
selective operative cholangiography
may lead to a small number of
symptomatic retained common-duct
stones (0.3% to 0.5%) but at the
same time save many patients un
necessary ERCP because of a smal
ler number of false-positive cholangiograms (occurring in up to 17%
of the cases during routine opera
tive cholangiography21).
Many investigators advocate se
lective operative cholangiography.27
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Wilson, Hall and Watts28 also fa
voured a selective approach to cho
langiography. After reviewing 272
consecutive patients who under
went cholecystectomy and routine
operative cholangiography, they se
lected four criteria as indicators for
obtaining an operative cholangiogram as follows: an abnormal CBD
(6 mm or larger by current preoper
ative ultrasonography); a wide cys
tic duct (more than 4 mm at sur
gery); elevated levels of serum alka
line phosphatase in the previous 6
months; or elevated levels of serum
bilirubin documented in the previ
ous 6 months. Operative cholangi
ography would have been indicated
by the presence of one or more of
these criteria in only 139 (51%) of
the 272 patients in their study.
Only one unsuspected stone would
have been missed.
To these four indications for op
erative cholangiography we would
add a previous history of pancreati
tis or jaundice and difficult local
anatomy.
Stark and Loughry2 concluded,
after reviewing the charts of 440
patients who underwent cholecys
tectomy and routine operative cho
langiography, that the yield of oper
ative cholangiography with no clini
cal indication of choledocholithiasis
is extremely low, and the costbenefit ratio of routine operative
cholangiography is high.
A number of other studies agree
with the selective performance of
operative cholangiography accord
ing to indications similar to those
already mentioned.29-33
A final point concerning opera
tive cholangiography is its routine
performance to confirm normal
anatomy. We agree with Del Santo
and associates11 and the editors of
Selected Readings in General Surgery34 that operative cholangiogra
phy should be performed when
needed rather than routinely on all
patients who undergo elective cho

lecystectomy. The best way to avoid
bile-duct injuries during cholecys
tectomy is to perform careful surgi
cal dissection and isolation of the
im portant structures w ithout
clamping or cutting any of these
structures when the gallbladder is
dissected out of its bed from above,
downward toward the triangle of
Calot until the gallbladder is hang
ing from the cystic duct “like a
berry on a stem.” Again, in a few
patients, operative cholangiography
may be helpful, along with careful
dissection, to identify biliary anoma
lies.
During the performance of LC,
we have modified this technique,
but we adhere to the same princi
ples of careful dissection, which are
as follows:
• Never divide any structure in
the triangle of Calot before being
absolutely sure that it enters the
gallbladder.
• Start dissecting at the level of
Hartmann’s pouch and identify the
cystic duct entering it before divi
sion.
• If in doubt, because of adhe
sions or suspected anomalies, ob
tain a cholangiogram through the
cystic duct or the gallbladder (be
cause some congenital anomalies
can be recognized without bile-duct
injury only by injecting dye into the
gallbladder itself)-33
ERCP and ES in Perspective
What should the surgeon do
once choledocholithiasis has been
demonstrated in a candidate for LC?
ERCP and ES with stone extraction
are presently recommended as the
procedures of choice preoperatively
(and postoperatively if choledocholi
thiasis is diagnosed during LC).35"38
If a surgeon adopts the policy of
treating choledocholithiasis after
LC, he or she should know the
success and complication rates of
ERCP and ES in his or her milieu.

The success rate of biliary-tree
visualization by ERCP varies from
73%27 up to 97% in the best se
ries.39"42 Again, the complication
rate of ERCP is low in good hands.
Reiertsen and colleagues43 noted in
their series that diagnostic ERCP
had nonfatal complications in 15
(0.8%) of 1930 procedures, and
there was one death (0.05%).
In good hands ERCP with ES
and stone removal is an efficacious
technique.44 Bickerstaff and associ
ates45 reviewed the results of the
first 272 cases of ES attempted in
Oxford for bile-duct stones. ES was
achieved in 261 patients (96%) and
complete duct clearance was
achieved in 88% of these 261 pa
tients — an overall success rate of
85%. Complications occurred in 26
patients (10%), 5 of whom required
an emergency laparotomy. Eight
patients died within 30 days of ES,
but in only 2 was death attributed
directly to the procedure. Bickerstaff and associates stated that their
results were similar to those from
other large series.
Ginestal-Cruz and associates46 re
ported the experience of 530 con
secutive cases of choledocholithia
sis treated with ES. Therapeutic
goals (drainage and complete stone
removal) were achieved in 95% of
patients with an immediate morbidi
ty of 9% and mortality of 1%.
In his series of 128 patients,
Kullman, Borch and Liedberg47
noted that the common duct was
cleared of stones in 118 cases
(92%). Early complications were
noted in 27 (16%) of 164 sphinc
terotomies, with hemorrhage being
the most common. There were four
deaths within 1 month, two of them
directly attributable to ES. Kuhlman and associates48 reviewed a
series of 36 patients referred for
computed tomography to evaluate
possible complications after ERCP
with sphincterotomy. Complications
detected were acute pancreatitis (23
CJS, VOL. 35, NO. 1, FEBRUARY 1992
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patients), duodenal perforation (11
patients), retroperitoneal dissection
of air (4 patients), pneumoperito
neum (4 patients) and development
of a retroperitoneal abscess (4 pa
tients).
It can be seen that ERCP with ES
is not a benign procedure, carrying
at best 7% morbidity and 1% mor
tality. The success rate varies from
73% to 96%. However, formal sur
gical CBDE also has its complica
tions.
Risks Associated With Formal
CBDE

Herzog and Bertschmann49 noted
a 2.5% death rate in their patients
operated on for cholelithiasis and
choledocholithiasis. Lennert and
Muller50 recorded a morbidity of
16% in their series of 499 patients
and a mortality of 3.8%. Forster
and associates51 analysed periopera
tive data on 284 patients who had
simultaneously undergone cholecys
tectomy and CBDE. They recorded
no deaths but an 18% morbidity in
patients without any or with only
one risk factor. In patients with
four or more risk factors there were
five deaths and 38% morbidity.
Three of the patients who had died
had been operated on because of
septic, obstructive cholangitis with
a serum bilirubin level greater than
85.5 /tmol/L. Operation was per
formed as an emergency in 50 pa
tients. The mortality was 10% and
the morbidity 44%. They concluded
that in an emergency and in pa
tients at risk, ES and stone extrac
tion should precede cholecystecto
my. But surgery remains the man
agement of choice for patients with
few or no risk factors.
Combined LC and Laparoscopic
CBDE

Few studies have been performed
evaluating the morbidity and mor
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tality associated with combined LC
and CBDE. Phillips52 conducted a
prospective study from January
1989 to February 1991, involving
459 consecutive patients who had
LC. CBD stones were detected in 39
of the patients. Twenty-eight of
them had transcystic CBDE, 2 had
laparoscopic CBDE, 4 open CBDE,
1 preoperative ERCP, 1 intraopera
tive ERCP, 1 postoperative ERCP
and 2 who had stones 3 mm or less
in dimension in their CBD were
observed. In one patient there was
failure of the intraoperative ERCP
and in two failure of transcystic
CBDE (among the four offered open
CBDE). There were two major com
plications — a pancreatic pseudo
cyst after intraoperative ERCP and
a bile leak after open CBDE. Nine
patients suffered minor complica
tions — three cases of hyperamylasemia after transcystic CBDE and
six cases of elevated LFT (five after
transcystic CBDE and one after
open CBDE).
The operative time was 161 min
utes for transcystic CBDE and 375
minutes for laparoscopic CBDE.
Postoperative hospital stay was 2.5
days for transcystic CBDE, 8 days
for laparoscopic CBDE and 7 days
for open CBDE. Return to work
time was 7 days after a transcystic
CBDE, 25 days after a laparoscopic
CBDE and 31 days after an open
CBDE. The postoperative stay was
2 days after ERCP and time to
return to work was 7 days, except
for the patient in whom a pseudo
cyst developed, who returned to
work 6 months later.
We believe that a selective ap
proach for removal of CBD stones
either through the cystic duct or
through the common duct greatly
reduces morbidity and mortality
compared with the conventional
surgical approach. For example,
our patient no. 4 had his common
duct drained through the cystic
duct and a Davol drain left in the

subhepatic space, but he had very
little pain on the day after surgery
because he had no incision. He was
able to eat that day and ambulate
freely. He also had no respiratory
problems because he could breathe
and cough painlessly. Patient no. 3
went home 2 days after operation
like our other patients who had LC.
This approach to the removal of
common-duct stones through the
cystic duct has been used during
conventional surgery.5354 Also, our
radiologists are experienced in the
technique of pushing stones into
the duodenum. Stones as large as 9
mm can pass spontaneously into
the duodenum, so this technique of
pushing small stones is not accom
panied by deleterious sequelae.55
Berkman and associates56 pushed
the CBD stones of 17 patients into
the duodenum through a transhepatic approach. They were able
to clear the common duct in all
patients without serious complica
tions and found it an effective alter
native to surgery or ES.
We recommend that laparoscopic
choledochotomy be reserved for pa
tients not amenable to treatment
through the cystic duct. Since clos
ing the choledochotomy around a T
tube can be quite difficult (case 2),
we have inserted a drainage cathe
ter through the cystic duct (case 4),
a technique that Ashrafov57 found
most reliable. For case 1 we should
have used the rigid choledochoscope and proceeded to the usual
piecemeal evacuation of the impact
ed stone.58 We used this technique
in case 2.
We have used the technique de
scribed by Phillips52 for CBDE in
cases of open cholecystectomy and
have found it reliable. We advocate
dilatation of the cystic duct to at
least the diameter of the largest
stone to avoid impaction in the
cystic duct. Phillips did not recom
mend dilatation of the duct to more
than 9 mm. Choledochoscopy
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through the cystic duct and CBD
stone removal is relatively easy
then, especially when stones are in
the distal common duct. When
stones are in the common hepatic
duct or higher, their choledochoscopic removal through the cystic
duct is virtually impossible.
In case 5, we should have dilated
the cystic duct before attempting to
remove the bile-duct stone. This
would have prevented the impaction
and subsequent loss of the stone
into the common hepatic duct. We
thought that the smooth conforma
tion of the basket would permit the
required dilatation of the cystic
duct, but that was not the case.
O u r Current Policy

Our present policy for removal of
CBD stones is as follows:
• If choledocholithiasis is dis
covered preoperatively, ES is of
fered to patients, after informing
them of the possible complications
and the mortality associated with
this technique.
• If a common-duct stone is
present peroperatively (demonstrat
ed by intraoperative cholangiogra
phy or when ES has failed, or due
to a patient’s refusal of ERCP and
ES), we favour laparoscopic treat
ment as outlined in Table I. Howev
er, we would not hesitate to per
form open CBDE if necessary be
cause, as already mentioned, post
operative ES has an inherent failure
rate, which would dictate return of

the patient to the operating room.
Although conservative treatment of
a small stone has been suggested,
we do not advise this approach.
• If a CBD stone is discovered
postoperatively, usually when symp
toms appear, the patient is advised
to undergo ERCP and ES.

Conclusions
We believe that laparoscopic
CBDE, performed either through
the cystic duct or through a choledochotomy, will inevitably follow
the introduction of laparoscopic
cholecystectomy. However, at pres
ent it is a difficult procedure to
perform because of lack of appro
priate instruments. Careful studies
must be conducted before it is wide
ly recommended.
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T isseel in Hypospadias Repair
Thomas J. Kinahan, MD; Hjalmar W. Johnson, MD, FRCSC, FAAP
Tisseel (Immuno AG, Vienna, Austria), a fibrin sealant, adhesive and hemostatic
agent made up of sterilized human and bovine components, was used in hypospadias
repairs. The incidence of fistula and significant edema and the duration of
hospitalization were all reduced in 30 patients who underwent modified Mustarde
repairs in which Tisseel was used when compared with a matched group of 30
repairs without Tisseel. In addition, the rate of complications in fistula repairs and
complex revisions was reduced when Tisseel was used on urethral suture lines and
under all skin flaps.

Tisseel (Immuno AG, Vienne, Autriche), un agent de scellage adhesif et
hemostatique a base de fibrine, fabrique a partir de constituants humains et bovins,
a ete utilise lors d’interventions correctrices dans des cas d’hypospadias. L’incidence
de fistules et d’oedeme important, et la duree d’hospitalisation se sont trouvees
reduites chez les 30 patients qui ont subi une reparation de Mustarde modifiee,
comparativement a un groupe de 30 patients apparies qui n’ont pas eu de Tisseel.
De plus, le taux de complications des reparations de fistules et des revisions
complexes a ete diminue lorsque Tisseel a ete utilise sur les sutures uretrales et
sous les lambeaux de peau.

he use of fibrin in hypospadias
repair has been reported in the
European literature.1 Tisseel (Im
muno AG, Vienna, Austria) is one
such agent currently approved for
use in Canada. It is composed of
human-derived fibrinogen, fibronectin, Factor XIII and plasminogen, to
which bovine thrombin and calcium
chloride solution are added immedi
ately before application to the sur
gical site.
Despite the large number of tech
niques available for hypospadias re
pair, significant complications oc
cur, including urethrocutaneous fis

T

tula, at rates of 4% to 56%,2 edema,
suture-line separation and flap ne
crosis.
We describe our efforts to reduce
complication rates in hypospadias
repair with the use of fibrin sealant.

Patients and Methods
We undertook a retrospective re
view of 175 consecutive procedures
performed, by three operators, for
hypospadias on 115 patients be
tween June 1986 and June 1989.
Procedures evaluated included a

From the Department o f Surgery (Urology), British Columbia Children’s Hospital, University o f
British Columbia, Vancouver, BC
Accepted fo r publication Mar. 11, 1991
Reprint requests to: Dr. Hjalmar W. Johnson, Department o f Surgery, University o f British
Columbia, 950 W 10th Ave., Vancouver, BC V5Z 4E3

modified Mustarde technique, used
for midshaft to distal hypospadias,
Thiersch-Duplay or Broadbent-type
procedures for more severe degrees
of hypospadias and microscopic fis
tula repair (Table I). From Novem
ber 1987 Tisseel was used as a
surgical adjunct in 78 of these
repairs.
The technique of application is as
follows: two solutions, one of fibrin
ogen, aprotinin, Factor XIII, fibronectin and plasminogen and the
other of thrombin and calcium, are
prepared at least 15 minutes before
use; a double-barrelled, singletipped syringe simultaneously mixes
and applies the solution to the
surgical site (Fig. 1); a thin layer is
applied, and coagulation, signified
by the appearance of an opaque
film, occurs within seconds; further
layers may be applied as required
for long suture lines or extensive
dissection. In addition, we placed
sealant under skin flaps, a tech
nique that we believed decreased
subsequent edema and improved he
mostasis. The solutions may be
used for up to 4 hours after prepa
ration.
Complication rates were evaluat
ed with respect to the occurrence or
recurrence of fistula, development
of significant edema, defined as a
postoperative increase in penile di
ameter of more than 50%, suture
line separation and flap necrosis.
The total duration of hospitaliza
tion was also noted for the patients
who underwent the modified Mus
tarde procedure.
CJS, VOL. 35, NO. 1, FEBRUARY 1992
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Results
Modified Mustarde Repair

FIG. 1. Double-barrel, single-tip syringe for application of fibrin sealant.

Table 1. Procedures P erform ed on 115 P atients

The two groups of patients who
underwent modified Mustarde3 re
pairs, with and without Tisseel, are
not comparable in that three sur
geons were involved and the proto
col was not randomized. Postopera
tive fistula formation and objective
comparison of the amount of edema
noted during the hospital stay
formed the basis for comparison.
Fistula occurred in 2 (7%) of 30
patients in whom Tisseel was used,
compared with 6 (20%) of 30 pa
tients in whom Tisseel was not used
(Table II).
The incidence of marked edema
was reduced from 13% (4 of 30) in
the repairs not using Tisseel to 7%
(2 of 30) when Tisseel was used
(Table III).

No. of procedures
W ith Tisseel

Procedure

W ithout Tisseel

M od ifie d M ustarde
Extended tubularized fla p *
F istula repair*
C o m plex revisio n M ustarde*
O rth o p lasty o n ly *

30
24
15
7
2

30
26
32
7
2

Total
M ean fo llo w -u p , mo.

78
10

97
17.1

'In c lu d e s all types: T hiersch--D u p la y o r B roadbent procedures and m icro sco p ic fis tu la repair

Table II. F istula Rates in H ypospadias Repairs
W ith Tisseel,
no./total no. (% )

Procedure

W ithout Tisseel,
no./total no. (% )

M od ifie d M ustarde
Extended tubularized flap
F istula repair
C o m p le x revisio n M ustarde
O rth o p lasty o nly

2 /3 0 ( 7)
3 /2 4 (13)
1 /1 5 ( 7)
0/ 7
0/ 2

6 /3 0
1 0 /2 6
7 /3 2
4/ 7
0/ 2

(2 0 )
(3 8 )
(2 2 )
(57)

Total

7 /7 8 ( 9)

2 7 /9 7 (2 8 )

Table III. Edem a Rates in H ypospadias Repairs
Procedure
M od ifie d M ustarde
Extended tubularized flap
F istula repair
C om plex revision M ustarde
O rth o p la s ty o n ly
Total

76
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W ith Tisseel,
no./total no. (% )

W ithout Tisseel,
no./total no. (% )

2 /3 0 ( 7)
7 /2 4 (29)
0 /1 5
1 / 7 (14)
0/ 2

4 /3 0 (1 3 )
1 1 /2 6 (42)
0 /3 2
3 / 7 (43)
0/ 2

1 0 /7 8 (13)

1 8 /9 7 (18)

Fistula Repair

Of the patients who underwent
fistula repairs by one of three sur
geons, the incidence of recurrence
was 22% (7 of 32) when Tisseel was
not used compared with 7% (1 of
15) when Tisseel was used. Evalua
tion of suture-line separation, flap
necrosis and duration of hospital
ization revealed no significant dif
ference for these parameters.
There were no complications or
side effects of the use of Tisseel
over a follow-up of 3 years.

Discussion
Although fibrin tissue sealant has
been available for 12 years in Eu
rope, it has only recently been made
available in North America.4 Tisseel
is approved for clinical use in Cana
da, and approval is pending in the
United States. The approximate
cost will be $60 US per 0.5-mL
application.

FIBRIN SEALANT IN HYPOSPADIAS REPAIR
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The potential risks of using Tisseel include foreign-body reaction,
wound infection and transmissible
disease from human blood pro
ducts, but none of these has oc
curred in over 1 million applica
tions.5 Donors are screened for
hepatitis B surface antigen, hu
man immunodeficiency virus and
alanine aminotransferase levels, an
indirect screen for non-A, non-B
hepatitis. All human-derived pro
ducts are heat-treated for steriliza
tion.
When we evaluated two groups
(with and without the use of Tisseel) of distal hypospadias repairs
performed by three surgeons, we

found a reduced incidence of fistula
occurrence or recurrence and of
postoperative edema when Tisseel
was used. Closure of fistulas was
also more successful when Tisseel
was included with the microscopic
repair.

Conclusions
The use of Tisseel in hypospadias
and fistula repairs appears to confer
some benefit — the sealant effect
may be responsible for decreased
fistula formation, and the hemostat
ic and adhesive effects may improve
wound healing.
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surgeons through the important areas
of this science.
After a brief and delightful historical
review by Charles Kelman, the creator
of PE, and a chapter on instrument
design and operation, the remaining
three chapters weave the skills of the
contributing authors into the surgical
procedure of PE. The special topics of
small-pupil PE surgery, anterior-cham
ber PE and astigmatism control are
nicely presented. Although I believe
that anterior-chamber PE should not be
routinely used, Kelman describes his
technique and adds considerably to any
ophthalmologist’s understanding of the
PE process.
Much is gained in the quality of the
presentations through the clear notes
and related diagrams and tables, as
individual surgeons describe their
unique styles and express opinions on
important PE subjects. Capsulorhexis,
two-handed nuclear handling, cortical
aspiration and wound-closure tech
niques are thoroughly detailed. General
ly, the editors have made the many
principles and techniques flow smooth
ly, while presenting the variations
unique to each author.
The section on control of astigma
tism by Lee Nordan is the best summa

ry of this important subject that I have
seen. With illustrations and tables it
comprises only eight pages!
The section on complications, as pre
sented, is well done but incomplete. The
review is limited to major intraoperative
problems.
This book is clear and easy to read. It
will be helpful mainly to ophthalmolo
gists early in their experience with PE,
because it covers the essential PE sci
ence and surgery very well. Surgeons
experienced in PE will enjoy the book
mainly as a review and may find the
tables describing the authors’ prefer
ences of local anesthetic, instrument
settings, sutures and so on useful.
If there is a weakness in this manual,
it lies in the author’s preponderance of
two-handed surgery. In all but the dens
er cataracts, one-handed PE surgery is
popular and requires a more thorough
review of the many ways to break the
circumferential continuity of the nucle
ar rim and to remove the nucleus safely
through the relatively small anterior
capsulotomy or capsulorhexis. Readers
will have to go to other texts for this
information. As is typical in areas of
expanding science, other books will
also be required to broaden and deepen
the understanding necessary to be com

fortable with PE surgery. Schools of
ophthalmic surgical science should con
sider this book essential for their collec
tion.
Rod A. Morgan, MD, FRCSC,
Dipl ABO
Consultant opthalmologist
Ste. 1152
10830 Jasper Ave.
Edmonton, AB
T5J 2B3

DISORDERS OF THE FOOT AND
ANKLE. MEDICAL AND SURGICAL
MANAGEMENT. 3 volumes. 2nd edi
tion. Edited by Melvin H. Jahss. 2957
pp. Illust. W.B. Saunders Co., Phila
delphia, 1991. $493.75. ISBN 0 7 2 1 6 -1 3 2 7 -6 (set)

The new edition of this definitive text
has been enlarged to three volumes,
containing a total of 109 chapters. The
books are divided into 11 sections.
There are two new sections on biome
chanics and current research; the bi

continued on page 97
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in combination with 5-fluorouracil

Prescribing Information
ACTION
ERGAMISOL (levamisole hydrochloride) is capable of restoring impaired immune responses
preferentially of the cell mediated type in compromised hosts. Therapeutic doses of lev
amisole restore to normal the functions of monocytes (phagocytes) and T lymphocytes
but do not directly influence B cells.
Levamisole is rapidly absorbed from the gastrointestinal tract following a single oral ingestion
of 150 mg. In patients with neoplastic disease, a mean peak blood level of 0.86 mcg/mL
is attained within 2 hours of intake.
The half-life of elimination of levamisole alone is between 3-4 hours. The metabolites are
eliminated more slowly with a terminal half-life of approximately 16 hours. Levamisole
is extensively metabolized by the liver in man and excreted mainly by the kidneys (70%
over 3 days). Approximately 5% is excreted in the feces. Less than 5% of the unchanged
dose is excreted in the urine and less tnan 0.2% in the feces.
INDICATIONS
ERGAMISOL (levamisole hydrochloride) is indicated as adjuvant therapy in poor prognosis
malignant melanoma following complete surgical excision and exclusion of metastatic
disease. In such patients, levamisole has been shown to produce an improvement in relapse
free survival and overall survival when compared to observation alone, particularly in patients
aged 55 years or older.
ERGAMISOL is also indicated as adjuvant therapy, in combination with 5-fluorouracil, in
patients with completely resected Dukes' stage C colon cancer. Evidence of metastatic
disease must be excluded before initiating therapy. In patients with Dukes' stage C carcinoma
of the colon, a regimen of levamisole plus 5-fluorouracil has been shown to produce sig
nificant reductions in both cancer recurrence and overall death rate.
CONTRAINDICATIONS
Levamisole is contraindicated in patients with a known hypersensitivity to the drug.
WARNINGS
ERGAMISOL (levamisole hydrochloride) has been associated with reversible leukopenia
and agranulocytosis, therefore it is essential that appropriate hematological monitoring
be done routinely during therapy with ERGAMISOL.
Patients should be instructed to report immediately any sudden change in their state of
health which may be manifested by influenza-like symptoms (fever, lassitude, sore throat,
shivering or sweating) so that appropriate hematological testing can be done.
Leukopenia (total WBC below 3000 mm!) is not necessarily a sign of impending agran
ulocytosis; recovery is possible w ithout withdrawal of the drug. However, with a reduced
neutrophil count (less than 20% of the total white blood cell count) levamisole should be
discontinued permanently. (Agranulocytosis is attributed to antibody formation and absorp
tion of immune complexes. This process initiates complement activation and cell lysis;
levamisole itself does not directly damage granulopoiesis.)
The HLA genotype B27 predisposes to the development of agranulocytosis, particularly
in females with concomitant rheumatoid arthritis. The onset is frequently sudden and may
be asymptomatic. Following discontinuation of levamisole, neutrophil counts normalize
within a week to 10 days. There is no evidence that steroids or WBC transfusions are of
significant therapeutic value; prophylaxis of infection during the acute phase of agranu
locytosis should be an important consideration.
PRECAUTIONS
Drug Interactions; The therapeutic effect of levamisole may be antagonized by concomitant
administration of corticosteroids.
Additional caution is necessary when levamisole is used in combination with other drugs
potentially affecting hemopoiesis.
Levamisole has been reported to produce “ANTABUSFM"-like side effects when given con
comitantly with alcohol,
ADVERSE REACTIONS
Approximately half of all patients treated with ERGAMISOL (levamisole hydrochloride) expe
rience adverse effects of the medication. Due to the intermittent nature of the dosage sched
ule, drug discontinuation may not be necessary for successful resolution.
The adverse reactions observed when levamisole is used in combination with 5-fluorouracil
are consistent with those anticipated if 5-fluorouracil is given alone in a comparable dose
and schedule.
The incidence of adverse reactions fo r levamisole alone in malignant melanoma patients
and for levamisole plus 5-fluorouracil in colonic cancer patients is presented in the following
table:
LEVAMISOLE
ADVERSE REACTIONS
GASTROINTESTINAL
nausea
vomiting
diarrhea
taste change
anorexia

MELANOMA
24
6
10
1

INCIDENCE (%)
LEVAMISOLE+5-FU
COLONIC
MAINTENANCE
INDUCTION
37
8
25
2

56
17
47
7

ADVERSE REACTIONS
MUCOCUTANEOUS
stomatitis
dermatitis
severe
alopecia
conjunctivitis
hyperpigmentation
HEMATOLOGICAL
leukopenia
2000 to 4000/mm3
less than 2000/mm3
thrombocytopenia
50000 to 130000/mm3
less than 50000 /mm3
agranulocytosis
MUSCULOSKELETAL
arthralgia/myalgia
NEUROLOGIC
visual change
smell change
headache
dizziness/vertigo

MELANOMA
1
4

COLONIC
INDUCTION
MAINTENANCE
27
8
1
4
1

28
22
1
22
7
2

38
7

38
2

4
2

18
4

2

4

8
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2
5
4
3
2
2
1
1
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1
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1
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2
1
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Product monograph available on request.
1. Moertel CG et al. Levamisole and fluorouracil for adjuvant therapy of resected colon
carcinoma. New Engl J Med. 1990;322:352-8.
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DOSAGE AND ADMINISTRATION
In patients with malignant melanoma
ERGAMISOL (levamisole hydrochloride) should be administered at a dose of 2.5 mg/kg
given as a single daily dose, preferably at night, on 2 consecutive days every week. Higher
doses are not recommended as they are associated with increased toxicity and have not
been shown to provide any additional therapeutic benefit.
In patients with Dukes' stage C carcinoma of the colon
Levamisole plus 5-fluorouracil should be administered only by or under the supervision
of qualified physicians, experienced in cancer chemotherapy, and well versed in the use
of potent antimetabolites.
Therapy with ERGAMISOL may be initiated as soon after resection as patients are able
to tolerate oral medication, but no sooner than one week and no later than five weeks after
surgery.
ERGAMISOL should be administered orally at a dose of 50 mg t.i.d., for three consecutive
days, every two weeks. This therapy should be continued for at least one year.
Administration of 5-fluorouracil should be timed to begin concomitantly with the second
three day course of levamisole. The initial dosage of 5-fluorouracil should be 450 mg/m!/day,
given intravenously, fo r five consecutive days.
Four weeks following the initial five day course of 5-fluorouracil, patients should begin
maintenance therapy on a once weekly basis with an intravenous injection of 5-fluorouracil
at a dose of 450 mg/m3. Treatment should continue for as long as levamisole is administered.
If the patient experiences stomatitis, diarrhea or leukopenia, the weekly 5-fluorouracil admin
istrations should be deferred until these side effects have subsided. If these side effects
are moderate to severe in intensity, 5-fluorouracil should be resumed with a 20% reduction
in the dose.
Dosage Forms:
Availability: ERGAMISOL tablets 50 mg are available in blister packages of 36 tablets.
Storage:
ERGAMISOL tablets 50 mg should be stored at room temperature and pro
tected from moisture and light.
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SYMPTOMS AND TREATMENT OF OVERDOSAGE
There is no experience of overdosage with ERGAMISOL (levamisole hydrochloride). At
high doses ERGAMISOL exhibits positive inotropic and chronotropic properties on heart
muscle as well as convulsant properties. General supportive measures are recommended.
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Syndrome cardio-cutane et myxomes
cardiaques : presentation d’un cas
et experience chirurgicale de 17 ans
Richard Baillot, MD, FRCSC;* Jean-Frangois Tanguay, MD;f Real Lebeau, MD, FRCPC;t
Marc Klein, MD, FRCPC;t Serge Allard, MD, CSPQ;J Anne-Marie Grothe, MD, FRCPC;t
Leon Dontigny, MD, FRCSC;* Pierre Page, MD, FRCSC;* Robert Cossette, MD; FRCSC*
De 1971 a 1988, plus de 4000 patients ont subi une chirurgie a coeur ouvert a
l’Hopital du Sacre-Coeur de Montreal. Parmi ceux-ci, 13 etaient porteurs d’un
myxome cardiaque (0,003 %). Un de ces malades etait porteur de tumeurs multiples
de l’oreillette droite et presentait une pigmentation cutanee anormale, syndrome
recemment identifie sous le terme de complexe de Carney. Ce syndrome peut
egalement s’accompagner d’anomalies endocriniennes dont l’hyperplasie nodulaire
surrenalienne, avec ou sans syndrome de Cushing. Les auteurs ont revu la
litterature, y comparant leur experience anterieure dans le traitement chirurgical du
myxome cardiaque.

Between 1971 and 1988, cardiac myxoma was identified in 13 (0.003%) of 4000
patients who underwent open-heart surgery at the hopital du Sacre-Coeur in
Montreal. One patient with multiple right atrial tumours also had abnormal
cutaneous pigmentation compatible with the recently identified syndrome of
“Carney's complex.” This syndrome has also been associated with endocrine
abnormalities such as primary nodular adrenal hyperplasia, with or without
Cushing’s syndrome. The authors review the literature and compare the findings
with their experience in the surgical treatment of cardiac myxomas.

L

e myxome, malgre sa faible
incidence, demeure la tumeur
cardiaque la plus frequente. Identi
fie au 16e siecle par Columbus,1 il
fallut attendre les progres tech
niques de la chirurgie a coeur ouv
ert pour en realiser l’exerese. Crafoord2 en 1954 proceda le premier a
la resection d’un myxome de l’oreil
lette gauche sous circulation extracorporelle et Gerbode et collegues,3
en 1967, decrivaient une recidive

d’un myxome 4 ans apres son exerese.
Au cours des 17 dernieres annees, plus de 4000 maladesont subi
une chirurgie a coeur ouvert dans
notre centre hospitalier. De ce nombre, 13 etaient porteurs d’un myxo
me cardiaque (0,003 %). Le dernier
de ces malades, porteur d’une pig
mentation cutanee associee a de
multiples tumeurs de l’oreillette
droite, nous a conduit a reviser

Du *departement de chirurgie. fdepartement de medecine et fdepartement de pathologie,
Hopital du Sacre-Coeur, Universite de Montreal, Montreal, Que.
Accepte pour publication le 12 decembre 1990
Les demandes de tires a part doivent etre adressees a : I> Richard Baillot, 12 245, rue Grenet,
Ste. 303, Montreal, QCH4J2J6

notre experience dans le traitement
de cette affection.

Observation clinique
Un homme age de 27 ans est
re$u pour investigation d’un souffle
cardiaque en janvier 1988. Les an
tecedents medicaux revelent un epi
sode de purpura thrombocytopenique en 1987, attribue a la prise
d’alcool, alors que sur le plan chi
rurgical, on ne signale que des
fractures traumatiques du femur et
de l’avant-bras droit survenues en
1973. Sur le plan familial, la mere
agee de 53 ans, est connue hypertendue et hypercholesterolemique
alors que l’on compte 10 freres et 7
soeurs dont l’etat de sante est sans
particularite.
La symptomatologie du malade
est caracterisee par des episodes de
dyspnee nocturne paroxystique, accompagnes de diaphorese. A l’examen, on retrouve un jeune malade
mesurant 1,66 m et pesant 48 kg.
A l’inspection des teguments, on
note une pigmentation noiratre autour des levres et des yeux (figs. 1
et 2). L’examen des jugulaires met
en evidence une onde V proeminente et, au niveau du thorax, un
fremissement systolique est palpe.
Le rythme cardiaque demeure regulier et un souffle systolo-diastolique
III / VI est audible a tous les foyers
CJS, VOL. 35, NO. 1, FEBRUARY 1992
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d’auscultation. La tension arterielle
s’eleve a 1 3 0 /8 0 mm Hg. Le foie
est percute sur 12 cm et il n’y a pas
de splenomegalie. L’examen des organes genitaux externes est normal.
La formule sanguine temoigne
d’une thrombocytopenie a 82,000
plaquettes / mL et le taux de sedi
mentation demeure normal. Le profil biochimique revele une elevation
des phosphatases alcalines a 206
U / L (normale, 40 a 135 U / L), et
un taux de gamma GT a 108 U / L
(normale, 7 a 64 U / L). Une etude
de la moelle osseuse demontre une
cellularite normale avec des megacaryocytes augmentes en nombre.
I p rnagulogramme est sans particularite. Le dosage urinaire du corti
sol libre sur 24 h s’eleve a 187
nmol / dL (normale, 50 a 250 nmo1 / dL), et le dosage du cortisol
sanguin a 8 : 00 et 16 : 00 demeure
a un taux normal.
L’electrocardiogramme demontre

un bloc de branche droit avec une
hypertrophie ventriculaire droite. A
la radiographie pulmonaire, on retrouve une cardiomegalie aux
depens des cavites droites et une
absence de dilatation de l’artere
pulmonaire. L’index cardiothoracique est mesure a 1 7 /3 0 ,5 cm
(0,55), et des calcifications se projettent au niveau de l’aire tricuspidienne.
Une echographie cardiaque (fig.
3) met en evidence un volumineux
myxome de l’oreillette droite (OD)
d’aspect heterogene, faisant protru
sion dans le ventricule droit avec
dilatation importante de l’oreillette
et du ventricule droits (40 mm).
Une insuffisance tricuspidienne
severe est demontree. Aucune anomalie n’est signalee au niveau des
autres valves et la fonction systolique du ventricule gauche demeure
normale.
Une scintigraphie pulmonaire exclut la presence de phenomenes
emboliques. Une serie digestive

complete le bilan en raison de l’atteinte muco-cutanee et elimine
toute anomalie ou polypose intestinale.
r '•*'

Technique chirurgicale
Sous circulation extra-corporelle
avec hypothermie moderee et cardioplegie sanguine, une auriculotomie droite est pratiquee et une
volumineuse tumeur plurilobulee et
calcifiee par endroits est retrouvee,
originant du septum inter-auriculaire. Cette tumeur occupe completement le ventricule droit et se projete
dans la chambre de chasse de celuici.
Cette tumeur est enlevee et deux
autres foyers d’implantations satelli
tes sont par la suite identifies au
niveau du septum inter-auriculaire,
dont un pres de la valve d’Eustache.
L’anneau tricuspidien etant fortement dilate et les feuillets valvulaires erodes, on procedea un rempla-
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FIG. 1. Pigmentations cutanees periorbitaires.

a
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FIG. 2. Pigmentations muco-cutanees
de la region peribuccale.
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FIG. 3. Echographie bidimensionnelle: volumineux myxome auriculaire droit
(fleches). OD = oreillette droite, VD = ventricule droit; OG = oreillette gauche; VG
= ventricule gauche.
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cement valvulaire tricuspidien avec
une heterogreffe porcine de 31 mm,
apres fermeture de la communica
tion interauriculaire creee par
l’exerese de la tumeur.

ce myxoi'de renferme de rares cellu
les tantot etoilees, tantot polyhedriques, et montre des foyers d’hemor
ragies anciennes et recentes avec
des calcifications importantes.

Pathologie

Etude retrospective

L’examen macroscopique des
trois formations tumorales prele
vees fait etat de masses mesurant
1,0 X 1,5 X 1,5 cm pour la plus
petite et 5,5 X 6 X 10 cm pour la
plus volumineuse qui occupait la
chambre de chasse du ventricule
droit (fig. 4). Elies ont des contours
arrondis, legerement polylobes avec
une surface luisante et rougeatre.
En coupe, le parenchyme d’aspect
gelatineux, presente une coloration
blanc-rougeatre et est parseme de
foyers d’hemorragies punctiformes.
L’histologie confirme le diagnos
tic d’un myxome dont le stroma est
pale, legerement acidophile et ho
mogene. II se colore'faiblement a
1’acide periodique-Schiff (APS) et
devient fortement positif au bleu
alcian, coloration qui s’attenue
apres hyaluronidase. Cette substan

De 1971 a 1988, 12 autres pa
tients ont subi l’exerese de myxomes cardiaques dans notre milieu
(tableau I). De ce nombre, quatre
etaient des hommes et huit des
femmes dont l’age moyen respectif
etait de 51 et 52 ans (ecart de 43 a
76 ans). Parmi ces cas, on doit
souligner la presence d’un myxome
bi-auriculaire et d’une tumeur originant du feuillet posterieur de la
valve mitrale. Au plan physiopathologique, sept (58,3 %) de ces pa
tients ont presente des phenomenes
emboliques, six (50,0 %) ont eu des
perturbations de leur hemodynamique et quatre (33,3 %) des manifes
tations systemiques.

V r

V
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Modes de presentation

Embolies. Parmi les sept malades
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FIG. 4. Pathologie macroscopique des trois implantations tumorales.

(58,3 %) qui ont eu des embolies,
cinq se sont presentes avec un
tableau neurologique caracterise
par une ischemie cerebrale transitoire dans le territoire vertebro-basilaire avec ophtalmoplegie chez l’un,
une atteinte cerebelleuse avec nys
tagmus chez un second, et une
ophtalmoplegie avec dysarthrie
chez un troisieme malade.
Deux autres cas se sont respectivement manifestos par une hemiparesie gauche, et un autre par une
hemiplegie droite accompagnee
d’une paralysie faciale et embolies
retiniennes.
Le diagnostic de myxome a ete
fait suite a une embolectomie au
membre superieur chez un autre
malade et, quant au dernier patient
de ce groupe, des lesions inflammatoires d’allure embolique presentes
au niveau des membres inferieurs
menerent au diagnostic de myxome
cardiaque par echographie.
Cette derniere patiente est
decedee 6 mois apres son operation,
des suites d’embolies myxomateuses au niveau du cerveau, du foie et
de la rate. En coupe, le cerveau
presentait des hemorragies multi
ples secondaires a la rupture des
vaisseaux embolises (fig. 5).
Alterations hemodynamiques.
Six patients (50 %) se sont presen
tes suite a une perturbation de leur
equilibre hemodynamique. Cinq pa
tients accusaient une dyspnee importante avec oedeme pulmonaire
chez deux d’entre eux, un avait eu
une syncope et deux etaient porteurs d’une stenose mitrale, le
myxome ayant ete une decouverte
fortuite lors de l’exploration chirurgicale.
Manifestations systemiques. Des
manifestations de nature systemique ont ete retrouvees plus specifiquement chez 4 patients (33 %)
comprenant deux cas avec anemie
(16,6 %). Nous notons plus particulierement des myalgies importantes
au niveau des membres inferieurs
CJS. VOL. 35, NO. 1, FEBRUARY 1992
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en effet l’hopital 10 jours apres
l’operation, le taux des plaquettes
s’etant normalise. Un an apres son
intervention chirurgicale, le malade
est completement asymptomatique,
sans recidive ou hypercortisolisme.
Les resultats biologiques temoignent en effet d’une cortisolurie des
24 heures de 363 nmol / j (normale, 110 a 436) avec freinage adequat
a la dexamethasone.
La radiographie pulmonaire
demontre une regression de l’index
cardiothoracique qui est mesure a
13 / 30,5 cm (0,42), et une echographie cardiaque met en evidence
une bioprothese en position tricuspidienne dont l’aire est de plus de 2
cm2, avec un gradient moyen de 2
mm Hg. A ce jour aucun autre cas
n’est identifie dans la famille im
mediate du patient.

chez un patient, et chez un autre
malade, une perte de poids de plus
de 20 kg.

Resultats
devolution immediate de ces malades fut favorable dans 12 cas. Une
patiente est decedee en periode
perioperatoire, soit une mortality
chirurgicale immediate de 7,6 %.
Aucune complication ne fut par
ailleurs relevee et le sejour hospitalier moyen fut de 24 jours (ecart 8 a
71 jours). Une patiente est decedee
durant la premiere annee suivant
son intervention, d’hemorragies
cerebrales secondaires aux embolies
myxomateuses. Un autre deces fut
enregistre 6 ans apres la chirurgie,
la cause du deces n’etant pas attribuable au myxome (tableau I). Par
ailleurs, aucune recidive locale de la
pathologie initiale n ’a, a ce jour, ete
mise en evidence.
Les suites postoperatoires de
notre dernier patient demeurent
sans particularite. Le malade quitte

etait porteur de multiples tumeurs
de l’oreillette droite associees a une
pigmentation cutanee anormale.
Cette association ou syndrome cardio-cutane fut decrite en 1973 par
Rees, Ross et Deen4 et en 1980 par
Atherton et collegues,5 sous le
terme de “name syndrome” (naevus, myxome auriculaire, neurofibrome myxoi'de et ephelides). En
1984, Rhodes et collegues6 rapporterent un cas de myxome cardiaque
associe a des lesions cutanees carac-

Commentaires
Cette etude retrospective nous a
permis d’identifier 13 patients souffrant de myxome cardiaque dont 1

FIG. 5. Hemorragies cerebrales secon
daires aux embolies myxomateuses.

Tableau I. Myxomes cardiaques, Hopital du Sacre-Coeur de Montreal, 1971 a 1988
Patient

Annee

Sexe

Age, an

1

1972

F

48

2

1972

M

65

3

1973

F

66

4

1977

F

50

5

1979

F

58

6
7
8

1982
1982
1983

F
M
F

53
51
46

9

1983

F

43

10
11
12
13

1986
1987
1987
1988

F
M
M
M

52
76
45
27*

Presentation

Type

Electrocardio
graphic

Diagnostic
poumons

Asymptomatique
Asymptomatique

Dyspnee/syncope
Stenose mitrale
Embolie membre
superieure
Hemiparesie gauche
Stenose mitrale

H

FA

HTP

E

N

N

E

FA

HTP

Embolies
peripheriques
H6miplegie droite
Paralysie faciale
Oedeme pulmonaire
Dyspnee
ICT
Vertebro-basilaire
Embolies cerveau et
aorto-iliaque
Embolie tronculaire
Oedeme pulmonaire
Dyspnee
Souffle
Dyspnee

E

N

N

E

N

N

H
H
E

N
N
N

0G,HTP
OG.HVG
N

E,H

N

N

E
H
H
H

N
N
OG.BBD
BBD
HVD

N
HTP
0G
HVD
Calcifications

Evolution

Deces 6 ans postop
Insuffisance
cardiaque
Deces embolies
cerveau foie et rate
Asymptomatique
Asymptomatique
Asymptomatique
Asymptomatique
Deces 24 h postop
Coma
Asymptomatique
Pneumonie
Asymptomatique
Asymptomatique

* = syndrome cardio-cutane, ICT = ischdmie cerebrale transitoire, H = hemodynamique, E = embolie, FA = fibrillation auriculaire, N = normal, 0G oreillette gauche, BBD = bloc de branche droit, HVD = hypertrophie ventricule droit, HTP = hypertension pulmonaire, HVG = hypertrophie ventriculaire
gauche
______________________________________ ________
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terisees par la presence de myxomes, d ’une lentiginose cutaneomuqueuse et de naevi bleus. Les
auteurs decrivirent le syndrome
sous le terme de “lamb syndrome”
(lentigos, myxomes auriculaires,
myxomes muco-cutanes et naevi
bleus). Cette meme annee, Peterson
et Serrill7 decrivaient un cas similaire, et en 1985, Carney et collegues8
de la Clinique Mayo, rapportaient
que le syndrome de Cushing, secondaire a la dysplasie micronodulaire
de la surrenale avait ete retrouve
chez des patients porteurs de myxo
mes cardiaques et atteints de pig
mentation cutanee anormale, associant ainsi des anomalies endocriniennes au syndrome cardio-cutane.
Dans cet article, 40 cas etaient
decrits dont 4 de la Clinique Mayo,
presentant au moins deux des caracteristiques suivantes : myxome
cardiaque ou cutane, fibroadenome
myxoide de la glande mammaire,
pigmentation cutanee anormale ou
une endocrinopathie. Parmi les autres anomalies endocriniennes rapportees, on retrouvait des tumeurs
testiculaires (tumeurs calcifiees originant des cellules de Sertoli et
tumeurs des cellules de Leydig), des
tumeurs hypophysaires secretantes
(gigantisme et acromegalie), et une
maladie surrenalienne nodulaire et
pigmentee avec ou sans syndrome
de Cushing.
En
1986, Reed, Mellette et
Fitzpatrick9 rapporterent de nouveaux cas dont un complique d'un
anevrisme cerebral et Carney et
collegues10 decrivirent une famille
dont les stigmates du syndrome se
retrouvaient sur trois generations
successives, evoquant un mode de
transmission autosomique dominant
ou lie au chromosome X. Wilsher,
Roche et Neutze11 et Danoff et

collegues12 corroborerent ces obser
vations en 1986 et 1987, et recemment, Andre et collegues13 rappor
terent un autre cas, insistant sur
l’importance de distinguer une
ephelide d’une lesion lentigineuse.
Ici, seul l’examen histologique confirme le diagnostic demontrant l’hyperplasie melanocytaire.
Alors que le myxome cardiaque
isole constitue 30 % a 50 % des
tumeurs cardiaques, le syndrome
myxoide ne se retrouve que dans
5 % a 7 % de celles-ci.14'15 Dans ces
cas, les patients sont plus jeunes,
generalement ages de moins de 40
ans, et on retrouve parfois une
predisposition familiale. Les tu 
meurs cardiaques sont plus souvent
multiples et situees dans les cavites
droites. La recidive etant possible
apres exerese,15 un suivi echographique annuel est recommande.
Peu de cas ont ete rapportes9’11-1316 depuis la revue de Vidaillet et collegues15 qui relevaient 44
cas dans la litterature, dont un seul
en provenance du Canada.17 Ce syn
drome demeure d’une extreme rarete et notre malade, que nous
croyons etre le deuxieme rapporte
dans la litterature canadienne, illustre l’interet et la pertinence du suivi
face a ces lesions.
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Hemodynamic and Temperature Changes
After Aortocoronary Bypass Grafting
Diamond A. Kassum, MA, MB, BChir, FRCSC, FRCS, FACS;* Ian R. Thomson, MD, FRCPCt
Perioperative hemodynamic and temperature changes were reviewed in 58 patients
who underwent aortocoronary bypass grafting. Core temperature showed an
immediate decline postoperatively, secondary to core temperature cooling during
bypass. Subsequent rewarming occurred over the next 8 to 12 hours, with the
temperature often increasing above normal. The reason for this pyrexial response is
discussed. The cardiac index was depressed immediately postoperatively, again with
substantial recovery within 8 hours. This improvement over time occurred not only
because of recovery of intrinsic function but also because of reduction in myocardial
work due to falling systemic vascular resistance. The latter was high immediately
postoperatively and then consistently fell during the rewarming phase. During the
first 8 hours postoperatively there were significant changes in temperature and
cardiac and systemic vascular resistance indices. The hemodynamic data correlated
strongly with changes in temperature. Falling systemic vascular resistance required
the institution of a-agonist therapy in 25% of patients.

Les changements peroperatoires hemodynamiques et de temperature ont ete etudies
chez 58 patients qui ont subi un pontage aortocoronarien. La temperature centrale a
montre une chute immediate apres l’operation, secondaire au refroidissement de la
temperature centrale durant le pontage. Un rechauffement subsequent survint sur
une periode de 8 a 12 heures, la temperature depassant souvent la normale. Les
raisons de cette reponse febrile sont commentees. L’indice cardiaqu qui etait
deprime immediatement apres l’operation, se retablit aussi de fa?on marquee en
moins de 8 heures. Cette amelioration avec le temps n’est pas seulement attribuable
a la recuperation de la fonction intrinseque, mais aussi a la reduction du travail
myocardique consecutive a la chute de la resistance vasculaire generale. Cette
derniere, elevee immediatement apres I’intervention, s’abaissa regulierement durant
la phase de rechauffement. Durant les 8 premieres heures postoperatoires, on
observa des changements importants de la temperature et des indices cardiaques et
de resistance vasculaire generale. Les donnees hemodynamiques montrent une forte
correlation avec les changements de temperature. La chute de la resistance
vasculaire necessita l’administration d’un agoniste a chez 25 % des patients.

s anesthetic and surgical tech
niques have developed in the
field o f aortocoronary bypass sur
gery, the postoperative hemody

A

namic profiles o f the patients have
changed. In the late 1970s, postop
erative hypertension was seen in the
first 3 hours after bypass in 30% to
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60% o f patients.1-3 The hyperten
sion contributed to myocardial isch
emia, and prolonged nitroprusside
therapy to reduce afterload was
com m on.4 Early in the 1980s in our
institution, we noted that early
postoperative hypertension was
often
followed by hypotension
caused by low systemic vascular
resistance; occasionally an a-agonist such as phenylephrine was re
quired to maintain blood pressure in
an appropriate range. Approximate
ly 5% o f the aortocoronary bypass
patients required such support in
1981; this number increased to 12%
in 1982 and to 25% to 30% thereaf
ter. The drop in systemic vascular
resistance appeared to accompany
the rise in temperature during post
operative rewarming.
This review was undertaken to
clarify the relation between temper
ature changes, cardiac index and
systemic vascular resistance index
(SVRI) immediately after aortocoro
nary bypass surgery. Drugs admin
istered perioperatively were also
carefully evaluated to determine
their impact on cardiovascular pa
rameters, and laboratory data were
reviewed to identify rheologic fac
tors and to define other possible
causes o f the postoperative increase
in temperature.

Method
A total o f 73 patients who under
went aortocoronary bypass over a
3-month period were reviewed. Of
CJS, VOL. 35, NO. 1, F E B R U A R Y 1992
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these, 15 were excluded: 4 had
undergone reoperation, 4 required a
second operation within the first 24
hours postoperatively, 4 required
intra-aortic balloon counterpulsa
tion postoperatively, 1 had a docu
mented intraoperative transfusion
reaction and 2 had inadequate he
modynamic data for analysis.
The following demographic data
were collected for the remaining 58
patients (42 men, 16 women): age
and sex; height; weight; derived
body surface area; history, includ
ing evidence of preoperative hyper
tension; and cardiac angiographic
data with specific reference to the
left ventricular ejection fraction. In
traoperative data collection included
the number of bypass grafts placed
and the length of the operation. All
patients received fentanyl citrate,
with or without diazepam and mor
phine intraoperatively. The dosage
and total amounts given were re
corded.
All patients had Swan-Ganz
thermistor catheters flow directed
into the pulmonary artery. Cardiac
outputs were measured by the ther
modilution technique and reported
as the mean of three estimates. The
cardiac index was calculated as car
diac output (L/min) divided by sur
face area (m2). The systemic vascu
lar resistance index (SVRI) was cal
culated as mean systemic blood
pressure minus central venous pres
sure (mm Hg) divided by the car
diac index and multiplied by 80
(dynes/c m ”5*m2).
Intraoperatively, temperature was
obtained from nasopharyngeal and
rectal probes. Cold potassium cardi
oplegia was used in all patients with
core cooling to about 25° to 28°C.
The induction cardiac index and
SVRI were recorded (time 0).
Hemodynamic data were collected
and pulmonary artery temperatures
recorded at 1, 2, 4, 8, 12, 18 and
24 hours postoperatively. Postoper
ative administration of morphine
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JCC, VOL. 35, N ° 1, FEVRIER 1992

and diazepam, including the total
dose over 6-hour periods for the
first 24 hours postoperatively, was
recorded. Also noted was the post
operative use of phenylephrine, nor
epinephrine, nitroprusside, dopa
mine and dobutamine. Laboratory
data reviewed in the first 24 hours
postoperatively included hemoglo
bin level, leukocyte count, platelet
count, creatine phosphokinase
(CPK) and CPK isoenzymes-MB
fraction, and serum calcium level.
Blood cultures were performed rou
tinely if the patient’s temperature
exceeded 38.5°C.
All patients received mechanical
ventilation following surgery to
maintain an arterial pH in the nor
mal range of 7.35 to 7.45 and a
partial pressure of oxygen of at
least 70 mm Hg with over 90%
saturation. The time to extubation
was recorded. The perioperative
myocardial infarction rate (CPK-MB
values of over 75 with electrocar
diographic findings of new patho
logic Q waves) was recorded.
Statistical Methods
Fisher’s exact test for 2 X 2
contingency tables was used to
identify significant relationships be
tween paired data. Two-way analy
sis of variance (ANOVA) was used,
blocking for subject and time with
each of three dependent variables:
cardiac index, temperature and
SVRI. Adjustment for the level of
significance for multiple compari
sons was made with Bonferroni si
multaneous 95% confidence inter
vals.

Results
Demographic Data
The mean age of the 58 patients
was 56.2 ± 14.7 years (range from
45 to 78 years). The mean surface

area was 1.8 ± 0.41 m2 (range from
1.42 to 2.30 m2). Twenty-one (36%)
of the patients had a history of
hypertension.
Preoperative angiographic data
demonstrated a mean left ventricu
lar ejection fraction of 59.6% ±
12.1% (range from 40% to 84%).
Preoperative Drug Use
Fifty-seven (98%) of the patients
received morphine as premedica
tion; 13 (22%) also received diaze
pam. Of the 58 patients, 36 (62%)
were taking calcium antagonists
preoperatively.
Intraoperative Data
The number of grafts placed was
3.6 ± 0.9 (range from 1 to 6). The
length of the operation was 4.6 ±
0.9 hours (range from 2.0 to 6.75
hours). All patients received fenta
nyl citrate intraoperatively at a
mean dose of 98.4 ± 12.1 /ug/kg
(range from 60 to 115 pg/kg).
Twenty-eight (48%) of the pa
tients received diazepam intraopera
tively (mean dose 7.0 ± 4.2 mg;
range from 2.5 to 20 mg); 14 (24%)
received morphine (mean dose 23.2
± 13.1 mg; range from 4.5 to 50
mg); and 12 (21%) received chlorpromazine (mean dose 6.35 ± 5.95
mg; range from 1.5 to 25.0 mg).
Postoperative Drug Use
Nitroprusside was used in 35
(60%) of the patients, phenylephrine
in 15 (26%), dopamine in 25 (43%)
(10 [17%] of whom required doses
over 7 /rg/kgmnin-1), dobutamine
in 14 (24%), and norepinephrine in
5 (8%). The postoperative use of
morphine and diazepam is shown in
Table I. It is routine for sedation to
be minimized after 12 to 18 hours
so the patients can be weaned from
the ventilator and the endotracheal
tube removed.
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Laboratory Data
Hemoglobin levels were routinely
maintained between 100 and 120
g /L in our unit during the study.
The mean hemoglobin level was
101 ± 12.5 g /L (range from 75 to
137 g/L). There was no relation
between the lowest hemoglobin
level measured and the cardiac
index for the group.
Acute temperature rises may
occur secondary to septicemia and
with disseminated intravascular co
agulation, resulting in leukopenia

and thrombocytopenia. The lowest
mean leukocyte count in the first
24 hours was 6.56 ± 2.21 X
109/L . There was no relation be
tween leukopenia (or leukocytosis)
and postoperative pyrexia. The low
est mean platelet count was 124.3
± 34.9 X 109/ L (range from 50 to
115 X 109/L ). Fourteen patients
had platelet counts of 50 to 100 X
109/L , 4 (28%) of whom had a
temperature over 38.5°C. Twelve
patients had CPK-MB levels over 75
U/L; 10 of these had a total CPK
level over 1000 U /L, and 2 had

.

T a b le 1 P o s to p e ra tiv e U se o f M o rp h in e and D ia zep a m (2 .5 - to 5 -m g A liq u o ts ) in 58 P a tie n ts in
F irs t 2 4 H o u rs (6 -h o u r T im e B lo c k s ) A fte r A o rto c o ro n a ry B y p a s s

A d m in istratio n
tim e
M o rp h in e
F irs t 6 h
S econd 6 h
T h ird 6 h
F o u rth 6 h
D iazepam
F irs t 6 h
S econd 6 h
T h ird 6 h
F o u rth 6 h

M ean to tal
dose (m g) ±
s ta n d a rd d e v ia tio n

No. of
patients

P e rc e n ta g e of
p a tie n ts

46
45
31
5

7 9 .3
7 7 .6
5 3 .4
8 .6

7 .6
5 .6
5 .0
1.9

48
42
23
2

8 2 .8
7 2 .4
3 9 .7
3 .4

8.1 ± 6 . 5
5 .7 ± 6 . 0
7 .8 ± 5 . 6
2 .5

± 6 .0
± 4 .5
± 3 .1
± 1.1

FIG. 1. Postoperative temperature in 58 patients who underwent aortocoronary
bypass.

levels ranging from 500 to 1000
U/L. For 4 (7%) of the 58 patients
electrocardiographic changes were
seen; these patients were therefore
considered to have had a periopera
tive myocardial infarction. None of
the patients were hemodynamically
unstable. There was also no relation
between temperature and elevated
CPK levels.
For the 20 patients for whom
blood cultures were taken, the re
sults were negative. The mean
serum calcium level was 2.03 ±
0.21 mmol/L (range from 1.63 to
2.52 mmol/L).
Postoperative Course
Time to extubation was 25.6 ±
9.0 hours (range from 14 to 53
hours). There were no deaths in
this group of patients.
Hemodynamic Data
For each patient, postoperative
temperature, cardiac index and
SVRI were plotted against time (in
hours). All 58 patients were pooled,
and the mean values with one stan
dard deviation were plotted (Figs. 1
to 3). Note that time 0 represents
the preinduction hemodynamic
data.
Two-way ANOVA for each of
three dependent variables (tempera
ture, cardiac index and SVRI) resul
ted in significant (p < 0.0001)
mean differences for all variables
over time. Two subsequent analy
ses, conducted with temperature as
a covariate for both cardiac index
and SVRI, demonstrated tempera
ture to be a significant covariate (p
< 0.001), but after adjustment for
temperature, significant mean dif
ferences over time were still found
for cardiac index and SVRI. The
following is a summary of (mean
ingful) significant differences over
time for the three dependent varia
bles, using Bonferroni simultaneous
CJS, VOL. 35, NO. 1. FEBRUARY 1992
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from times 2 and 8; cardiac index
— mean at time 0 different from
mean at time 1, mean at time 2
different from mean at time 4 and
mean at time 4 different from mean

95% confidence intervals to adjust
the level of significance for multiple
comparisons: temperature — mean
at time 2 different from all other
times and mean at time 4 different
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FIG. 2. Postoperative cardiac index in same group of patients.

at time 8; SVRI — mean at time 4
different from mean at times 2 and

8.
The correlation coefficients relat
ing temperature and cardiac index,
.cardiac index and SVRI, and tem
perature and SVRI were calculated
for each of the 58 patients at each
of the eight time points (Table II).
Cardiac index and SVRI were obvi
ously related, because one is partly
derived from the other; this relation
is, of course, independent of time.
Temperature was positively associ
ated with cardiac index and nega
tively associated with SVRI. Signifi
cant associations were found be
tween temperature and cardiac
index and temperature and SVRI at
4 hours. Table III shows the distri
bution of correlation coefficients in
volving temperature, cardiac index
and SVRI with time; at 24 hours
there were significant changes in all
three variables within individuals.
Table IV demonstrates the highly
significant correlations in the first 8
hours.

Discussion
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FIG. 3. Postoperative systemic vascular resistance index (SVRI) in same group of
patients.
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Temperature changes occur im
mediately after coronary artery by
pass grafting. At the end of warm
ing on bypass, core temperature is
usually normal; however, a decline
in temperature, referred to as after
drop, occurs over the next 90 min
utes.5 This drop is thought to be
caused by heat transfer from a
warm core to cold constricted pe
ripheral vascular beds.6 There is
rewarming over the next 8 to 12
hours, with the temperature often
increasing above normal.57 This
pattern was demonstrated in our
patients, an overshoot (more than
38.5°C) occurring in 34%. Subse
quently, there was very little change
up to 24 hours postoperatively.
The cardiac index was depressed
immediately postoperatively with

AORTOCORONARY BYPASS GRAFTS

significant recovery within 8 hours.
This partly reflects interventions to
improve cardiac output. Systemic
vascular resistance was high imme
diately postoperatively, which coin
cides with the hypothermic state,
and then consistently fell during the
rewarming phase, reaching a nadir
at about 8 hours and being static
thereafter. In the first 8 hours there
were significant changes and corre
lations between temperature, cardi
ac index and SVRI. From 8 to 24
hours the patients were much more
stable but usually demonstrated
improving myocardial function with

little change in temperature or
SVRI.
The rapid increase in central tem
perature may reflect resetting of the
hypothalamus secondary to the hy
pothermic insult. It has been sug
gested that the temperature may
overshoot because heat loss is ini
tially prevented by vasoconstric
tion induced by the prior hypo
thermia;8-9 however, a decrease in
the SVRI (i.e., vasodilation) occurs
as the temperature rises. It has also
been suggested that narcotic anes
thetic agents such as fentanyl ci
trate may reset the hypothalamic

Table II. C orrelation C oefficients fo r Tem perature, C ardiac Index (C l) and System ic V ascular
Resistance Index (SVR I) Over Tim e
Correlation between
Tim e, h

Tem p and Cl

0
1
2
4
8
12
18
24

0.25
0.06
0.17
0.38*
0.17
0.04
0.21
0.28

Tem p and SVRI
-

Cl and SV R I*

0 .2 6
0.0 3
0.2 9
0 .5 3 *
0.15
0 .0 9
0 .2 3
0 .2 8

-

0.72
0.77
0.72
0.78
0.78
0.76
0.85
0.70

* p < 0.001

Table III. D istribu tio n of C orrelation C oefficients In vo lving Tem perature, Cl and SVRI W ith T im e
(2 4 H ours)
Correlation
coefficients,
percentile
90th
75th
50th
25th
10th
Mean

Correlation between
Tim e and temp

T im e and Cl

0.858
0.752
0.613
0.441
0.204

0 .8 5 0
0 .7 4 9
0 .5 8 2
0 .3 9 2
0 .1 2 9

-

0.575

0.5 4 4

- 0.523

Tim e and SVR I
0.224
0.424
0.553
0.665
0.774

Table IV. D istribu tio n o f Correlation C oefficients In vo lvin g Tem perature, Cl and SVRI W ith T im e
(8 H ours)
Correlation
coefficients,
percentile
90th
75th
50 th
25th
10th
Mean

Correlation between
Tim e and temp

Tim e and Cl

0.989
0.964
0.9 0 7
0.7 7 6
0.602

0 .9 8 3
0.9 3 4
0 .7 7 3
0 .5 8 0
0.2 6 4

-

0.8 2 8

0.6 6 2

- 0.594

Tim e and SVRI
0.002
0.434
0.754
0.867
0.949

thermostat.10 More recent work im
plicates endotoxin from the gas
trointestinal tract as producing a
postperfusion syndrome similar to
septic shock.11-12 In this review at
tempts to identify alternative causes
for the temperature rise postopera
tively were not successful. There
was no evidence of transfusion reac
tions, complement activation with
resultant leukopenia or throm
bocytopenia, or bacteremia.
During the initial hypothermic
stage with a high SVRI, nitroprusside is often required to reduce the
SVRI and thus reduce myocardial
work. As the temperature rises,
however, the SVRI falls, and in
approximately 25% of patients
phenylephrine is required to main
tain mean blood pressure in an
appropriate range. The dynamic
component of the rewarming pro
cess is seen in the significant asso
ciation between temperature and
SVRI and between temperature and
cardiac index 4 hours postopera
tively. Opiates and benzodiazepines
also affect systemic resistance. An
esthesia with high-dose fentanyl ci
trate results in a hyperdynamic re
sponse in some patients during in
duction, which suggests a sympa
thomimetic effect;13 however, most
patients tend to be hemodynamically stable.14-15 Intraoperatively, highdose fentanyl citrate anesthesia
abolishes catecholamine, adrenocor
ticotropic hormone, cortisol,
growth hormone and vasopressin
responses.16-17 Wynands and col
leagues18 found that patients receiv
ing high-dose fentanyl citrate anes
thesia tended to have high-normal
cardiac output and systemic hypo
tension (i.e., a low SVRI) in the
recovery room. Tomicheck and as
sociates19 noted that if fentanyl ci
trate is given after diazepam there
is an immediate decrease in mean
arterial pressure. Diazepam alone
produces a decrease in plasma lev
els of catecholamines, and these
CJS, VOL. 35, NO. 1, FEBRUARY 1992
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levels remain depressed after fentanyl citrate infusion. Postoperative
drug interactions may also contrib
ute to a reduction in systemic re
sistance (e.g., treatment with mor
phine and diazepam may reduce
stress and thus catecholamine out
put).
Other drugs that may affect sys
temic vascular resistance include
chlorpromazine, calcium channel
blockers and quinidine. None of the
patients in our series received calci
um channel blockers or quinidine
postoperatively, and chlorproma
zine was used infrequently intraoperatively and not at all postopera
tively. Protamine may produce hy
potension by inducing histamine re
lease;20 this effect, however, only
lasts a few minutes.

Conclusions
In the first 8 hours after aor
tocoronary bypass, hypothermia is
followed by a consistent rise in
temperature with some degree of
overshoot into a pyrexial state. This
may be due to resetting of the
hypothalamus by the hypothermic
insult, or to drug effects or endotoxemia, or both. The tempera
ture rise appears to be advanta
geous in that systemic vascular re
sistance consistently drops, with a
resultant beneficial effect on cardiac
function. Cardiac output, however,
may not be adequate to sustain
mean blood pressure. In this situa
tion an a-agonist such as pheny
lephrine may be required to raise
the SVRI and maintain mean blood
pressure. The effect of high-dose

fentanyl citrate plus diazepam and
morphine interactions on systemic
resistance requires further elucida
tion. Endotoxin release from the
gastrointestinal tract is of particular
interest and should be investigated
further.
We are grateful for the invaluable assis
tance of R. Tate, MSc, of the Biostatist
ics Consulting Unit, University of Mani
toba, who analysed the hemodynamic
data. We also thank the members of the
Section of Cardiovascular Surgery at
St. Boniface General Hospital for allow
ing us to review their patients, and Ms.
Tanis Bennet for typing the manuscript.
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ORIGINAL ARTICLES

Subendocardial Abscess as a Complication
of Prolonged Central Venous Access
for Parenteral Nutrition
Ralph L. George, MD; Garry Cornel, MS, BS, FRCSC
Patients with chronic gastrointestinal diseases may require long-term parenteral
nutrition. The authors describe a case in which a subendocardial abscess developed
in the right atrium in association with staphylococcal septicemia. The patient, a
15-year-old boy, had a malpositioned Silastic catheter, the tip of which was in his
right atrium. Staphylococcal abscess of the heart has been described previously after
cardiac surgery, but the authors believe this is the first reported case related to a
central venous catheter.

L’alimentation parenterale de longue duree peut etre necessaire chez les patients
souffrant de maladies gastro-intestinales chroniques. Les auteurs decrivent un cas
oil un abces sous-endocardique est apparu dans l’oreillette droite en association avec
une septicemie staphylococcique. Le patient, un gar?on de 15 ans, avait un catheter
de Silastic mal positionne, dont l’extremite penetrait dans l’oreillette droite. L’abces
cardiaque a staphylocoque a deja ete decrit en rapport avec la chirurgie cardiaque
mais les auteurs croient signaler le premier cas relie a un catheter veineux central.

ome patients with chronic gas
trointestinal diseases require
long-term parenteral nutrition. We
describe a patient who had a suben
docardial abscess in his right atrium
in association with staphylococcal
septicemia. The patient had long
term catheterization with a Silastic
catheter, the tip of which was mal
positioned in his right atrium.
Staphylococcal abscess has been de
scribed previously following cardiac
surgery,1 but we believe this is the
first reported case related to a cen
tral venous catheter.

S

Case Report
A 15-year-old boy with severe
Crohn’s disease had been treated
for 6 months with steroids and
enteral feeding. Continued weight
loss resulted in the decision to use

centrally administered parenteral
nutrition.
A Broviac subclavian catheter
was positioned on the patient’s
right side under sterile conditions
through a subcutaneous tunnel. An
intraoperative chest x-ray film
showed the tip of the catheter just
within the patient’s right atrium.
Parenteral nutrition was started
using a standard preparation con
taining 25% dextrose, 5% amino
acids and a 20% lipid emulsion.
In the first weeks the boy gained
weight. However, 28 days after
catheter insertion his body tempera
ture rose to 40°C, and the leuko
cyte count was 21.0 X 109/L .
Blood cultures showed gram-posi
tive cocci and subsequently grew
Staphylococcus aureus. Emergency
echocardiography revealed an atrial
filling defect, 1.9 cm in diameter, at
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the tip of the central catheter and
adherent to the right atrial wall.
This lesion was interpreted to be an
atrial thrombus.
The line was removed and antibi
otics were started intravenously as
follows: cloxacillin 400 m g /k g
every 6 hours, metronidazole 50
m g/kg every 8 hours and gen
tamicin 2.5 m g /k g every 8 hours.
Heparin therapy was begun, and his
partial thromboplastin time was
kept at twice the preheparin value.
His fever resolved over 48 hours,
and after 3 days of antibiotic thera
py his leukocyte count had fallen to
8.1 X 109/L .
Ten days later the patient was
afebrile and clinically well on hepa
rin and antibiotics. Repeat echocar
diography, however, showed persis
tence of the atrial defect, now 2.5
cm in diameter, on the right atrial
wall and occupying the tricuspid
ring. It gave the appearance of
being mobile, abutting the tricuspid
valve and causing some tricuspid
regurgitation.
The patient underwent explora
tion of his right atrium through a
right thoracotomy incision using
cardiopulmonary bypass. Within the
right atrium a smooth egg-shaped
subendocardial lesion was discov
ered. Upon opening the endocardi
um over the mass, cream-coloured
pus was encountered. The abscess
was completely drained. Gram’s
staining showed copious leuko
cytes. Cultures of the pus failed to
grow any aerobic or anaerobic or
ganisms.
Postoperatively we continued the
cloxacillin and heparin, assuming
that the organism responsible for
the abscess was S. aureus as culCJS, VOL. 35, NO. 1, FEBRUARY 1992
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DIFLUCAN
(fluconazole/pfizer)

A N OPPORTUNISTIC WAY
TO TREAT FUNGAL INFECTION
PRODUCT INFORMATION
NAME OF DRUG
DIFLUCAN TABLETS
DIFLUCAN INTRAVENOUS INFUSION 2 mg/mL in 0.9% SODIUM CHLORIDE
(fluconazole)
THERAPEUTIC CLASSIFICATION Antifungal
ACTIONS: Fluconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14alpha-demethylation. Mammalian cell demethylation is much less sensitive to fluconazole
inhibition. The subsequent loss of normal sterols correlates with the accumulation of f 4-alphamethyl sterols in fungi and may be responsible for the fungistatic activity of fluconazole.
INDICATIONS AND CLINICAL USE: DIFLUCAN (fluconazole) is indicated for the treatment of:
1. Oropharyngeal and esophageal candidiasis. 0IFLUCAN is also effective for the treatment of
serious systemic candidal infections, including urinary tract infection, peritonitis, and
pneumonia. 2. Cryptococcal meningitis. 3. Prevention of the recurrence of cryptococcal
meningitis in patients with acquired immunodeficiency syndrome (AIDS).
Specimens for fungal culture and other relevant laboratory studies (serology, histopathology)
should be obtained prior to therapy to isolate and identify causative organisms. Therapy may
be instituted before the results of the cultures and other laboratory studies are known: however,
once these results become available, anti-infective therapy should be adjusted accordingly.
CONTRAINDICATIONS: DIFLUCAN (fluconazole) is contraindicated in patients who have shown
hypersensitivity to fluconazole, to any of its excipients, or other azole related compounds.
WARNINGS: Patients with baseline abnormal liver function tests and those who develop
abnormal liver function tests during DIFLUCAN (fluconazole) therapy should be monitored for
the development of more severe hepatic injury. Although serious hepatic reactions have been
rare and the causal association with DIFLUCAN uncertain, if clinical signs and symptoms
consistent with liver disease develop that may be attributable to fluconazole, DIFLUCAN
should be discontinued, (see ADVERSE REACTIONS).
Immunocompromised patients, especially those with AIDS, who develop rashes during
treatment with DIFLUCAN should be monitored closely and the drug discontinued if lesions
progress, (see ADVERSE REACTIONS).
In rare cases, as with other azoles, anaphylaxis has been reported.
PRECAUTIONS
Use in Pregnancy: There are no adequate and well-controlled studies in pregnant women.
DIFLUCAN (fluconazole) is not recommended in pregnant women unless the potential benefit
outweighs the potential risk to mother and fetus.
Use in Nursing Mothers: Fluconazole is secreted in human breast milk at concentrations
similar to plasma, hence its use in nursing mothers is not recommended.
Use in Children: The clinical use of DIFLUCAN in children below 13 years of age has not been
established.
Use in Elderly: DIFLUCAN was well tolerated by patients aged 65 years and over.
Drug Interactions
Cimetidine and Antacids Absorption of orally administered DIFLUCAN does not appear to be
affected by gastric pH. Cimetidine did not affect oral bioavailability of fluconazole to a
clin ica lly m eaningful extent; reduction of about 13% in A1JC (area under the plasma
concentration-time curve) and 21% in peak plasma concentration (Cmax) was observed.
Administration of magnesium/aluminum hydroxide formulation, just prior to DIFLUCAN
administration had no clinically relevant effects on the absorption or elimination of fluconazole
in normal volunteers.
Cyclosporine DIFLUCAN administered at 100 mg daily dose does not affect cyclosporine
pharmacokinetic levels in patients with bone marrow transplants. There have been several
reports in the literature associating concomitant administration of high doses of DIFLUCAN with
an increase in cyclosporine plasma concentrations in renal transplant patients with or without
impaired renal function. Therefore, when DIFLUCAN and cyclosporine are coadministered,
cyclosporine levels should be monitored and cyclosporine dose accordingly adjusted.
Warfarin DIFLUCAN increased the prothrombin time after warfarin administration in healthy
males. Though the magnitude of change was small (12%), careful monitoring of prothrombin
time in patients receiving coumarin-type anticoagulants is recommended.
Hydrochlorothiazide Concomitant administration of multiple doses of DIFLUCAN and
hydrochlorothiazide was associated with increases in fluconazole plasma levels which were
not considered to be clinically significant.
Sulfonylurea-Oral Hypoglycemics The potential for hypoglycemia due to decreased elimination
and increased blood levels of sulfonylurea oral hypoglycemics (glibenclamide. glipizide and
tolbutamide) has been demonstrated with concomitant administration of DIFLUCAN. Blood
glucose levels should be monitored closely and the dose of the hypoglycemic agent should be
adjusted as necessary,
Phenytoin Concomitant administration of DIFLUCAN at steady state and phenytoin at steady
state resulted in an increase of up to 75% in AUC of phenytoin. Since phenytoin has a low
therapeutic ratio, phenytoin plasma levels should be closely monitored when DIFLUCAN is
coadministered. The dose of phenytoin should be adjusted to maintain therapeutic levels.
Rifampin Concomitant administration of DIFLUCAN and rifampin resulted in a 25% decrease
in the AUC and a 20% shorter half-life of fluconazole. The dosage of fluconazole should be
increased by 25% when fluconazole is administered with rifampin.
Zidovudine (AZT) and/or Pentamidine Isethionate Though no formal interaction studies have
been completed for DIFLUCAN and concomitant zidovudine and/or pentamidine isethionate,
these drugs have been used together in patients with AIDS with no clinically im portant
difference in the pattern of adverse events.
Theophylline Concomitant administration of DIFLUCAN and theophylline resulted in an 18%
decrease in the mean plasma clearance of theophylline. Patients who are receiving high doses
of theophylline or who are otherwise at increased risk for theophylline toxicity should be
observed for signs of theophylline toxicity while receiving fluconazole, and therapy modified
appropriately if signs of toxicity develop.
Oral Contraceptives In pharmacodynamic studies, single and multiple 50 mg oral doses of
DIFLUCAN had no clinically significant effects on ethinyl estradiol or levonorgestrel
pharmacokinetics in healthy women taking oral contraceptives. However, at 200 mg daily, the
AUCs of ethinyl estradiol and levonorgestrel were increased, 40% and 24%, respectively.

Drug/Drug Interaction Interaction studies with other medications have not been conducted, but
such interactions may occur,
Drug/Laboratory Test Interactions: None known.
ADVERSE REACTIONS: Sixteen percent of over 4000 patients treated with DIFLUCAN
(fluconazole) in clinical trials of 7 days or more experienced adverse events.
Treatment was discontinued in 1.5% of patients due to adverse clinical events and in 1.3% of
patients due to laboratory test abnormalities.
Adverse clinical events were reported more frequently in HIV infected patients (21%) than in
non-HIV infected patients (13%). However, the patterns of adverse events in HIV infected and
non-HIV infected patients were similar. The proportions of patients discontinuing therapy due
to clinical adverse events were similar in the two groups (1.5%). The two most serious
adverse clinical events noted during clinical trials with DIFLUCAN were: 1. Exfoliative skin
disorders 2. Hepatic necrosis Because most of these patients had serious underlying disease
(predominantly AIDS or malignancy) and were receiving multiple concomitant medications,
including many known to be hepatotoxic or associated with exfoliative skin disorders, the causal
association of these reactions with fluconazole is uncertain. Two cases of hepatic necrosis
and one exfoliative skin disorder (Stevens-Johnson syndrome) were associated with a fatal
outcome.
The following treatment-related clinical adverse events occurred at an incidence of 1% or
greater in 4,048 patients receiving fluconazole for 7 or more days in clinical trials: Nausea 3.7%
Headache 1.9% Skin Rash 1.8% Vomiting 1.7% Abdominal Pain 1.7% Diarrhea 1.5% Other
treatment-related clinical adverse events which occurred less commonly (0.2 to <1%) are
presented by organ system below:
Skin and Appendages: pruritus.
Musculoskeletal: myalgia.
Central and Peripheral Nervous System: convulsions, dizziness, paresthesia, tremor, vertigo.
Autonomic Nervous System: dry mouth, increased sweating.
Psychiatric: insomnia, somnolence.
Gastrointestinal: anorexia, constipation, dyspepsia, flatulence.
Liver and Biliary System: cholestasis, hepatocellular damage.
Special Senses: taste perversion.
Hematopoietic: anemia.
General: fatigue, malaise, asthenia, fever.
In rare cases, anaphylaxis has been reported.
LABORATORY TEST ABNORMALITIES
Liver Function: Clinically significant increases were observed in the following proportions of
patients: AST (SGOT) 1%, ALT (SGPT) 1.2%, Alkaline Phosphatase 1.2%, Total bilirubin
0.3%. The incidence of elevated serum transaminases was independent of age or route (p.o.
or i.v.) of administration but was greater in patients taking DIFLUCAN concomitantly with one
or more of the following medications: rifampin, phenytoin, isoniazid, valproic acid, or oral
hypoglycemic agents. Clinically significant increases also were more frequent in patients
who: 1) had SGOT or SGPT elevations greater than three times the upper limit of normal
(>3xULN) at the time of entering the study (baseline), 2) had a diagnosis of hepatitis at any
time during the study and, 3) were identified as alcohol abusers. The overall rate of serum
transaminase elevations of more than 8 times the upper limit of normal was approximately
1% in patients treated with DIFLUCAN during clinical trials. (See table below)
Percent
Number
Percent
Number*
Percent
Drugof
Percent
DrugLab
of
Abnormal
Related
Abnormal
Patients
Related
Parameter
Patients
Baseline < 3xULN
Baseline:> 3xULN
3007
4.2
0.8
9.4
3.8
SGOT
53
2874
4.8
1.0
SGPT
65
3.1
0.0
Non-Hepatitis Patients
Hepatitis Patients
3.9
0.8
1.9
2900
SGOT
160
10.6
2799
4.4
1.0
2.1
SGPT
140
11.4
Non-Alcohol Abuse
Alcohol Abuse
4.2
0.9
2.4
3018
SGOT
42
9.5
4.7
1.0
2899
SGPT
2.5
40
10.0
Never
Received
Received
I.V.
Fluconazole
I.V. Fluconazole
144
1.4
2916
4.2
0.9
SGOT
5.6
0.7
2800
4.7
1.0
SGPT
139
5.0
< 65 Years Old
> 65 Years Old
1.1
2783
4.3
0.9
SGOT
277
4.3
1.2
2681
4.8
1.0
SGPT
258
3.9
'Note: Only patients who had measurements at baseline and during therapy were included.
Renal Function: Clinically significant increases were observed in the following proportions of
patients: blood urea nitrogen (0.4%) and creatinine (0,3%).
Hematological Function: Clinically meaningful deviations from baseline in hematologic
values which were possibly related to DIFLUCAN were observed in the following proportions
of patients: hemoglobin (0.5%), white blood cell count (0.5%), and total platelet count
( 0 . 6% ) .

SYMPTOMS AND TREATMENT OF OVERDOSAGE
Symptoms: There has been one reported case of overdosage with DIFLUCAN. A 42-year-old
patient infected with human immunodeficiency virus developed hallucinations and exhibited
paranoid behavior after reportedly ingesting 8200 mg of DIFLUCAN. The patient was admitted
to the hospital, and his condition resolved within 48 hours.
Treatment: In the event of overdosage, symptomatic treatment (with supportive measures
and gastric lavage if necessary) may be adequate. Fluconazole is largely excreted in urine. A
three hour hemodialysis session decreases plasma levels by approximately 50%.
Mice and rats receiving very high doses of fluconazole, whether orally or intravenously,
displayed a variety of nonspecific, agonal signs such as decreased activity, ataxia, shallow
respiration, ptosis, lacrimation, salivation, urinary incontinence and cyanosis. Death was
sometimes preceded by clonic convulsions.
DOSAGE AND ADMINISTRATION
Oral and Intravenous Treatment: Fluconazole is well absorbed and excreted predominantly
unchanged in urine following oral administration in man. The oral bioavailability is essentially
complete (greater than 90%), and is independent of dose. Peak plasma concentrations after
oral administration are attained rapidly, usually within 2 hours ot dosing. Since oral absorption
is rapid and almost complete, the daily dose of DIFLUCAN (fluconazole) is the same for
oral and intravenous administration. The term inal plasma elimination half-life is
approximately 30 hours (range 20-50 hours).
The daily dose of DIFLUCAN and the route of administration should be based on the infecting
organism, the patient’s condition and the response to therapy. Treatment should be
continued until clinical parameters and laboratory tests indicate that an active fungal infection

SUBENDOCARDIAL ABSCESS

tured earlier. No further complica
tions relating to the subendocardial
abscess occurred. The boy remained
afebrile and echocardiography sug
gested complete resolution of the
abscess.

Comments
Although all intravascular cannu
las are potential sources of infec
tion, this patient also had a chronic
state of malnutrition and a history
of long-term steroid use, adding to
the risk. Staphylococci are the most
frequently cultured organisms in
sepsis of parenteral nutrition lines.2
We believe that trauma from the
catheter tip injured the right atrial
endocardium, allowing subendocar
dial seeding to occur during the S.
aureus septicemia, leading to the
later development of a subendocar
dial abscess.

This case adds to reports of ca
theter-tip complications. Examples
of vascular perforations,3 cardiac
tamponade ,4 central venous throm
bosis and endocarditis5 have all
been described. Line sepsis is the
most common complication of pro
longed central venous access,6 and
septicemia in these patients may
result in a subendocardial abscess if
the atrium has been damaged by
the catheter tip. Such an abscess
may be confused with atrial throm 
bus on echocardiography because
both are seen as atrial filling de
fects. Persistence of the echocardiographic findings associated with a
history of sepsis suggests abscess
formation. We believe echocardiog
raphy should be performed routine
ly after septicemic episodes in pa
tients having central venous access
lines in place for long periods. Also
the possibility of endocardial dam

has been cured or has subsided. An inadequate period of treatment may lead to recurrence of
active infection. Patients with AIDS and cryptococcal meningitis or recurrent oropharyngeal
candidiasis usually require maintenance therapy to prevent relapse.
Recommended Adult Dosages
Loading Dose: Administration of a loading dose on the first day of treatment, consisting of
twice the usual daily dose, results in plasma concentrations close to steady state by the
second day. Patients with acute infections should be given a loading dose equal to twice
the daily dose, not to exceed a maximum single dose of 400 mg, on the first day of
treatment.
Oropharyngeal Candidiasis: 100 mg once daily. Treatment should be continued for at least 2
weeks to decrease the likelihood of relapse.
Esophageal Candidiasis: 100 mg to 200 mg once daily. Patients should be treated for a
minimum of 3 weeks and for at least 2 weeks following resolution of symptoms.
Systemic Candidiasis: 200 mg to 400 mg once daily. These patients should be treated for a
minimum of 4 weeks and for at least 2 weeks following resolution of symptoms.
Cryptococcal Meningitis: 200 mg to 400 mg once daily. Although the duration of therapy for
cryptococcal meningitis is unknown, it is recommended that the initial therapy should last a
minimum of 10 weeks.
Prevention of Recurrence of Cryptococcal Meningitis in AIDS: 200 mg once daily.
DIFLUCAN (fluconazole) may be administered either orally or by intravenous infusion. The
intravenous infusion of DIFLUCAN should be administered at a maximum rate of approximately
200 mg/hour given as a continuous infusion. See Directions for Use .
Dosage in Patients With Impaired Renal Function
Fluconazole is cleared primarily by renal excretion as unchanged drug. In patients with impaired
renal function, an initial loading dose of 50 to 400 mg should be given. After the loading
dose, the daily dose (according to indication) should be based on the following table:
Creatinine Clearance (mL/min)
>50
21-50
11-20
Patients receiving
regular hemodialysis

Percent of Recommended Dose
100%
50%
25%
one recommended
dose after each dialysis

When serum creatinine is the only measure of renal function available, the following formula
(based on sex, weight, and age of the patient) should be used to estimate the creatinine
clearance.
Males:
Weight (kg) x (140-age)
72 x serum creatinine (mg/100 mL)
Females:
0.85 x above value
Composition: DIFLUCAN Tablets (pink) contain 50, 100 or 200 mg fluconazole. Also
contains the following non-medicinal ingredients: microcrystalline cellulose, dibasic calcium
phosphate anhydrous, povidone, croscarmellose sodium, FD & C Red No. 40 aluminum lake
dye, and magnesium stearate.

age could be reduced by ensuring
catheter-tip placement in the superi
or vena cava as opposed to the
right atrium.
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DIFLUCAN I.V. for infusion is a sterile solution of fluconazole in saline at a concentration of
2 mg/mL which is made iso-osmotic with sodium chloride 9 mg/mL.
Directions for Use: Inspect visually for particulate matter or discoloration prior to
administration. Do not use if cloudiness or precipitation is evident.
Reject the contents as unsterile if the metal seal is broken. NOT INTENDED FOR MULTIDOSE
USE: discard any portion not used when the seal is first broken.
Connect an intravenous giving set to the bottle of DIFLUCAN (fluconazole) intravenous
solution and also insert a venting set through the bung. Infuse DIFLUCAN intravenous
solution at a maximum rate o f200 mg/hour. Flush DIFLUCAN intravenous solution remaining
in the giving set with sterile normal saline.
Because fluconazole is available as a dilute saline solution, in patients requiring sodium or
fluid restriction, consideration should be given to the rate of fluid administration.
Incompatibility: It is recommended that DIFLUCAN I.V. be infused separately.
Compatibility: Administration sets ( “giving” sets).
DIFLUCAN I.V. infusion is compatible with (i.e. not susceptible to absorption) sets constructed
of a delivery tube (PVC) luer lock (modified phenylene oxide), flash bail (latex) drip chamber
(polypropylene) and piercing spike (polypropylene).
DOSAGE FORMS
Availability: DIFLUCAN TABLETS are available as pink tablets containing 50 mg, 100 mg,
and 200 mg of fluconazole.
Supplied in bottles (opaque polyethylene) of 50 or 100 tablets.
DIFLUCAN I.V. is available as a sterile aqueous solution for direct infusion. Each mL contains
2 mg fluconazole and 9 mg sodium chloride. Supplied in clear glass bottles of
100 mL and 200 mL, affording doses of 200 mg and 400 mg fluconazole respectively, sealed
with a rubber bung.
STORAGE
DIFLUCAN TABLETS (fluconazole) 50,100, and 200 mg: Store below 30°C.
DIFLUCAN I.V. (fluconazole) 2 mg/mL: Store below 30°C. Do not freeze.
References: 1. DIFLUCAN new drug submission, Data on file, Pfizer Canada Inc.
2. Product monograph-DIFLUCAN*.
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Surgical Management of Perforated
Benign Gastric Ulcer in High-Risk
Patients
Claudio Di Quinzio, MD;* P. Terry Phang, MD, FRCSCf
The authors compared the outcome in 40 high-risk patients who had a perforated
benign gastric ulcer with respect to management by omental patch closure (OPC) or
partial gastrectomy (PG). The patients were considered to be at high risk because of
the presence of one or more of the following factors: age more than 70 years; initial
hypotension; delay from presentation to operation of more than 12 hours; and
significant premorbid illness. OPC was performed in 22 patients and PG in 10; the
other 8 patients were initially managed nonoperatively (NonOp). Death rates were
40% overall — 36% for patients in the OPC group, 30% for those in the PG group
and 63% for those in the NonOp group. The hospital stay was more than 12 days for
57% of the OPC group, 86% of the PG group and 67% of the NonOp group.
Sixty-eight percent of patients in the OPC group, 90% in the PG group and 89% in
the NonOp group had complications. There was no significant difference in death
rates between those treated with OPC and PG. There was a trend to lower death
rates in patients over 70 years of age who underwent PG (1 of 6) compared with
those who underwent OPC (7 of 12). The authors concluded that partial
gastrectomy, a definitive surgical treatment for gastric ulcer disease, is not
contraindicated in high-risk patients who have a perforated benign gastric ulcer.

Chez 40 patients a risque eleve presentant un ulcere gastrique perfore benin, les
auteurs ont compare les resultats du traitement par greffe de plaque epiploique
(GPE) et par gastrectomie partielle (GP). Les patients ont ete consideres a risque
eleve lorsqu’ils presentaient au moins un des facteurs suivants : plus de 70 ans
d’age; une hypotension initiale; un delai operatoire de plus de 12 heures; et une
maladie importante. Une fermeture par GPE fut pratiquee chez 22 patients et une
GP chez 10; les 8 autres patients furent initialement traites de fa^on non operatoire
(NonOp). La mortalite globale fut de 40 % : 36 % pour le groupe GPE, 30 % pour le
groupe GP et 63 % pour le groupe NonOp. Le sejour hospitalier fut superieur a 12
jours pour 57 % du groupe GPE, pour 86 % du groupe GP et pour 67 % du groupe
NonOp. Soixante-huit pourcent du groupe GPE, 90 % du groupe GP et 89 % du
groupe NonOp eurent des complications. On n’a observe aucune difference
significative de mortalite entre les groupes GPE et GP. On note une tendance en
faveur d’une plus faible mortalite chez les patients de plus de 70 ans du groupe GP
(1 sur 6) comparativement au groupe GPE (7 sur 12). Les auteurs concluent que la
gastrectomie partielle, une intervention chirurgicale definitive pour l’ulcere gastri
que, n’est pas contre-indiquee chez les patients a risque eleve souffrant d’ulcere
gastrique benin perfore.

From the Department o f Surgery, University o f British Columbia, Vancouver, BC

he most appropriate surgical
treatment for patients with a
perforated benign gastric ulcer re
mains unresolved. Surgeons advo
cate either omental patch closure
(OPC) or partial gastrectomy (PG).
Those in favour of a definitive pro
cedure for perforated benign gastric
ulcer have suggested that primary
gastric resection would remove oc
cult gastric carcinoma and avoid
complications of OPC, such as
gastric-outlet obstruction, upper
gastrointestinal bleeding and reper
foration.1'2 Some studies have
shown that patients who undergo
PG have a lower death rate and a
much lower rate of ulcer recurrence
than those who undergo OPC.1’34
Surgeons in favour of OPC argue
that because patients with perforat
ed benign gastric ulcers tend to be
old and have serious underlying
illness it would be inappropriate to
expose them to the added intraoper
ative risks of definitive gastric ulcer
surgery.5 Studies supporting OPC
for perforated benign gastric ulcer
have shown that this procedure can
be undertaken with low mortality
and morbidity.5'6
Our study was undertaken to
compare the outcome of high-risk
patients with a perforated benign
gastric ulcer treated with PG as
opposed to OPC. We asked whether
PG is contraindicated in high-risk
patients.

T

*Postgraduate surgical assistant
fAssistant professor o f surgery
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We reviewed the charts of all
patients who had a diagnosis of

PERFORATED BENIGN GASTRIC ULCER

perforated benign gastric ulcer at
St. Paul’s Hospital and Vancouver
General Hospital (two University of
British Columbia teaching hospi
tals) between 1979 and 1989. For
ty-eight patients (27 men, 21 wom
en) were identified, and the site of
the perforation was confirmed by
reviewing operative and pathology
reports. We classified patients as
high risk according to the follow
ing: age greater than 70 years,
significant underlying medical ill
ness, delay in treatment and pres
ence of initial hypotension.4-6 Pa
tients in class 3 or greater of the
American Society of Anesthesiolo
gists (ASA) risk classification were
considered to have significant un
derlying medical illness.7 Because
accurate documentation of the time
of ulcer perforation was unavailable
in most cases, we reported the
treatment delay as the time from
first physician contact to induction
of anesthesia. Hypotension was de
fined as an initial systolic blood
pressure below 90 mm Hg. Other
patient characteristics recorded
were a history of peptic ulcer dis
ease, smoking, alcohol abuse or use
of ulcerogenic drugs (nonsteroidal
anti-inflammatory agents, acetylsalicylic acid, corticosteroids).
Patients were assigned to three
treatment groups: OPC, PG, and
initial nonoperative management
(NonOp). The third group was fur
ther subdivided into (a) nasogastric
suction and intravenous fluid re
placement without surgical inter
vention, and (b) subsequent laparot
omy and drainage of abscess. We
judged patient outcome on the
basis of mortality, length of hospi
tal stay and postoperative complica
tions. Deaths were reported as
death during the hospital stay.
Length of hospital stay was consid
ered as 12 days or less, or more
than 12 days. Postoperative compli
cations were determined from prog
ress notes, radiology reports and

laboratory reports. Septic complica
tions were recorded as wound infec
tions, intra-abdominal abscess, bac
teremia and pneumonia. Respiratory
failure was considered to have oc
curred when the patient required
prolonged intubation postoperatively or was reintubated. Cardiac com
plications were recorded as conges
tive heart failure, dysrhythmia and
cardiac arrest. Renal failure was
recorded as the requirement for
dialysis or serum creatinine level
greater than 309.4 ^mol/L. Multi
ple organ failure was considered as
the failure of three or more organ
systems. Other recorded complica
tions included deep venous throm
bosis, stroke and gastrointestinal
bleeding.
We tested whether the mortality
in high-risk patients treated by PG
differed from that in high-risk pa
tients treated with OPC using Fish
er’s exact test.

Results
The 48 patients ranged in age
from 21 to 94 years (mean 65
years). The overall mortality was
33% (16 patients). Factors predis

posing to gastric ulceration were as
follows: ulcerogenic drugs, 17
(35%) patients; smoking, more than
one pack per day, 18 (38%) pa
tients; alcohol abuse, 20 (42%) pa
tients; history of peptic ulcer dis
ease, 21 (44%) patients.
One or more high-risk factors
were present in 40 (83%) of the 48
patients. The mortality in this highrisk group was 40% (16 of 40)
(Table I). There was no difference in
mortality between high-risk patients
treated with OPC (36%, 8 of 22)
and with PG (30%, 3 of 10) (p <
0.42). Of the high-risk patients who
were discharged from hospital after
more than 12 days, 57% had under
gone OPC and 86% PG (Table I).
One or more postoperative compli
cations were present in 32 (80%) of
the high-risk patients (Table I).
However, there were higher inci
dences of respiratory and renal fail
ure in patients treated with OPC
than with PG (Table II).
When we compared the outcome
of high-risk patients in OPC and PG
groups for each risk factor, we
found that the mortality was similar
for patients with significant under
lying illness, initial hypotension and
delay to surgery (Table III). There

Table 1. Outcome in 40 Patients Who Had Perforated Benign Gastric Ulcer and One or More
High-Risk Factors
Outcome, no./total no. (%) of patients
Group
OPC
PG
NonOp
Nasogastric suction,
intravenous therapy
Drainage of abscess

Death

Discharge > 12 d

Complications

8/22 (36)
3 /1 0 (3 0 )

8/14 (57)
6 /7 (86)

15/22 (68)
9 /1 0 (9 0 )

3 /4 (75)
2/4 (50)

1/1 (100)
1/2 (50)

4 /4 (1 0 0 )
4 /5 (80)

OPC = omental patch closure, PG = partial gastrectomy, NonOp = nonoperative.

Table II. Complications in the 40 High-Risk Patients With Perforated Benign Gastric Ulcer
Complications, no.
Group

Septic

Cardiac

Renal

Respiratory

Multiple
organ failure

OPC
PG
NonOp

15
5
8

6
6
6

3
0
0

5
0
2

5
1
1
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was a trend toward lower mortality
in elderly patients who underwent
PG than in those who underwent
OPC (p < 0.15) (Table III).
We also compared the incidence
of high-risk factors in the OPC and
PG groups. It was similar in both
groups except with respect to delay
to surgery longer than 12 hours.
The incidence of delay to surgery
longer than 12 hours was 25% for
OPC and 45% for PG (Table IV).

Discussion
The mortality for high-risk pa
tients with a perforated benign
gastric ulcer in our study was 40%
(16 of 40 patients). We found a
slightly lower mortality in high-risk
patients treated with PG (30%) than
in those treated with OPC (36%). As
well, mortality was similar between
groups with respect to individual
high-risk factors, except for age
greater than 70 years (PG 17%,
OPC 58%). Furthermore, the treat
ment groups PG and OPC in our
study were comparable with respect
to high-risk factors except that the
PG group had more patients with
delay to surgery longer than 12
hours (PG 45%, OPC 25%).
There is ongoing debate over the
most appropriate treatment for pa
tients who have benign perforated

gastric ulcer. McGee and Sawyer1
and Hodnett and colleagues,3 in
separate studies, reported lower
mortality for PG (15% and 11%,
respectively) than for OPC (29%
and 23%, respectively). In contrast,
Turner, Thompson and Thai6 re
ported a much higher mortality for
11 patients who received PG (45%)
than for 81 patients who received
OPC (12%). However, in their study
PG was performed only in patients
who had ulcers too large to treat
adequately with OPC. Since large
ulcers (greater than 4 cm diameter)
are found most often in elderly
patients with significant underlying
illness and with prolonged delay
between perforation and surgical
treatment, the selection of surgical
treatment based solely on the size
of the ulcer creates unfair bias
against PG. Thurston5 also recom
mended OPC rather than PG on the
basis of a 25% mortality in 36
patients with a benign perforated
ulcer. However, in that study only
one patient had PG, and that pa
tient survived. Therefore, there is
little evidence from the literature to
support the recommendation of
OPC rather than PG for the surgi
cal management of benign perforat
ed gastric ulcer.
Although the majority of patients
who present with a perforated
gastric ulcer have high-risk factors,

T a b le III. Num ber o f Deaths A ccord in g to In dividual R isk Factors fo r Patients Treated by
OPC and PG
Risk factors, no./total no. (% ) ol patients
Group
OPC
PG

Age > 70 yr

Underlying
m edical illness

Initial
BP < 90 m m Hg

D elay in
therapy > 12 h

7 /1 2 (5 8 )
1 / 6 (17)

3 /1 0 (30)
2 /6 (33)

5 /7 (7 1 )
2 /3 (67)

1 /6 (17)
1 /5 (20)

Table IV. C om parison o f th e Presence o f H igh -R isk Factors in P atients Treated by
OPC (28 ) and PG (11)
Risk factor, no. (% of patients
Group
OPC
PG

96

Age > 70 yr

Underlying
m edical illness

Initial
BP < 90 m m Hg

D elay in
therapy > 12 h

1 2 (4 3 )
6 (5 5 )

22 (79)
9 (8 2 )

7 (2 5 )
3 (2 7 )

7 (25)
5 (45)
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as reported in other studies, no
other studies have reported the out
come of high-risk patients separate
ly. The presence of high-risk factors
(hypotension, advanced age, delay
to surgery and significant medical
illness) in our study was similar to
that in other studies.1’68'9 The 40%
mortality of high-risk patients in
our study is comparably slightly
higher than the 18% to 32% overall
mortality reported in other
studies.13
Many surgeons believe that the
presence of high-risk factors con
traindicates the use of PG. Howev
er, we did not find that mortality
was worse in our high-risk patients
managed with PG compared with
OPC. In fact, high-risk patients
over 70 years of age who were
managed with PG had a slightly
lower mortality than patients of
similar age managed with OPC.
This trend is not explained by the
apparent difference in incidence of
other risk factors; furthermore, rel
atively more patients treated by PG
had a delay to surgery longer than
12 hours when compared with pa
tients treated by OPC. Although the
overall complications were greater
for PG than for OPC, patients treat
ed by PG had fewer episodes of
respiratory failure and renal failure.
We speculate that this decrease in
the frequency of respiratory and
renal failure could account for the
trend toward decreased mortality in
high-risk patients over age 70 who
were managed with PG.
Patients in our study who were
initially managed nonoperatively
had the highest mortality (63%).
McGee and Sawyer1 reported 100%
mortality for patients who did not
receive surgery. Also, in a recent
study10 of conservative treatment of
patients with a perforated duodenal
ulcer, patients over the age of 70
years did not respond well. There
fore NonOp does not appear to be
appropriate for the management of

PERFORATED BENIGN GASTRIC ULCER

high-risk patients with a perforated
benign gastric ulcer.
In summary, we did not find that
outcome of high-risk patients with
perforated benign gastric ulcers was
any more favourable when patients
were treated with OPC over PG.
Although the absence of any signifi
cant differences may be due to the
small number of patients in our
study, there was a trend toward
lower mortality in the subset of
patients over the age of 70 years
who had PG. We conclude that PG
is not contraindicated in high-risk
patients and may be the preferred

treatment for
gastric ulcer.

perforated

benign
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BOOK REVIEWS
continued from page 77

omechanics section contains 10 chap
ters. The new edition contains a total of
42 new chapters, which cover the role
of magnetic resonance imaging in the
investigation of disorders of the foot
and ankle, microsurgery and rehabilita
tion, including orthotic management
and conditioning of the athlete’s foot.
There are chapters on computerized
imaging and the role of arthroscopy.
The section on current research in
cludes the techniques of distraction
osteogenesis and a chapter on implants
and materials. A glossary of the termi
nology used in prescribing footwear is
included.
This text is comprehensive. The larg
est sections focus on the growing foot,
the adult foot, the foot in acquired and
systemic disorders, neurologic disorders
and trauma. Such widely diverse topics
as metabolic disorders, hemophilia and
vascular disease are covered. The pedi
atric section has chapters on clubfoot,
vertical talus, pes cavus, pes planus,
tarsal coalition and “skewfoot” (serpen
tine foot). The text contains the report
of the Committee of the American Foot
and Ankle Society, “Guidelines for Hos
pitalization for Foot and Ankle Sur
gery.” This report provides an indica
tion of the constraints under which
reconstructive surgery must be prac

tised in both the United States and
Canada. Some chapters provide alterna
tive points of view on controversial
subjects. For instance, chapter 97 is
entitled “Fusion vs total ankle place
ment: an overview.” As is common with
multiauthored texts there is repetition.
For instance, there are four chapters on
the heel and its disorders with overlap
between them. However, in general, the
quality of the contributions is quite
high. I noted that there was no chapter
on the history of foot surgery, which,
considering the breadth and depth of
the text, would be desirable.
This definitive textbook should be in
the hospital library of any institution
training foot and ankle surgeons. It
would be a useful addition to the library
of any surgeon with a major interest in
foot and ankle surgery. The cost and
exhaustive nature of the text would
militate against its being in the personal
libraries of generalists and trainees.
Robin R. Richards, MD, FRCSC
Associate professor
Department of Orthopedic Surgery
University of Toronto.
Head
Division of Orthopedic Surgery
St. Michael’s Hospital
30 Bond St.
Toronto, ON
M5C 1R6

MALIGNANT CEREBRAL GLIOMA.
American Association of Neurological
Surgeons Publications Committee, Mi
chael L.J. Apuzzo. Neurosurgical Top
ics Series. 231 pp. Illust. American
Association of Neurological Surgeons,
Chicago, 1990. AANS members, $70;
nonmembers, $80; residents, $60.
ISBN 0 -9 6 2 4 2 4 6 -3 -3

The malignant cerebral glioma (as
trocytoma) remains the commonest pri
mary brain tumour treated by the neu
rosurgeon. Despite the relative frequen
cy with which this tumour is encoun
tered, the overall patient prognosis has
not changed substantially in the last
three decades. However, recent clinical
clues have stimulated basic research in
neuro-oncology, which has led to an
increased understanding of this unusual
neoplasm. More successful clinical trials
will certainly follow. Dr. Michael Apuz
zo, a world-renowned authority on ma
lignant glioma, has recruited a impres
sive cadre of neuro-oncologists to help
write this landmark volume.
One of the fundamental problems
with gliomas has been our inability to
synthesize a universally acceptable
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Histamine H2 Receptor Antagonist
CLINICAL PHARMACOLOGY
PEPCID® (famotidine) is a competitive inhibitor of
hista m ine H2-receptors. The prim ary clinically
im portant pharmacologic activity of PEPCID® is
in h ib itio n of gastric ju ice secretion. PEPCID®
reduces the acid and pepsin content, as well as the
volume, of basal, nocturnal, and stimulated gastric
secretion.

INDICATIONS AND CLINICAL USE
PEPCID® (famotidine) is indicated in the treatment
o f the fo llow in g conditions where a controlled
reduction of gastric secretion is required:
1. Treatment of acute duodenal ulcer;
2. Prophylactic use in duodenal ulcer;
3. Treatment of acute benign gastric ulcer;
4. T re a tm e n t of p a tholog ical h y p e rs e c re to ry
conditions (e.g., Zollinger-Ellison Syndrome);
5. Treatm ent of gastroesophageal reflux disease
(GERD).
PEPCID® I.V. is indicated in some hospitalized
pa tients w ith pathological hypersecretory con
ditions or intractable ulcers, or as an alternative to
the oral dosage form for short-term use in patients
who are unable to take oral medication.

CONTRAINDICATIONS
H y p e rs e n s itiv ity to any com pone nt o f th is
medication.

PRECAUTIONS
Patients with Severe Renal Insufficiency
D osing inte rvals may need to be prolonged in
p a tie n ts w ith advanced renal in s u ffic ie n c y
(creatinine clearance <10 mL/min.) to adjust for the
long er elim ination half-life of fam otidine. (See
CLINICAL PHARMACOLOGY and DOSAGE AND
ADMINISTRATION).
Drug Interactions
Studies with famotidine in man, in animal models,
and in vitro have shown no significant interference
with the disposition of compounds metabolized by
the hepatic microsomal enzymes, e.g., cytochrome
P450 system . Compounds tested in man have
in c lu d e d w a rfa rin , th e o p h y llin e , p h e n yto in ,
d ia ze p a m , am inopyrine and an tipyrine . Ind o
cyanine green as an index of hepatic blood flow
and/or hepatic drug extraction has been tested and
no significant effects have been found.
Use in Gastric Ulcer
G astric malignancy should be excluded prior to
initiation of therapy of gastric ulcer with PEPCID®.
Symptomatic response of gastric ulcer to PEPCID®
therapy does not preclude the presence of gastric
malignancy.
Use in Pregnancy
Reproductive studies have been performed in rats
and ra b b its a t oral doses of up to 2000 and
500 mg/kg/day, respectively (approximately 2500
and 625 times the maximum recommended human
dose, respectively), and have revealed no evidence
of im paired fertility or harm to the fetus due to
PEPCID®. There are, however, no adequate or
well-controlled studies in pregnant women.
Since the safe use of PEPCID® in pregnant women
has not been established, the benefits of treatment
with PEPCID® should be weighed against potential
risks.
® Tradem ark Merck & Co., Inc.
M erck Frosst Canada Inc., R. U.

Nursing Mothers
Famotiaine is detectable in human milk. Nursing
mothers should either stop this drug or should stop
nursing.
Pediatric Use
Safety and effectiveness in children have not been
established.
Use in Elderly Patients
No dosage adjustment is required based on age (see
HUMAN PHARMACOLOGY, Pharmacokinetics).

ADVERSE REACTIONS
PEPCID® (famotidine) is usually well tolerated;
m o st adverse re actions have been m ild and
transient. The adverse reactions listed below have
been reported during clinical trials in 2333 patients.
In those controlled clinical trials in which PEPCID®
was compared to placebo, the overall incidence of
adverse experiences in the group which received
PEPCID®, 40 mg at bedtime, was similar to the
placebo group. No antiandrogenic or other adverse
hormonal effects have been observed.
The fo llo w in g adverse re a ctio n s have been
reported at a rate of greater than 1% in patients on
therapy with PEPCID® in controlled clinical trials,
and may be causally related to the drug: headache
(4.6%), dizziness (1.2%), constipation (1.2%) and
diarrhea (1.6%).
Other reactions have been reported in clinical trials
but occurred under circumstances where a causal
relationship could not be established. However, in
these rarely reported events, that possibility cannot
be excluded. Therefore, these observations are
listed to serve as alerting information to physicians.

u su ally not co n sid e re d se rio u s. A m ong the
laboratory changes that were reported during
clinical trials were increases in AST, ALT, BUN, and
serum creatinine. These changes were rarely of
clinical significance.
Only three patients had to be discontinued from
therapy because of laboratory adverse experiences,
however laboratory abnormalities were present at
baseline.

SYMPTOMS AND TREATMENT
OF OVERDOSAGE
There is no experience to date with deliberate
overdosage. Doses of up to 800 mg/day have been
em ployed in patients with pathological hyper
secretory conditions with no serious adverse
effects. In the event of overdosage, treatment should
be sym ptom atic and supportive. U nabsorbed
m aterial should be removed from the ga stro
intestinal tract, the patient should be monitored,
and supportive therapy should be employed.
The oral LD50 of famotidine in male and female rats
and mice was >5000 mg/kg.

DOSAGE AND ADMINISTRATION
DUODENAL ULCER
Acute Therapy
The recommended adult oral dosage of PEPCID®
(famotidine) for acute duodenal ulcer is 40 mg once
a day at bedtime. Treatment should be given for 48 weeks, but the duration of treatm ent may be
shortened if healing can be documented. Healing
occurs within 4 weeks in most cases of duodenal
ulcer.

Gastrointestinal

8.0%

Nausea
Vomiting
Anorexia
Abdominal discomfort
Dry mouth

1.6%
0.9%
0.5%
0.3%
0.2%

Maintenance Therapy
For the prevention of recurrence of duodenal ulcer,
it is recommended that therapy with PEPCID® be
continued with a dose of 20 mg once a day at
bedtim e, for a duration of up to 6-12 months
depending on the severity of the condition.

Nervous System/Psychiatric

7.3%

BENIGN GASTRIC ULCER

Insomnia
Somnolence
Anxiety
Paresthesia
Depression
Libido decreased

0.6%
0.4%
0.3%
0.3%
0.2%
0.1%

Respiratory
Bronchospasm

4.4%
<0.1%

Body as a Whole

3.0%

Fatigue
Asthenia
Fever

0.6%
0.3%
0.2%

Musculoskeletal

1.7%

Musculoskeletal pain
Arthralgia

0.1%
0.1%

Skin

1.7%

Pruritus
Rash
Alopecia
Flushing
Acne
Dry skin

0.4%
0.3%
0.2%
0.2%
0.1%
0.1%

Cardiovascular

1.0%

Palpitations

0.2%

Special Senses

0.9%

Taste disorder
Tinnitus
Orbital Edema
Urogenital

0.1%
0.1%
<0.1%
0.9%

The adverse reactions reported for PEPCID®
Tablets may also occur w ith PEPCID® I.V. In
addition, transient irritation at the injection site has
been observed with PEPCID® I.V.
The following additional adverse reactions have
been reported since the drug was m arketed:
urticaria, liver enzymes abnormalities, cholestatic
jaundice, anaphylaxis, angioedema.
T h e fo llo w in g adverse re a ctio n s have been
reported; however, a causal relationship to therapy
with PEPCID® has not been established: agitation,
confusion, hallucinations, grand mal seizures, rare
cases of impotence, thrombocytopenia, pancyto
penia, leukopenia and agranulocytosis.
Laboratory Abnormalities
Laboratory parameters may be affected during
treatm ent with PEPCID®, but the changes are

Acute Therapy
The recommended adult oral dosage for acute
benign g a stric ulcer is 40 mg once a day at
bedtim e. Treatm ent should be given fo r 4 to
8 weeks, but the duration of treatm ent may be
shortened if healing can be documented.
PATHOLOGICAL HYPERSECRETORY CON
D ITIO N S (SUCH AS Z O LLIN G E R -E LL IS O N
SYNDROME)
The dosage of PEPCID® in p a tie n ts w ith
pathological hypersecretory conditions varies with
the individual patient. The recommended adult oral
starting dose for pathological hypersecretory
conditions is 20 mg q6h. In some patients, a higher
starting dose may be required. Doses should be
adjusted to individual patient needs and should
continue as long as clinically indicated. Doses up to
800 mg/day have been adm inistered to some
patients with severe Zollinger-Ellison syndrome.
GASTROESOPHAGEAL REFLUX DISEASE
The recommended dosage for the symptomatic
relief of gastroesophageal reflux disease is 20 mg
of famotidine twice a day.
For the tre a tm e n t o f esophageal ero sio n or
ulceration associated with gastroesophageal reflux
disease, the recommended dosage is 40 mg of
famotidine twice a day.
Intravenous Administration
In some hospitalized patients with pathological
hypersecretory conditions or intractable ulcers, or
in patients who are unable to take oral medication,
PEPCID® I.V. may be administered. The recom
mended dosage is 20 mg every 12 hours.
Intravenous injection therapy should be changed to
oral treatment as soon as the acute situation is
under control.
Concomitant Use with Antacids
Antacids may be given concomitantly if needed.
Dosage Adjustment for Patients with Severe
Renal Insufficiency
In patients with advanced renal insufficiency, i.e.,
with a creatinine clearance less than 10 mL/min., the
elim ination half-life of PEPCID® may exceed
20 hours reaching approximately 24 hours in anuric
patients.
To avoid excess accumulation of the drug, the
dosing interval of PEPCID® may be prolonged to
36-48 hours as indicated by the patient’s clinical
response.

PHARMACEUTICAL INFORMATION
Tablets
Each tablet for oral administration contains either
20 mg or 40 mg of famotidine.
Injection
Each mL of the solution for intravenous injection
contains 10 mg of famotidine and the following
inactive ingredients: L-aspartic acid 4 mg, mannitol
20 mg, and Water for Injection, q.s., 1 mL. The
multidose injection also contains benzyl alcohol
0.9% added as preservative.
STABILITY AND STORAGE
RECOMMENDATIONS
PEPCID® I.V. Solution
Store at 2 - 8°C. Protect from light. If solution
freezes, bring the solution to room temperature;
a llo w s u ffic ie n t tim e to s o lu b iliz e all the
components.
Diluted PEPCID® I.V. Solutions should be used
within 24 hours due to the possibility of microbial
contamination during preparation.
NOTE: P a re n te ra l drug pro d u c ts should be
inspected visually for particulate matter and
d is -c o lo u ra tio n prio r to a d m inistra tion
whenever solution and container permit.
RECONSTITUTED SOLUTIONS
Parenteral Products
Dilution of PEPCID® I.V.
for Infusion
Volum e of
P E P C ID ® I.V. Com patible
Final
S olution
I.V. S olution Volume
2 mL

3 mL

5 mL

2 mL

8 mL

10 m L

2 mL

100 m L

102 m L

Final
C oncen
tration
4 m g /m L

2 m g /m L

0 .1 9 6 m g /m L

Rate of
Infusion
N o t le s s th a n
2 m in u te s
N o t le s s th a n
2 m in u te s
1 5 -3 0
m in u te s

PEPCID® I.V. Solutions are compatible with:
Water for Injection
0.9% Sodium Chloride Injection
5% Dextrose Injection
10% Dextrose Injection
Lactated Ringer's Injection
Sodium Bicarbonate Injection 5%

AVAILABILITY OF DOSAGE FORMS
Tablets PEPCID® (fam otidine tablets) are Dshaped, film-coated tablets supplied as follows:
No. Ca 8102 - 20 mg beige coloured, coded 963.
Available in bottles of 100 tablets.
No. Ca 8103 - 40 mg light brownish orange, coded
964. Available in bottles of I00 tablets.
Each tablet for oral administration contains the
following non-medicinal ingredients: hydroxypropyl
cellulo se, hydroxypropyl methylcellulose, iron
oxides, m agnesium stearate, m icrocrystalline
cellulose, starch, talc, titanium dioxide.
No. Ca 3539 - PEPCID® I.V., 10 mg per 1 mL, is a
clear, colourless solution and is available as a nonpreserved unit dose containing 2 mL of injectable
solution. Available in 10 x 2 mL vials.
No. Ca 3541 - PEPCID® I.V., 10 mg per 1 mL, is a
clear, colourless solution and is available as a
p re s e rv e d m u ltip le dose c o n ta in in g 4 mL of
injectable solution. Available in 4 mL vials.
Each mL of the solution for intravenous injection
contains the following non-medicinal ingredients:
L-aspartic acid 4 mg, mannitol 20 mg, and Water
for Injection q.s. 1 mL. The multidose injection also
c o n ta in s benzyl alcoh ol 0.9% added as
preservative.

subjects; mean gastric acid secretion was inhibited
by 86% and 94%, respectively, for a period of at
least 10 hours. Similar doses given in the morning
suppressed food-stimulated acid secretion in all
subjects, with mean suppression of 76% and 84%,
respectively, 3 to 5 hours after drug, and of 25%
and 30%, respectively, 8 to 10 hours after drug;
however, in some subjects who received the 20 mg
dose, the an tisecretory effect was d issip a te d
earlier, within 6-8 hours. There was no cumulative
effect with repeated doses. The basal nocturnal
intragastric pH was raised by evening doses of 20
and 40 mg of PEPCID® to mean values of 5.0 and
6.4, respectively. When PEPCID® was given in the
morning, the basal daytime interdigestive pH at 3
and 8 hours after 20 or 40 mg of PEPCID® was
raised to about 5.0.
Fasting and postprandial serum gastrin levels may
be s lig h tly e leva ted d u ring p e riods of d ru g
antisecretory effect, and with chronic therapy an
incre ase in ga stric bacterial flora may occur.
Gastric emptying and exocrine pancreatic function
are not affected by PEPCID®.
The presence of gastroesophageal reflux disease
appears to correlate best with the percentage of
time over 24 hours during which the esophagus is
e xp osed to acid. In g a stroe soph agea l re flu x
disease patients, 20 mg twice a day and 40 mg
twice a day of PEPCID® reduced intraesophageal
acid exposure into the normal range as measured
by 24 hour intraesophageal pH m onitoring. In
clinical studies of gastroesophageal reflux disease
patients with endoscopically verified erosive or
ulcerative esophagitis, 40 mg twice a day was more
e ffe c tiv e than 20 mg tw ice a day in h e a lin g
esophageal lesions. Both dosage regimens were
superior to placebo.

4. Texter, E.C. et al.: Maintenance therapy of
duodenal ulcer with famotidine. A m ulti
center United States study, Am J Med,
81(suppl 4B):20-27, Oct 1986.
Reference for ad PCD-90-3392-JA
1. Texter, E.C. et al.: Maintenance therapy of
duodenal ulcer with famotidine. A m ulti
center United States study. Am J Med,
81(suppl 4B):20-27, Oct 1986.
Reference for ad PCD-90-3103-JA
1. Ryan, J.R. et al.: Comparison of effects of
oral and intravenous famotidine on inhi
bition of nocturnal gastric acid secretion,
Am J Med, 81(suppl 4B):60-64, Oct 1986.
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Other Effects
Systemic pharmacologic effects of PEPCID® in the
CNS, cardiovascular, respiratory or endocrine
system s have not been found to date. Serum
prolactin levels do not rise after intravenous bolus
doses of 20 mg PEPCID® and no antiandrogenic
effects have been detected.
Pharmacokinetics
PEPCID® is incompletely absorbed. The bioavaila
bility of oral doses is 40-45%. Bioavailability may
be slightly increased by food, or slightly decreased
by antacids; however, these effects are of no
clinical consequence. PEPCID® undergoes minimal
firs t-p a s s m etabolism . A fter oral doses, peak
plasma levels occur in 1-3 hours. Plasma levels
after multiple doses are similar to those after single
doses. Fifteen to 20% of PEPCID® in plasma is
protein bound. PEPCID® has an elimination half-life
of 2.5-3.5 hours. PEPCID® is eliminated by renal
(65-70%) and metabolic (30-35%) routes. Renal
clearance is 250-450 mL/min., indicating som e
tubular excretion.
Twenty-five to 30% of an oral dose and 65-70% of
an intravenous dose are recovered in the urine as
un ch a n g e d com poun d. The only m e ta b o lite
identified in man is the S-oxide. There is a close
relationship between creatinine clearance values
and the elimination half-life of PEPCID®. In patients
with severe renal insufficiency, i.e ., creatinine
clearance less than 10 mL/min., PEPCID® elim i
nation h a lf-life may exceed 20 hours and a d 
justment of dosing intervals may be necessary (see
P R E C A U TIO N S , DOSAGE AND A D M IN IS 
T R A T IO N ). In e ld e rly pa tie n ts, th e re are no
clinically significant age-related changes in the
pharmacokinetics of PEPCID®.

PRODUCT MONOGRAPH AVAILABLE ON
REQUEST
(354-a,6,91)

HUMAN PHARMACOLOGY

•Tradem ark Merck & Co., Inc./
Merck Frosst Canada Inc., R.U.

In both normal volunteers and hypersecretors,
PEPCID® inhibited basal nocturnal and daytime
gastric secretion, as well as secretion stimulated by
a variety of stimuli, such as pentagastrin and food.

References for ads PCD-90-3105-JA,
PCD-90-3106-JA and PCD-90-3391-JA

After oral administration, the onset of the antisecretory effect occurred within one hour; the
maximum effect was dose-dependent, occurring
within one to three hours. Duration of inhibition of
secretion was 10 to 12 hours. After intravenous
administration, the maximum effect was achieved
within 30 minutes. Single intravenous doses of
10 and 20 mg inhibited basal nocturnal secretion
for a period of 10-12 hours. The 20 mg dose was
associated with the longest duration of action in
most subjects. Single oral doses of 20 and 40 mg
inhib ited basal nocturnal acid secretion in all

3. Schunack, W.: What are the differences
between the H2-receptor antagonists?
A lim e n t Pharm acol T h e ra p , 1 :4 9 3 S 503S, 1987.

1. Bianchi Porro, G. et al.: Review of an
e x te n s ive w orld w id e study of a new
H2-receptor antagonist, famotidine, as
compared to ranitidine in the treatment of
acute duodenal ulcer, J Clin Gastroenterol
9(suppl. 2):14-18, 1987.
2. Savarino, V. et al.: “Continuous 24-hour
intragastric pH monitoring in the evalu
ation of the effect of a nightly dose of
fam otidine, ranitidine and placebo on
gastric acidity of patients with duodenal
ulcer, Digestion, 37:103-109, 1987.
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Aortoenteric Fistula 24 Years
After Aortic Endarterectomy
Roderick G. Syme, MD, FRCSC;* Budhendranauth S. Doobay, MB, FRCS, FRCS(Edin), FRCSC;*
Paul Gregor, MD, FRCSC, FACS;* Arlene Franchetto, MD, FRCPCt
Aortoenteric fistula is a well-recognized and potentially catastrophic complication of
aortic surgery. It usually follows aortic graft placement and removal of the
prosthesis. Extra-anatomic bypass is the treatment generally recommended. The
authors report the case of a 74-year-old woman who presented with an aortoenteric
fistula 24 years after aortic endarterectomy. The fistula was managed with an
anatomically placed Dacron graft. The radiologic findings and approach to
management of this uncommon problem are discussed.

La fistule aorto-enterique est une complication bien connue de la chirurgie aortique,
dont les consequences peuvent etre catastrophiques. Elle suit habituellement la pose
d’un greffon aortique ou le retrait de la prothese. On recommande generalement de
traiter par derivation extra-anatomique. Les auteurs decrivent le cas d’une femme de
74 ans chez qui est apparue une fistule aorto-enterique, 24 ans apres une
endarterectomie aortique. La fistule fut corrigee par la pose d’un greffon de Dacron
en position anatomique. On commente les observations radiologiques et la marche a
suivre face a ce probleme peu commun.

ortoenteric fistula is an uncom
mon but potentially catastroph
ic complication of aortic surgery. It
occurs most often after aortic graft
placement but may also occur after
aortic surgery without graft place
ment or spontaneously. We report a
case of aortoenteric fistula occur
ring at an aortic endarterectomy
site 24 years after the original sur
gery.

A

Case Report
A 74-year-old woman was seen at
a hospital in another city with fecal

urgency, melena and non-bloody
vomiting. Her medical history was
remarkable only for a myocardial
infarction 19 years earlier and an
aortic endarterectomy with place
ment of a right iliofemoral bypass
graft 24 years earlier. She was
hemodynamically stable, and upper
gastrointestinal endoscopy showed
a “possible small ulcer” but no
bleeding. Results of a barium enema
examination were reported as nega
tive, and she was discharged after 5
days on an H2 receptor antagonist.
Two weeks later she had a similar
episode and was hospitalized again.
Repeat upper gastrointestinal en
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doscopy was negative and, as no
further bleeding occurred, she was
discharged after 1 week still on an
H2 receptor antagonist.
Nine days later, while visiting
another city, the patient had a third
episode, this one associated with
syncope and a hemoglobin level of
68 g/L . She received a blood trans
fusion, and upper and lower gas
trointestinal endoscopy was per
formed. The upper gastrointestinal
endoscopy report stated “query
blood in the third part of the duode
num.” She remained stable in the
second hospital for 5 days with a
hemoglobin level of 113 g /L and
was then transferred to our hospi
tal, at which time a diagnosis of
aortoenteric fistula was first consid
ered. The patient was asymptomatic
and hemodynamically stable when
assessed on arrival, and the hemo
globin level was 110 g/L . Angio
graphy and computed tomography
were carried out.
The angiogram (Fig. 1) revealed
only diffuse atherosclerotic disease
of the abdominal aorta without evi
dence of pseudoaneurysm or con
trast extravasation. However, the
right common iliac artery was noted
to be occluded at the site of the
previously placed graft.
Abdominal computed tomogra
phy, performed with both oral and
intravenous contrast, showed a dif
fusely atherosclerotic aorta with
heavy calcifications. No periaortic
fluid, aortic gas or contrast extrava
sation was seen. However, at the

AORTOENTERIC FISTULA AFTER AORTIC ENDARTERECTOMY

level of the third part of the duode
num there was local interruption of
the calcific rim of the aorta on its
right anterolateral aspect (Fig. 2).
In addition, there was persistent
loss of the fat plane between the
aorta and the duodenum with ex
cess soft tissue. During the investi
gation, the patient was placed in
both the left posterior oblique and
prone positions. In each position
the duodenum remained closely ap
plied and presumably adherent to
the right anterolateral aspect of the
aorta. These findings were consid
ered suggestive, although not diag
nostic, of an aortoenteric fistula.
Along with these radiologic in
vestigations, the patient was seen
by an internist preoperatively. Dur
ing this assessment period, recur
rent melena developed, and the pa
tient was taken urgently to the
operating room. Access for proxi
mal and distal vascular control was
secured well away from the third
part of the duodenum. As the duo
denum was reflected off the infrarenal aorta, it was found to be densely
adherent at the right anterolateral
aspect of the aorta. Before the
dissection was completed, the aorta
was clamped and opened, and the
fistula site was identified, in part, by
bile staining of atherosclerotic
plaque in the aortic wall. The duo
denum was then dissected free and
repaired, and a bifurcated Dacron
graft was placed in the aorto-left
iliac-right femoral position. The oc
cluded right iliofemoral graft, which
was removed, was not involved in
the fistula site. The patient recov
ered slowly and was discharged
from hospital with no sign of infec
tion or limb compromise. She was
well 1 year later.

FIG. 1. Angiogram showing occluded right iliofemoral graft.

Discussion
Gastrointestinal bleeding in a patient with previous aortic surgery

FIG. 2. Computed tomography scan showing close application of duodenum to aorta
and interruption of calcific rim of aorta.
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requires urgent investigation and,
often, exploratory surgery. Failure
to consider the diagnosis of aortoenteric fistula and the desire to
avoid a major operative procedure
in an elderly patient with arterial
disease may lead to delay in proper
diagnosis and definitive surgery. In
addition, these patients often stabi
lize after their initial presentation,
further tempting the unwary clini
cian to choose a nonoperative
course of management. In our case,
the remoteness of the aortic proce
dure and the fact that it did not
involve the placement of graft mate
rial into the aorta may have further
delayed the correct diagnosis.
Not all patients with a history of
aortic surgery and subsequent gas
trointestinal bleeding will have an
aortoenteric fistula. However, re
gardless of the cause of bleeding,
this clinical condition carries a high
death rate. Yeager and associates1
identified 19 patients with an infrarenal aortic graft in a series of
512 patients admitted with gas
trointestinal bleeding to their insti
tution over a 7-year period. Al
though only 5 were eventually
found to have an aortoenteric fistu
la (4 had ischemic intestine and 10
had other morbid conditions), 11
(58%) of the 19 patients died.
The key to the diagnosis of aor
toenteric fistula is acute aware
ness of the condition, followed by
prompt investigation and interven
tion. Upper gastrointestinal endos
copy is usually recommended as the
initial study, largely to help identify
other disorders.12 If this demon
strates blood in the third part of the
duodenum or if the patient is unsta
ble, immediate laparotomy should
be the next diagnostic and thera
peutic step. If endoscopy gives neg
ative findings and the patient is
stable, computed tomography or
angiography, or both, have been
recommended.13 Whereas angiogra
phy rarely demonstrates the fistula
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itself, one may see a false aneurysm
or obtain other information useful
in planning surgery. In addition,
angiography may be diagnostic of
other conditions such as mesenteric
ischemia. Perigraft fluid, gas in the
graft bed more than 3 months postoperatively, intraluminal aortic gas
and paraprosthetic extravasation of
ingested water-soluble contrast ma
terial have been reported as com
puted tomography findings sugges
tive of aortoenteric fistula.4"7 Al
though these diagnostic manoeu
vres may give the surgeon useful
indirect information, surgical explo
ration remains the definitive diag
nostic step. In our case, angiogra
phy did not identify the fistula but
did demonstrate occlusion of the
right iliofemoral graft. Abdominal
computed tomography did not show
any of the signs mentioned above
but did show persistent adhesion of
the third part of the duodenum to
the aorta with local interruption of
its calcified rim.
Primary aortoenteric fistula, first
described by Sir Astley Cooper in
1829,8 by definition involves no
previous aortic surgery. In 1953,
Brock9 first described secondary
aortoenteric fistulas and, 6 years
later, Gryska reported the first suc
cessful repair of this condition.10
Most aortoenteric fistulas seen
today occur after aortic graft place
ment, and Elliot, Smith and Szilagyi11 estimated an incidence of 0.6%
to 2.3% (varying with the nature of
the aortic procedure) in a series of
over 2000 cases.
Owing to the history of previous
aortic surgery, our case represents
a secondary aortoenteric fistula.
However, it is unusual in that graft
material was not involved at the
fistula site, and symptoms occurred
24 years after surgery. We could
find only three reports of aortoent
eric fistulas after aortic endarterec
tomy.21213 In the first case a mas
sive retroperitoneal hematoma re

quired reoperation 1 week after the
endarterectomy and hemorrhage
from an aortoenteric fistula 2 weeks
later.12 In the second a saphenous
vein patch was used to close the
endarterectomy, which fistulized
and bled 8 months after surgery.13
Although placement of an aortic
prosthesis in the anatomic position
is the generally accepted manage
ment of primary aortoenteric fistu
las,14 most authors recommend
graft excision, aortic closure and
extra-anatomic bypass for second
ary fistulas.2'11,15'16 However, mor
bidity and mortality remain high
with this approach because of prob
lems with the aortic stump and the
length and extensive nature of the
procedure being carried out, usually
in an elderly patient with arterial
disease who may be relatively unsta
ble. This prompted Walker and col
leagues17 to recommend anatomic
graft placement for all aortoenteric
fistulas combined with the use of an
extensive omental patch. Of 20 pa
tients Walker and colleagues ma
naged in this fashion, 18 survived
the procedure and 15 remained
alive without limb loss after a fol
low-up of at least 1 year (average 5
years). Although this violates the
basic principle of avoiding place
ment of a foreign body in an in
fected field, the results obtained by
Walker and colleagues compare fa
vourably with those of several se
ries in which patients were ma
naged with aortic closure and extraanatomic bypass.2'3111516
The case presented was a second
ary aortoenteric fistula and was
managed, as Walker and col
leagues17 suggested, by anatomic
graft placement. We believe that the
absence of graft material at the
fistula site makes this approach
acceptable in managing this uncom
mon problem.
We thank Dr. Homer Beattie for his
advice on this case.
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continued from page 97

pathologic grading system. Highly ac
claimed neuropathologist Dr. Peter
Berger reviews the classification sys
tems that have evolved and describes a
unified concept for grading gliomas.
The chapters dealing with the basic
biology and immunology of gliomas by
Herman and associates and by Couldwell and colleagues are extremely well
written and current. In particular, I
found the summary of immunotherapeutic strategies for clinical trials
very useful.
The chapter by Segall and colleagues
on the comparison of computed tomog
raphy and magnetic resonance imaging
(MRI) in malignant gliomas is especially
timely. We are moving into an era of
increased sophistication with respect to
imaging modalities, and MRI scans have
become the gold standard for diagnos
ing brain tumours. In this chapter the
presentation of clinical material and the
physics of MRI are well balanced.
One of the biggest advances in neu
rosurgery in the last decade has been
the methodology for accurately and
safely procuring tissue from deep-seat
ed, previously inaccessible locations in

the brain through the use of stereotactically directed techniques. Dr. Apuzzo
boasts perhaps the world’s largest expe
rience in this regard, and there is an
excellent chapter by Lunsford and Cof
fey from the University of Pittsburgh
describing their results with stereotactic
techniques. In addition, these authors
describe stereotactic radiosurgery using
the “gamma knife” which is now avail
able in a few centres in North America.
While the gamma knife has been used
for selected malignant gliomas, its role
is still being defined.
There has been a resurgence of inter
est in the radical resection of malignant
gliomas in accessible regions of the
brain, and Civic and associates review
the relevant literature concerning the
radical removal of such tumours. Malig
nant gliomas are diffusely infiltrative
lesions that generally cannot be com
pletely excised for fear of causing seri
ous brain injury. Although still contro
versial, there now appears to be some
support in the literature for attempting
gross total removal of malignant gli
omas in selected patients. It has long
been known that conventional external

beam radiotherapy in conjunction with
surgery offers the best initial response
for patients with malignant gliomas. Dr.
Phillip Gutin has contributed a chapter
on the use of interstitial brachytherapy
for selected patients with malignant
gliomas. High-energy iodine-125-labelled seeds are placed stereotactically into
the tumour bed for 5 days before the
tumour is removed. Between 6000 and
8000 rad can be delivered primarily to
the tumour by this method. In selected
patients, the results have been extreme
ly gratifying, and there are now many
long-term survivors of treatment for
anaplastic astrocytoma.
The book concludes with chapters on
the current use of photodynamic thera
py and chemotherapy for malignant
gliomas. Photodynamic therapy is in its
infancy with respect to application to
neurosurgery, and chemotherapy now
encompasses new therapies such as
biologic-response modifiers and autolo
gous bone-marrow rescue.

continued on page 112
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Spontaneous Gastric Decompression
of Pancreatic Pseudocyst
J. Ali, MD, FRCSC, FACS;* H. Greenberg, MD, FRCPt
Spontaneous resolution of pancreatic pseudocysts is being reported with increasing
frequency. Although many mechanisms have been proposed one that is not
frequently recognized is spontaneous decompression into the gastrointestinal tract.
This case report demonstrates the mechanism of spontaneous resolution of a
traumatic pancreatic pseudocyst, several weeks after injury, through fistulization
between the pseudocyst and the stomach. Spontaneous resolution of a pancreatic
pseudocyst after a transient episode of diarrhea should suggest the mechanism of
gastrointestinal decompression of the pseudocyst.

La resolution spontanee de pseudokystes pancreatiques est signalee de plus en plus
frequemment. Bien que plusieurs mecanismes aient ete proposes, la decompression
spontanee dans les voies gastro-intestinales n’est pas souvent reconnue comme telle.
Cette histoire de cas demontre le mecanisme de resolution spontanee d’un
pseudokyste pancreatique traumatique par fistulisation entre le pseudokyste et
l’estomac, plusieurs semaines apres la blessure. La resolution spontanee d’un
pseudokyste pancreatique apres une poussee de diarrhee doit suggerer le mecanis
me de decompression gastro-intestinale du pseudokyste.

he frequency of spontaneous
resolution of pseudocysts of
the pancreas ranges from 8% to
85% in reported series.1-3 Several
mechanisms for this spontaneous
resolution have been proposed, in
cluding decompression by erosion
into the gastrointestinal tract.4 We
report a case of traumatic pancreat
ic pseudocyst, which was treated
initially by percutaneous drainage.
This was followed by recurrence of
the pseudocyst and subsequent
spontaneous gastric decompression.

T

Case Report
A 19-year-old man was admitted

to the Health Sciences Centre in
Winnipeg after a motor vehicle acci
dent in which he sustained a lacer
ated spleen, hematoma of the trans
verse mesocolon, retroperitoneal
hematoma, compound fractures of
the left tibia and fibula and a left
hemopneumothorax. After resusci
tation in the emergency depart
ment, the patient was taken to the
operating room where his severely
macerated spleen was removed. At
laparotomy there was contusion of
the tail of the pancreas, but no
pancreatic duct injury was identi
fied. After the laparotomy the lacer
ated leg was debrided and the frac
tured left tibia and fibula were re
duced.

Postoperatively a large left hy
drothorax developed, and there was
persistent abdominal pain with the
development of a mass in the epi
gastric area and fever. The mass
was displacing the stomach and
colon (Fig. 1). One week later the
patient was still febrile and a com
puted tomography (CT) scan
showed that the mass had increased
in size. The patient was still com
plaining of severe pain and was
vomiting intermittently. A CT scan
of the abdomen confirmed the pres
ence of a pseudocyst of the pancre
as (Fig. 2). The patient refused
another laparotomy, so the pseudo
cyst was treated by percutaneous
catheter drainage under CT control.
The large pleural effusion was
treated by thoracentesis.
Before discharge a sinogram
(Fig. 3) was obtained. It showed a
large cavity filling the left upper
quadrant with no extravasation of
fluid. Three days later the catheter
drainage decreased with an increase
in abdominal pain. A repeat sino-
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FIG. 1. Mass displacing stomach supe
riorly and colon interiorly (arrows).

y

DECOMPRESSION OF PANCREATIC PSEUDOCYST

gram showed kinking of the cathe
ter. This was corrected and good
drainage of the cavity continued.
The fever and abdominal pain sub
sided and the patient was dis
charged from hospital draining 200
to 300 mL of fluid daily.
Two weeks after discharge, the
patient stated that the drainage had
suddenly stopped, and he had expe
rienced 24 hours of loose liquid
stools; however, he did not com
plain of abdominal pain, vomiting
or fever. Sinography through the
drainage catheter opacifed the pan
creatic duct and showed a commu
nication with the stomach (Fig. 4).

On fluoroscopy, the duodenum did
not opacify before contrast ap
peared in the stomach. A CT scan
of the abdomen at that time showed
complete resolution of the pseudo
cyst (Fig. 5).
The patient has since remained
healthy with no recurrence of signs
or symptoms of a pseudocyst. Fol
low-up CT of the abdomen did not
demonstrate a pseudocyst.

Discussion
Pancreatitis frequently follows
blunt abdominal trauma.3’5 The like

FIG. 2. Computed tomography scan of abdomen. Arrow points to medial border of
large pseudocyst of pancreas.

FIG. 3. Sinogram obtained through percutaneous drainage tube shows large fluid
filled cavity.

lihood of pancreatitis is increased
when there is substantial hematoma
at the splenic hilum and when there
is oozing and contusion of the tail
of the pancreas as was evident in
this patient. Pancreatitis, with or
without ductal injury, predisposes
to pseudocyst formation. Experi
mental canine studies6 have sug
gested that ductal communication
between an actively secreting pan
creas and a potential cavity predis
poses to pseudocyst formation. Fur
thermore, pancreatic ductal ob
struction may also play a role in
pseudocyst formation.67 It is possi
ble that a missed ductal injury at
laparotomy may have predisposed
to pseudocyst formation in our
case.
The accuracy of ultrasonography
and CT of pancreatic pseudocysts
has allowed more precise follow-up
of these collections. This may ac
count for the reports of higher
rates of spontaneous resolution.
Several mechanisms have been pro
posed for spontaneous resolution of
pseudocysts of the pancreas. Com
munication of the cyst with a patent
pancreatic ductal system has been
considered a good predictor of
spontaneous resolution.7 Disappear
ance of pancreatic pseudocysts may
also occur after resolution of the
inflammatory process or after leak
age or rupture into the peritoneal
cavity. Leakage or rupture may be
associated with major morbidity and
mortality.23 Another mechanism
that has not often been recognized
is the erosion of the pseudocyst
into a hollow viscus. In reported
cases this has generally occurred
within 6 weeks of the pseudocyst
formation and has been preceded by
a transient period of diarrhea.4 Our
case falls into this category.
There is much controversy con
cerning the indications for and tim
ing of surgical treatment for pseu
docyst of the pancreas. The gener
ally recommended treatment is one
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of observation for at least 6 weeks,
during which time, if the pseudo
cyst decreases in size and the pa
tient remains stable or asymptomat
ic, spontaneous resolution is likely,

and surgical intervention becomes
unnecessary. In the case described
in this report surgery was consid
ered because of persistent symp
toms. However, the patient’s refusal

FIG. 4. Sinogram. Arrow points to pancreatic duct visualized through drainage
tube. Contrast appears in stomach and pseudocyst has disappeared.

to have a surgical procedure result
ed in the percutaneous drainage,
and spontaneous resolution resulted
from spontaneous fistulization into
the stomach. It should be noted
that this patient also had a transient
period of diarrhea which may repre
sent the sudden decompression of
the pseudocyst with a massive pro
tein osmotic load to the gastrointes
tinal tract leading to the diarrhea.
Since a communication between the
pancreatic duct and the pseudocyst
was demonstrated one would have
expected that this pseudocyst
should have resolved spontaneously
through drainage from the duct
into the duodenum. However, no
communication between the duct
and the duodenum was demonstrat
ed radiologically. It is possible,
therefore, that there may have been
some degree of pancreatic duct ob
struction which resulted in persis
tence of the pseudocyst which only
decompressed after spontaneous fis
tulization into the stomach.
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tableaux doivent etre numerotees d’apres l’ordre de la premiere mention du tableau dans le texte. Le style adopte pour la
bibliographie est celui qui est utilise dans ce numero du Journal.

Autres considerations
Les figures en couleur sont a la charge de l’auteur. II lui faudra fournir une diapositive et deux epreuves en couleur pour
chaque figure.
Les auteurs sont pries de nous preciser, le cas echeant, le logiciel ayant servi a preparer le manuscrit. Nous revisons les
manuscrits avec un systeme de traitement de texte compatible avec le systeme IBM. Les auteurs doivent nous indiquer s’ils
sont disposes a nous faire parvenir une disquette quand leur texte est acceptee.
Le processus relatif a l’etude preliminaire de l’article, a la revue critique et a la prise de decision de la redaction peut durer
a peu pres 8 semaines. La copie original de tout manuscrit refuse est retournee a ses auteurs et toutes les autres copies sont
detruites.
Tout manuscrit accepte est revise non seulement pour le rendre conforme au style du Journal canadien de chirurgie et
pour corriger les fautes de grammaire, de syntaxe et de ponctuation, mais aussi pour en assurer la clarte et la concision.
L’auteur de 1’article recevra une copie revisee ou les epreuves en placard avant la publication et doit obtenir Tapprobation des
coauteurs pour les changements apportes.
Avant la publication, tous les auteurs doivent signer un document par lequel les droits d’auteurs sont transferes au Journal
canadien de chirurgie. Tout manuscrit accepte devient propriety permanente de l’Association des medecins du Canada et ne
peut etre publies ailleurs, en entier ou en partie, sans la permission ecrite. Les tires a part sont disponibles sur demande et
peuvent etre distribues selon les desirs de l’auteur.*
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CLASSIFIED ADVERTISING
ANNONCES CLASSEES
The Canadian Journal o f Surgery is pleased to accept classified advertisements. The deadline is 1 month before issue date. Classified rates: $58
for the first 40 words or less, additional words 750 each (additional $23 for frame). Special Display under 100 words, 55 X 55 mm, $135. $17
charge (first insertion only) for CJS reply box numbers. Display rates available on request. VIS A, M A S TE R C A R D A N D A M E R IC A N
EXPRESS ACCEPTED.
Copy should be mailed to: Beverley Kirkpatrick, Manager, Classified Advertising, Canadian Journal o f Surgery, PO Box 8650, Ottawa, ON
K1G 0G8. Tel: (613) 731-9331. Fax: (613) 523-0937.
Send all box number replies to: Box . . . , Canadian Journal o f Surgery, PO Box 8650, Ottawa, ON K1G 0G8.
Le Journal canadien de ch iru rg ie accepte volontiers les annonces classees. Celles-ci doivent etre revues au Journal au plus tard 1 mois avant la
date de parution. Tarifs des annonces classees 58 $ jusqu’a 40 mots et 75 C par mot s u p p le m e n ta l (23 $ pour encadrement au trait). Encadre
special jusqu’a 100 mots, 55 X 55 mm, 135 $. L ’emploi d’une boite-reponse au Journal donne lieu a la perception d’un supplement de 17 $
(pour la premiere insertion seulement). Tarifs des encadres grand format disponibles sur demande. VIS A, M AS TE R C AR D E T A M E R IC A N
EXPRESS ACCEPTES.
La texte des annonces doit etre adresse a : Beverley Kirkpatrick, Gestionnaire des annonces classees, Journal canadien de chirurgie, CP 8650,
Ottawa, ON K1G 0G8. T e l : (613) 731-9331. Fax : (613) 523-0937.
Veuillez faire parvenir les reponses aux numeros de boites a l’adresse suivante : Boite . . . , Journal canadien de chirurgie, CP 8650, Ottawa,
ON K1G 0G8.

CARDIAC SURGICAL FELLOWSHIP: ON The Division of Cardiovascular Surgery at
Sunnybrook Health Centre of the University of
Toronto is currently seeking a fellow in adult
cardiac surgery. The position will be for 1
year initially beginning July 1992, and is
available to persons eligible for or possessing
FRCSC, ABS or ABTS. The fellow will be
involved in the clinical activities of a busy
adult open heart program (600 cases per
year). Clinical research encouraged and sup
ported. Salary commensurate with experi
ence. Canadian citizens with eligibility for
Ontario licence preferred. Please respond with
a CV to: Dr. Bernard S. Goldman, Head,
Cardiovascular Surgery, Sunnybrook
Health Science Centre, 2 0 7 5 Bayview
Ave., Ste. H 410, Toronto, ON M4N 3 M 5
Canada.
-S91-95

TRANSPLANT FELLOWSHIP: ON
University Hospital, London, Ontario has
openings for fellows in multi-organ trans
plantation starting July 1, 1992. Our 2-year
fellowship program includes experience in
clinical and experimental transplantation.
We expect to perform 40-50 heart, heartlung and lung transplants: 70 liver trans
plants: 80 kidney transplants and 5 bowel
transplants in 1992. Candidates who have
completed their training in anesthesia, inter
nal medicine, general surgery or pediatrics,
and are eligible for educational or general
licensure in Ontario will be given priority.
Submit resumes to:
Dr. David Grant, Director
Transplant Unit
PO Box 5339
University Hospital
London, ON N6A 5A5
-S91-82

FELLOWSHIP TRAINING AND SPINAL
SURGERY: ON - W ith emphasis on instru
mentation, adult reconstructive/trauma and
pediatric deformity, is offered under multiple
faculty at McMaster University, Hamilton On
tario for the 1992/93 academic year. Suc
cessful candidates will be expected to qualify
for general licensure in the province of Ontar
io. Please reply to: Dr. G.R. Viviani, Direc
tor, Spine Fellowships' Programme,
HSC-4E6, M cM aster University Medical
Centre, 1200 Main St. W ., Hamilton. ON.

BC/BE ORTHOPEDIC
SURGEON
BC/BE orthopedic surgeon to
join two very busy BC Canadian
orthopedists in a community of
60 000, located on the southeast
Gulf Coast of Texas, 1 hour
from Houston.

-S92-101

Referral base for practice is from
a service area of 123 000. No
buy in — take home what you
earn. Extremely com petitive
financial package offered with a
revenue guarantee provided for
1 year or longer.

SURGEON: NS - An opportunity exists for a
certified surgeon to locate in the town of
Glace Bay, Nova Scotia. Excellent surgical
facilities and support services. Excellent rec
reation facilities for persons who enjoy sail
ing, water sports, skiing, golf, and curling.
University within 16 km. A very good school
system. Apply in confidence with curriculum
vitae to: Mrs. Jean Hemsworth, Adminis
trator, Glace Bay General Hospital. 3 0 0
South St., Glace Bay. NS B1A 1W 5. Tel:
(902) 8 4 9 -5 5 1 1 , ext. 120.
-S91-91

Join them in a friendly atmos
phere where the quality of life is
good and you can avoid the
snow.
Please send resumes or direct
enquiries to:

RESEARCH FELLOWSHIP SPINE SUR
GERY: US - Orthopaedic Hospital Spine Cen
ter in Los Angeles, California is offering a
1-year spine research fellowship starting July
1, 1992. Fellowship training will include labo
ratory and clinical research with exposure to
clinical orthopedic surgery and academic con
ferences. Submit CV with references to:
Santi Rao, MD, Director, Orthopaedic Hos
pital Spine Centre. Ste. 200. 2 3 0 0 S.
Flower St., Los Angeles, CA 90007. Tel:
(213) 741 -08 0 0 . Fax: (213) 747-1716.

Pat Adams
Director of Physician Services
Park Place Medical Center
PO Box 1648
Port Arthur, TX 77642
Tel: (409) 985-0302,

-S 9 2-9 6

CLASSIFIED ADVERTISING Unlike a tabloid or newspaper that is read today and discarded tomorrow, an adver
tisement in the Classified Advertising section of CJS is read today and reread tomorrow.
CJS is the only Canadian publication exclusively for surgeons. No other Canadian surgical publication reaches over 9000
subscribers every 2 months, giving wide coverage for your advertising dollar.
Average issue readership of CJS (81%) is among the highest of any medical journal in Canada, the latest readership studies confirm the best and most cost efficient way to reach Canadian surgeons is through the pages of CJS.
LET CJS CLASSIFIED ADS WORK FOR YOU
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HOTEL-DIEU
OF
ST-JOSEPH

NCH

SCOTT & WHITE

Northern Carleton
Hospital

GENERAL SURGEON
Hotel-Dieu of St-Joseph, Perth-Andover, and Northern Carleton
Hospital, Bath, New Brunswick, are looking for a second surgeon.
These two hospitals are located in small communities in the
Upper Saint John Valley, about 20 minutes apart. They plan to
join surgery services to cover the needs of this area.
Both hospitals are extremely well equipped. The Perth Hospital
is a 65-bed acute care facility with a concentrated care unit and
a full-time surgeon. The surgical services are varied and the
volume is too much for a solo surgeon. The Bath Hospital is a
36-bed acute care facility, with a close observation unit, and the
present surgeon is about to retire. There should be an excellent
jo in t p ra c tic e b e tw e e n th e tw o c o m m u n itie s with an
above-average income. The position qualifies for a guaranteed
income for the first year of practice.
Enquiries are welcome.
For further information, please contact:

Dr. Brian Sykes
Hotel-Dieu of St-Joseph
Perth-Andover, NB
EOJ 1V0
Tel: (506) 273-2201 (work)
(506) 273-6767 (home)
or
Bath, NB
Mr. Roger Jones,
Tel: (506) 278-5231 (work)
(506) 328-4884 (home)

3'®me Co n g re s

—S91-83

GENERAL SURGEON

Nous somm es tiers d 'a n n o n c e r le
3 ‘®me Congres de VAssociation des
Orthopedistes de Langue Frangaise
s o u s I 'e g i d e de I ' A s s o c i a t i o n
d ' O r t h o p e d i e du Q u e b e c . Une
occasion uniqu e de r e n c o n tr e r le
m o n d e o r th o p e d i q u e f r a n c o p h o n e
des 5 continents.
le

CP 2 1 6 , Succ. Desjardins,
M o n tr e a l (Quebec)
H 5B 1G8
(514)844-0803
( 5 1 4 ) 8 4 3 - 6 7 1 2 —S91-88
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S cott & W hite provides a n exceptionally
attractive salary an d b enefits package to include
4 w eeks vacation a n d 3 w eeks C.M.E.

-S 9 1 -8 6

1 5 au 19 sept. 1 9 9 2
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S cott & W hite is lo cated in T em ple, Texas,
ap p ro x im ately 60 miles n o rth o f A ustin a n d 120
m iles s o u th o f Dallas/Ft. W orth. T em p le is a
family o rie n te d city o f 5 0,000 w ith n u m e ro u s
n earb y lakes a n d o u td o o r activities.

D e n n is J. L ynch, M.D.
C hairm an, D ep artm en t o f Surgery
Scott & W hite Clinic, Texas A&M
University C ollege o f M edicine
2101 S o u th 31st S treet
T em ple, TX 76508

Quebec - Chateau Frontenac -

Tel:
Fax:

Scott &
C ollege
to fill a
o f the

For m o re inform ation, p lease call B a rry H a rp e r
at 1 -8 0 0 -7 2 5 -3 6 2 7 o r se n d cu rricu lu m vitae to:

AOLF

Pour i n f o r m a t io n s , c o n t a c t e r
secretariat de I' A.O.Q. au:

T h e Division o f N eurological Surgery o f
W hite Clinic a n d Texas A&M U niversity
o f M edicine is seeking a N e u ro su rg e o n
clinical/faculty p o sitio n as D irecto r
D ivision o f N eurological Surgery.

The Miramichi Area, at the present time, has two acute
care hospitals. Hotel Dieu H ospital in Chatham
has 127 beds while the Miramichi Hospital has 104 beds.
These hospitals are located 8 km apart. A new regional
hospital is expected to be opened in the next 5 year.
Candidates must have their FRCSC and be eligible for
licence to practise in New Brunswick.
The area has excellent recreational facilities. The Mirami
chi area is world famous for its salmon fishing. A
general surgeon is required due to the increased work
load and in preparation for increased services in the new
hospital.
Additional Northern Services benefits are available.
For further information contact:
Phyllis Mossman
Executive Director
Miramichi Hospital
PO Box 420
Newcastle, NB
E1V 3M5
Tel: (506) 627-7045
OR
Robert Stewart
Executive Director
Hotel Dieu Hospital
53 Lobban Avenue
Chatham, NB
E1N 2W9
Tel: (506) 773-4401

—S91-89

G ENERAL SURGEON

NORTH YORK
GENERAL HOSPITAL

A n e x c e lle n t o p p o r t u n it y e x is ts t o w o r k in a
v e r y a c t iv e T o r o n t o c lin ic s p e c ia liz in g in c o lo n
a n d re c ta l s u rg e ry .

A 500-bed co m m un ity hospital
affiliated with the
U niversity o f T o ro n to
is seeking a

Our client seeks a fully qualified surgeon with
FRCSC to join a busy group practice with a national
reputation and more than 3500 referring physi
cians. The applicant will be a highly compatible
physician who is interested in and able to adapt to
learning the latest techniques in office outpatient
and colon surgery, as well as colonoscopy.

CHIEF OF SURGERY
C andidates m ust hold the
a ppropriate fe llo w sh ip and
be eligible to hold a
general licence in the
province o f O ntario

The successful applicant will benefit from an interesting and very rewarding practice with rare
night calls in a superior atmosphere. Gross income
for this fee-for-service practice exceeds $300 000
per annum.

Interested ca n d id a te s should
send a copy o f th e ir
curriculum vitae to:

Interested candidates are invited to submit a current curriculum vitae, quoting reference #91022
to:

Dr. M.P. G ran g er
V ice-P resid en t, M edical A ffa irs
N orth Y ork G en eral H ospital
4001 Leslie S tre e t
W ilio w d ale, O n tario
M 2K 1E1
—S92-98

S S -

.s s s s
S

S

CanMed

T

K a t h a r in e P a r s o n s
C a n M e d C o n s u lt a n t s In c .
6 2 Q u e e n S t r e e t S o u th
M is s is s a u g a , O n t a r io
LoM

lK 4

Te|. (416) 567_1080
F a x : ( 4 1 6 ) 5 6 7 -1 0 8 1

--S 9 2 -9 7

International Medical Course

Psychogeriatrics: current issues and recent advances
12-17 July 1992, Nottingham
This course aims to give an update on recent
advances, and an opportunity to discuss
clinical and organizational problems at an
advanced level. It concentrates on more
advanced aspects of the subject and has been
developed from a series of successful courses
containing more basic aspects which were
held between 1980 and 1988.
The course will be directed by Professor
T H D Arie who is head of the Nottingham
University Department of Health Care of the
Elderly (a joint department of psychiatrists,
physicians and others concerned with the
elderly).
The programme will comprise talks, clinical
demonstrations and seminars. Participants
will be invited to discuss developments in
their own countries.
The course is designed primarily for psychi
atrists already experienced in this field, but

workers in other relevant disciplines with
the requisite background would be welcome.
There are vacancies for 25 participants.
Course fee: £740 (inclusive)
Course sessions will take place at the Queen’s
Medical Centre, University of Nottingham.
Participants will be accommodated in single
bedrooms at Hugh Stewart Hall on the
University campus. Bathroom facilities will
be shared.

Further information and application forms are
available from your local British Council office
or from Courses Department, The British Council,
10 Spring Gardens, London SW1A 2BN.
•

00* 00*

O• O• O• O

oo***oo
oo***oo
o*o*o*o

• 0 0 * 0 0 *

The
British
Council

— S92-100
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This volume is an outstanding com
pendium o f information currently avail
able on malignant gliomas. In addition,
the book enables the reader to look
ahead to future therapies in neuro
oncology. The material within this vol
ume should be of interest to every
practising neurosurgeon and may be of
real value to surgical oncologists who
must also treat patients with other
types of prognostically poor cancers for
whom the therapeutic strategies out
lined in this text may apply.
James T. Rutka, MD, PhD, FRCSC
Assistant professor
Department o f Surgery
University o f T oronto.
Division o f Neurosurgery
The Hospital for Sick Children
555 University Ave.
Toronto, ON
M5G 1X8

Merck Sharp & Dohme Canada
Pepcid

18, 98, 99

SURGERY ANNUAL: 1990. Volume
22. Series editor: Lloyd M. Nyhus. 439
pp. Illust. Appleton & Lange, Nor
walk, Conn. 1990. $72.95 (US). ISBN
0 -8 3 8 5 -8 7 3 5 -6

Parke-Davis
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14

Pfizer Canada Inc.
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2, 92, 93

SURGERY ANNUAL: 1991. Part 2.
Volume 23. Series editor: Lloyd M.
Nyhus. 186 pp. Illust. Appleton &
Lange, Norwalk, Conn. 1991. $75
(US). ISBN 0 -8 3 8 5 -8 7 4 4 -5

Roussel Canada Inc.
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3M Canada Inc.
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The stated purpose o f these books is
“ to present critical discussion of recent
developments in the clinical manage
ment o f surgical diseases, to report
advances in the basic sciences as they
relate to the practice o f surgery, and to
discuss social and economic issues im
portant to surgeons and patients.” To
meet these objectives two types of pre
sentations are used. The first o f these is
an overview o f surgery by Leslie Wise
and Benjamin Pace. This 24-page arti
cle is reminiscent o f the articles entitled
“ What’s new in surgery” that appear in
the Bulletin o f the American College o f

Surgeons after each clinical congress.
The second type of presentation is a
series o f review articles on selected
topics written by acknowledged experts
in their fields. In general these articles,
from Great Britain, Germany, South
Africa and the United States, are well
written and illustrated. They cover a
very wide range o f topics, from basic
science to operative techniques and so
cioeconomic issues.
To give some idea of the diversity of
the topics covered consider three titles
from Surgery Annual: 1990. “ Adhesive
interactions between malignant cells
and the extracellular matrix” by Mary
Anne Kosir and Lloyd A. Culp (Case
Western Reserve School of Medicine,
Cleveland, Ohio) is an in-depth review
o f the characteristics o f malignant cells
related to the metastatic process. “ The
retroperitoneal approach to abdominal
aneurysms” by Charles B. Anderson,
Brent T. Allen and Gregorio A. Sicard
(Washington University School of Medi
cine, Seattle, Wash.) is a technical
paper on operative surgery. “ The psy
chological consequences o f the surgical
treatment o f cancer o f the breast” by
Peter Maguire (Christie Hospital, Man
chester, England) covers the psychoso
cial impact o f breast cancer treatment
on the patient. It is likely that books
covering topics this diverse will strug
gle to find an audience.
These books are targeted at the
surgeon who wishes to keep abreast of
new developments in surgery over a
wide range o f topics. Such individuals
are rare in an era of specialization.
Certainly for anyone wishing to delve
into a specific topic, the books provide
a valuable source o f information on the
topics covered. The books are more
likely to find a place in a reference
library than in an individual surgeon’s
library.
Olin G. Thurston, MD, FRCSC
Department of Surgery
University o f Alberta
Edmonton, AB
T6G 2B7

LEDERLE
SURGICAL

Ww S // /

• SI/

DEADLI NE

F OR

A P P L I C A T I O N S

APRI L

1,1992

pplications are invited for two fellowships offered by
Lederle Laboratories in cooperation with the Canadian
Association of General Surgeons. This year one award will be
given for research in colorectal surgery and another in surgical
infectious disease
Each fellowship carries a grant of $15,000 for one year to
support a surgical trainee in a Canadian Laboratory. A minimum
of 75% of the trainee’s time must be spent working on his/her
project.
Applications consisting of an outline of the proposed
research project, the curriculum vitae of the applicant and his/her
supervisor along with letters of support from the chairman of
the department and the supervisor, should be submitted by April
1,1992. The fellowship, which will start on July 1,1992, will be
announced at the Canadian Association of General Surgeons
Annual Meeting held in conjunction with the Royal College of
Physicians and Surgeons Meeting.
Successful fellows may reapply for a second year of funding
in competition with new applicants.

Inquiries and applications should be sent to:
Dr. Ori Rotstein
Toronto General Hospital
200 Elizabeth Street, Eaton North 9-236
Toronto, Ontario M5G 2C4

JexLerle
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Taking suture technology
to new heights
NEW

D
(BRAIDED SYN THETIC ABSORBABLE SUTURE)

75 c m ( 3 0 ")

3.5 Metric

D EXO
N®n
BI-COLOR™ Braided Polygtycoilc

Acid Suture wtth Poiycaprotate™
m Coating System

T-12
37 mm

BAm * m *

CYANAMID CANADA INC. MONTREAL. QUE. R8X 3N7

DAVIS+GECK
Cyanamid Canada Inc.
M arkham
®/mRegistered User: Cyanamid Canada Inc.

DEXONII, the newest generation
in the evolution of synthetic
absorbable sutures, offers markedly
different performance in handling,
tying and knot snug-in.
The unique new Polycaprolate™
Coating System...
•Allows the sutures to pass through
tissue smoothly with little or no
chatter or drag
• Provides superior suppleness and
silk-like feel
• Ensures minimal out-of-package
memory
In addition, DEXON II offers un
equalled out-of-package tensile
strength* and excellent knot security.

a

There is a difference. 4
See it .. .feel it.. .try it!
* DEXON com pared to V icryl.1, Data on file.
tTrade m ark of Ethicon.

